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THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS IN THE
IMMUNOTHERAPY OF BREAST CARCINOMAS
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Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature
cells at various stages of differentiation. These cells are broadly characterized by the
simultaneous expression of the surface markers CD11b and Gr1 and have been found to
accumulate in large numbers in response to many different tumors in both mice and
humans, including HER2/neu+ breast cancers. The adoptive immunotherapy of cancers
has been a promising field, yet the clinical efficacy of adoptive immunotherapies targeted

xxii

against human breast cancers and many other cancers has been extremely limited. Given
the influx of MDSC in tumor-bearing individuals, we hypothesized that these cells were
the reason for the failure of adoptively transferred T cells to effectively reject primary
tumors. Using either monoclonal antibodies or the chemotherapeutic drug, gemcitabine,
we aimed to eliminate MDSC cells in vivo to determine if adoptively transferred T cells
would be more effective in the absence of these cells. We further aimed to characterize
the mechanism of T cell suppression by MDSC and the tumor-derived soluble factor(s)
responsible for their accumulation. We have found that the elimination of MDSC in vivo
does result in significant tumor inhibition when adoptively transferred T cells are
administered. Furthermore, the use of gemcitabine in conjunction with adoptively
transferred T cells resulted in complete tumor rejection in 100% of mice and was
accompanied by large antibody titers against HER2/neu as well as strong recall responses
characterized by IFN-γ release and subsequent rejection of further tumor challenges. We
report herein that suppression by MDSC is contact dependent and affects the proliferation
of both CD4+ and CD8+ T cells. The accumulation of MDSC in tumor-bearing mice can
be entirely attributed to tumor-derived soluble factors, with GM-CSF specifically causing
the generation and maintenance of these cells. Our findings suggest that the adoptive
immunotherapy of breast carcinomas in a clinical setting should be combined with the
use of gemcitabine, and that the use of GM-CSF as an adjuvant in cancer vaccines should
be carefully re-evaluated as this cytokine may result in increased MDSC accumulation in
vivo.

xxiii

Introduction
I.

The ErbB Family of Receptor Tyrosine Kinases
A. Structure and Function: Breast cancer is the most frequently occurring cancer

in women in the United States, with an overall risk of developing breast cancer of 1 in 6,
and a risk of developing invasive breast cancer of 1 in 8 (1, 2). Of these cancers,
approximately 30% are positive for the overexpression of the HER2/neu oncogene (3),
which has been associated with a more aggressive phenotype and poor clinical prognosis
(4). HER2/neu, or its 89% homologous rat counterpart, neu (5), is a member of the
epidermal growth factor receptor family, or the ErbB family, of tyrosine kinase receptors.
The epidermal growth factor receptor (EGFR) was discovered in 1975 as a specific target
for epidermal growth factor, previously shown to stimulate the proliferation of epithelial
cells (6, 7). In 1978, Stanley Cohen’s group observed that the addition of EGF to
epidermoid carcinoma cells increased the incorporation of 32P in vitro (8). Hence the idea
that signals could be transmitted through the phosphorylation of receptors was initiated. In
1984, the peptide sequence of EGFR was discovered to share a high level of similarity
with a known avian oncogene, v-erbB (9). Thus, the first connection was made between a
known human receptor tyrosine kinase and a sequence exhibiting oncogenic function. In
1985, the discovery of a second member of the EGFR family was published, having been
1

discovered by Coussens et al using v-erbB as a screening probe (10). This 138,000-dalton
polypeptide, encoded by 4.8-kb of mRNA originating from the q21 region of chromosome
17 in humans was found to be widely expressed in many normal tissues including the
kidney, liver and colon (10). Furthermore, this paper noted that this newly coined “HER2”
gene shared its chromosomal location with that of the previously mapped neu protooncogene isolated from a rat neuroblastoma (10). The EGFR family is now comprised of 4
members: ErbB1 (the epidermal growth factor receptor, or EGFR), ErbB2 (or HER2/neu in
humans), ErbB3 (HER3), and ErbB4 (HER4) (11). Members of the ErbB family exhibit
structural similarity, with an extracellular region composed of four domains, a
transmembrane and juxtamembrane region, an intracellular tyrosine kinase domain, and an
C-terminal regulatory region (11-13). The extracellular region of the ErbB tyrosine kinases
is made up of four sub-domains. Domain I, which is the most distally located from the cell
membrane, along with domain III, are homologous members of the leucine rich repeat
family, and it is these domains that take part in binding to extracellular ligands (11-15).
Domains II and IV, on the other hand, are cysteine-rich domains and do not participate in
ligand binding. Rather, domain II acts as a dimerization arm, which, in the presence of
ligand, is exposed and contacts the domain II dimerization arm of a second ErbB molecule
(Fig. 1A, right) (11-13). In the absence of ligand, however, the ErbB molecule assumes its
“tethered” orientation, in which domain II interacts with domain IV in such a way as to
block the dimerization interface of domain II (Fig. 1A, center)(11-13). ErbB2, however, is
unique in that its domain II dimerization arm is constitutively exposed, thus making it
available to heterodimerize with any of the other ErbB family members (Fig. 1A, left) (16).
2

Unlike the other ErbB receptors, ErbB2 also has no known ligand, which may explain the
need for exposure of domain II, since ligand binding to domains I and III in other ErbB
molecules results in a conformational change that exposes domain II, resulting in a unique
dimerization that is entirely receptor-mediated (14, 15). Since ErbB2 is the only of the
ErbB molecules that has no ligand, overexpression of this molecule alone, with no further
stimulating factors leads to increased dimerization, both with other ErbB molecules and
with ErbB2 itself, and results in increased proliferation and survival (Fig. 1B) (12, 17).
While normal cells express 2-10 copies of the ErbB2 gene, amplification of ErbB2 in
breast cancer patients has resulted in as many as 200 copies, correlating with surface
expression of up to 2 million ErbB2 molecules, as compared to 20,000-50,000 molecules
on the surface of normal breast cells (18-20)Accordingly, experiments have shown ErbB2
to be the preferred dimerization partner for the other 3 ErbB molecules, with tyrosine
phosphorylation levels of ErbB molecules 1,3 and 4 in response to ligand being greatly
reduced in the absence of ErbB2 (17). In fact, it has been found that ErbB2 actually
enhances tyrosine phosphorylation of ErbB1 in response to its ligand, epidermal growth
factor as well as of ErbB3, the only ErbB molecule with no intrinsic kinase activity, and
ErbB4 in response to one of their ligands, neu differentiation factor in certain tumor cell
lines (21-23). The lack on ligand for ErbB2 can be explained by its crystal structure,
which reveals that domains I and III of the extracellular domain are in direct contact,
therefore eliminating the need for these two domains to be bridged by a ligand, as they are
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other ErbB receptors (16) This explains the constitutively active form of ErbB2
independent of a ligand, and justifies the observation that ErbB2 overexpression can lead
to cell transformation in the absence of ligand (11, 24).
The FVBN202 mouse model of spontaneously arising mammary carcinomas
provides a clinically relevant model for investigating the immunotherapy of neu positive
mammary tumors. These mice develop mammary carcinomas within 4-12 months of age as
a result of the overexpression of the inactivated form of rat neu oncogene, which lacks the
activating mutation that is present in the transmembrane domain of the activated form of
the oncogene, in their mammary glands under the regulation of the mouse mammary tumor
virus (MMTV) promoter (25). Spontaneously arising mammary carcinomas were then
harvested for the development of a neu overexpressing mouse mammary carcinoma cell
line, referred to as MMC. The persistent overexpression of the neu oncogene in FVBN202
mice results in mice that are immunologically tolerant to the neu oncoproteins, therefore
creating an ideal and clinically relevant model in which to investigate tumors arising from
“self” tissues to which immune responses are not robust. In contrast, parental FVB mice do
not express the rat neu oncogene and therefore are able to generate a robust immune
response against challenge with neu-expressing MMC. These mice subsequently reject
MMC, thus generating a pool of T cells with proven effectiveness against these tumors.
B. Signaling Pathways: RTK’s have extensive downstream signaling capabilities,
and signaling events stemming from ligation of the epidermal growth factor receptor have
been extensively studied. Specifically, activation of the ErbB family of RTK’s has been
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shown to result in cellular proliferation and pro-survival effects that are mediated through
one of three main pathways: the phosphatidylinositol 3-kinase (PI3K) pathway, the RasMAPK pathway, or the JAK-STAT pathway. (12, 26). Since ErbB2 does not have a ligand
of its own, but has a constitutively active dimerization arm, it frequently functions to
augment signaling by the other ErbB molecules, particularly ErbB1 and ErbB3, through
heterodimerization. In particular, overexpression of ErbB2 in breast cancers leads to
increased activation or constitutively active signaling through the PI3K and the MAPK
pathways (27). For example, binding of EGF to ErbB1 and subsequent dimerization results
in autophosphorylation of critical tyrosine residues on ErbB1 by its intrinsic kinase
function. Subsequently, the Src-homology 2 (SH2) domain of the p85 subunit of PI3K is
recruited to the phosphorylated tyrosines ErbB1 (28, 29). Heterodimerization of ErbB2
with ErbB3 also initiates this pathway, as activation of ErbB3 results in six
phosphotyrosine docking sites for the PI3K p85 subunit (27). The p110 subunit of PI3K
then generates phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol4,5-bisphosphate (PIP2). Phosphoinositide-dependent kinase 1 and Phosphoinositidedependent kinase 2 then phosphorylate and subsequently activate AKT, all of which were
recruited to PIP3 via their plekstrin homology (PH) domains (29). AKT is a serinethreonine kinase that exerts vast effects on cell cycle and survival. Importantly, AKT
prevents the translocation of the p21 and p27 cell cycle inhibitors into the nucleus through
the phosphorylation of both of these molecules (30, 31). Furthermore, AKT phosphorylates
and thereby inhibits the pro-apoptotic BAD molecule as well as activates NFкB, which
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activates genes to inhibit apoptosis as well as induce progression through the cell cycle and
cellular proliferation (29, 32-36).
A second important means of signaling used by the ErbB family of receptor
tyrosine kinases is the mitogen-activated protein kinases, or MAPK, cascade (27).
Increased MAPK signaling resulting from ErbB2 overexpression first goes through the
small GTPase Ras, which in turn activates Raf, MEK, and ERK, a cascade that has been
shown to be indispensable for Ras-meidated oncogenesis (27, 37-39). Hyperactivation of
Ras may result from mutation of Ras itself which occurs in 30% of all human cancers (40).
Mutated Ras molecules are insensitive to the GTPase-activating proteins which are
required to hydrolyze the GTP bound to the active form of Ras to GDP, thus resulting in
the restoration of the inactive form of Ras (37, 40). Conversely, hyperactivation of Ras
may result from overexpressed or mutationally active ErbB1 or ErB2 molecules. Of the
30% of breast cancers that overexpress ErbB2, it has been found that 20% of these result
from amplification of the ErbB2 gene at the DNA level (41), and mutations in the kinase
domain of ErbB1 or ErbB2 can lead to constitutively active signaling (42)(43).
Compounding this problem of increased signaling from constitutively active ErbB
molecules is the fact that Ras activation and the subsequent MAPK cascade causes results
in the transcription of ErbB1 ligands such as TGFα, heparin-binding EGF, and
amphiregullin, which then feed back further stimulate ErbB receptor signaling (44, 45).
Furthermore, signaling through ErbB1 was reported to be responsible for over half of the
total transcriptional effects mediated through the Raf protein (45). Signaling through the
MAPK pathway, primarily through the induction of Ras and Raf, is therefore a major
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means of signal transduction through the ErbB receptors, with alternations in this pathway
linked to a significant number of cancers.
Adding to the diversity of signal transduction through ErbB receptors, Yamauchi et
al reported that, although ErbB receptors possess intrinsic kinase ability, that treatment of
mice with growth hormone resulted in the phosphorylation of not only the growth hormone
receptor (GHR), but also of ErbB1. Further experiments proved that ErbB1 complexes
with activated GHR and that ErbB1 was directly phosphorylated by JAK2 which resulted
in the association of the adaptor molecule Grb2 to the phosphorylated ErbB1. Importantly,
it was shown that the expression of mutant ErbB1 molecules that lacked all intrinsic
receptor tyrosine kinase activity had no effect on the phosphorylation levels of ErbB1 in
response to growth hormone (46). As the downstream target of JAK molecules is the group
of transcription factors designated as signal transducers and activators of transcription
(STAT’s), it was also determined that binding of EGF to ErbB1 results in the
phosphorylation and translocation of both STAT1 (47) and STAT3 (48). Importantly,
STAT3 activation has been shown to maintain the proliferation of cancer cells and is
aberrantly activated in 50-90% of human cancers (49-51). Constitutively active STAT3C
can cause transformation in normal cells, whereas dominant negative STAT3 can block the
oncogenic transformation of cells in vitro (52-54). STAT3 mediates these effects through
the activation of genes that promote cellular proliferation such as c-myc and cylicn D1 and
suppress apoptosis such as MCl-1 and survivan (55-58). Additionally, vascular endothelial
growth factor, which aids in angiogenesis, and matrix metalloprotease-9, which degrades
components of the extracellular matrix to allow for invasion, are also activated by STAT3
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(59, 60). Furthermore increased levels of phosphorylated JAK2 and STAT3 have been
observed ovarian cancer cells and the levels of increased expression were positively
correlated with tumor grade and migratory phenotype (61, 62). Additionally, treatment of
ovarian cells with EGF was shown to significantly increase IL-6 production and secretion
in ovarian cancer cells lines. Since IL-6 is known to signal through STAT3 and is a
proinflammatory cytokine associated with chronic disease and promotion of cancer, the
upregulation of IL-6 by ErbB1 signaling and resultant increase in STAT3 activity
constitutes another mechanism of tumor promotion by ErbB1 (62).
II. Cancer Therapeutics
A. Chemotherapies: Many chemotherapeutic drugs have been developed to target
and treat rapidly dividing cancer cells. One of these, 5-fluorouracil (5-FU), is a uracil
analog that substitutes a fluorine at the C-5 position of uracil where a hydrogen atom
usually resides (63). This treatment was originally devised following the observation that
rat hepatomas incorporated the pyrimidine uracil into their RNA at a faster rate than
normal tissues. In addition to its disruption of RNA synthesis, 5-FU also inhibits the
synthesis of thymidylate, necessary for DNA replication, by blocking the binding site of
the thymidylate precursor on the thymidylate synthase enzyme. Despite these effects, 5-FU
treatment alone has had a relatively low response rate (10-15%) in patients with advanced
colorectal cancer, where it has been found to be most effective (63). Cyclophosphamide, an
alkylating agent showing particular potency against lymphocytes, is often used for the
treatment of lymphomas and autoimmune diseases (64, 65). Furthermore, the use of
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Cyclophosphamide in conjunction with adoptive immunotherapy results in increased
efficacy of adoptively transferred cells because of the elimination of endogenous
lymphocytes, and is able to drive the expansion of a predominantly Th1-skewed response
(66, 67). Cyclophosphamide exists in an inactive form that must be converted to its active
form by oxidase enzymes in the liver. The presence of the enzyme aldehyde
dehydrogenase results in the eventual formation of carboxyphosphamide, whereas low
levels of aldehyde dehydrogenase results in the formation of phosphoramide mustard,
which forms DNA cross-links and leads to cell death (64). Another class of potent, yet
highly toxic anti-cancer drugs are the platinum-based drugs cisplatin, carboplatin, and
oxaliplatin. The platinum molecule at the center of these drugs binds covalently to the N7
position on purines, resulting in DNA cross-linking and cell death (68). These drugs are
often administered in combination with 5-FU. Also administered in combination with
platinum drugs, Gemcitabine has offered several novel mechanisms of anti-cancer action.
Gemcitabine is a deoxycytidine analog that must be converted to its active form by
phosphorylation, which yields successive mono, di, and tri-phosphate forms of the
molecule. The first round of phosphorylation is mediated by deoxycytidine kinase, which
is the rate limiting step of these reactions (69). Once in its diphosphate form, Gemcitabine
can inhibit the ribonucleoside reductase molecule, which is needed for the synthesis of
deoxyribonucleoside diphosphates to be converted to deoxyribonucleoside triphosphates
that will be used in DNA synthesis. Additionally, in its triphosphate form, Gemcitabine is
able to incorporate into DNA and inhibit replication (69). A unique attribute of
Gemcitabine was found in its ability to decrease numbers of myeloid-derived suppressor
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cells (MDSC) in the spleens of tumor-bearing mice. These results were confirmed in vitro,
with the addition of Gemcitabine to splenocyte cultures causing a significant reduction in
MDSC while having no effect on CD4+ or CD8+ T cells or B220+ B cells (70).
Importantly, Gemcitabine has been shown to exert effects through the immune system,
given that the anti-tumor effects of Gemcitabine seen in immunocompetant mice were
completely lost in nude mice in some tumor models. Supporting the role of Gemcitabine
on the immune system were the findings that mice given immunogenic tumors resistant to
Gemcitabine in vitro still had significantly reduced tumor volumes after Gemcitabine
treatment in vivo, as opposed to mice given non-immunogenic, Gemcitabine-resistant
tumors, on which Gemcitabine had no effect. Therefore, it is plausible that at least some of
the anti-tumor effects of Gemcitabine are mediated through the immune system and that
this drug may be an ideal candidate to use in conjunction with immunotherapies such as
adoptively transferred T cells (71).
B. Monoclonal Antibodies: The use of monoclonal antibodies for the treatment of
ErbB overexpressing tumors is common clinical practice and has shown positive results.
Monoclonal antibodies function by disrupting the structure, ligand binding, or dimerization
of the ErbB receptors and have the added benefit of recruiting immune effector cells that
express Fc receptors. The first monoclonal antibody to be approved by the FDA for use in
patients with HER2 overexpressing metastatic breast cancer was Trastuzumab, a
humanized antibody directed against domain IV of HER2 which is capable of inhibiting
MAPK and PI3K signaling through HER2 (72). Preclinical in vitro studies using
trastuzumab indicated its ability to inhibit cell growth, downregulate HER2, reduce VEGF
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production, and elicit antibody-dependent cell-mediated cytotoxicity (73). Clinical trials
have shown objective responses in 15% and 26% of patients with metastatic breast
carcinoma, with clinical benefit being closely correlated with higher expression of HER2
(74, 75). A second monoclonal antibody, pertuzumab, is directed against the domain II
dimerization arm of HER2, thus blocking dimerization of HER2 with any of the other
ErbB molecules. Although promising in theory, a phase II clinical trial using pertuzumab
for the treatment of metastatic breast cancer showed limited benefit, however it must be
noted that patients had low expression of HER2 (37). Additionally phase II trials for both
hormone refractory prostate cancer and non-small cell lung cancer (NSCLC) have shown
no response to pertuzumab (37, 76), although results seem promising against ovarian
cancer (37). Cetuximab, which was approved in 2004 for the treatment of refractory
metastatic colorectal cancer (77) specifically targets domain III of the EGFR with a higher
affinity than its EGF or TNF-α ligands, and therefore blocks their binding (78, 79). A 2004
study using cetuximab monotherapy to treat EGFR positive colorectal cancer resulted in
partial responses in 8.8% of patients and 36.8% had stable disease (80). Another phase II
study carried out using a combination of cetuximab and the topoisomerase I inhibitor,
irinitecan found a significant reduction in the time to disease progression in patients
receiving both cetuximab and irinitecan as compared to patients receiving cetuximab alone,
although this did not correlate with a significantly increased survival time (78). Since
certuximab is a chimeric IgG1 antibody, anaphylactic reactions in patients prompted the
development of humanized and fully human monoclonal antibodies. In 2006,
panitumumab, a 100% human antibody, was approved for use in patients with progressive
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metastatic colorectal cancer (37). Although this antibody, which also targets the EGFR, is
an IgG2 antibody which does not cause antibody-dependent cell-mediated cytotoxicity, a
phase III trial showed an 8% response rate in patients with metastatic colorectal
cancer.(81), although phase II trials for panitumumab have not shown promise for patients
with NSCLC (82). Matuzumab, currently in phase II clinical trials, is a humanized IgG1
antibody that binds to domain III of EGFR and instead of blocking ligand directly,
sterically inhibits domain rearrangement of EGFR required for receptor dimerization (83).
Although matuzumab monotherapy in women with ovarian or primary peritoneal cancers
previously treated with chemotherapeutic agents showed not advantage (84), phase I
monotherapy trials have shown responses in esophageal squamous cell carcinoma and
colorectal cancer. A 23% response rate was seen in a phase I trail combining matuzumab
with paclitaxel for the treatment of NSCLC (82). Resistance to monoclonal antibody
treatment can arise given the fact that signaling through alternate ErbB receptors can
compensate for a loss of signaling in the target molecule. Resistance to trastuzumab has
been particularly well documented, showing that the vast majority of patients become
resistant to this therapy within one year, with 66%-88% of patients exhibiting resistance to
single agent trastuzumab treatment (72, 85). Several factors could influence resistance to
trastuzumab and other monoclonal antibody therapies. First, since trastuzumab binds to
domain IV of HER2, it is inefficient in blocking the heterodimerization of HER2 in the
presence of other ErbB ligands (12, 86). Second, since anti-neu antibody administered in
the FVBN202 mouse model has lead to downregulation of neu expression and the
emergence of ANV tumors, it is possible that HER2 negative tumor cell clones, selected
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under immunological pressure, may also lead to relapse in humans (87). Another prevalent
mechanism of trastuzumab resistance is loss of the phosphatase PTEN, which antagonizes
the phosphorylation of the PI3K-AKT pathway and has been shown to have increased
activity after trastuzumab treatment (72, 85) Patients with HER2 overexpressing breast
tumors that are deficient in PTEN show a poor clinical response to trastuzumab. For these
patients, treatment with tyrosine kinase inhibitors, which are not dependent upon surface
expression of HER2 and can ameliorate signaling directly stemming from ErbB receptors,
are an attractive alternative (85).
C. Tyrosine Kinase Inhibitors: The existence of over 58 currently known receptor
tyrosine kinases (RTK’s), and the observation that overexpression or mutation of over half
of these molecules is associated with hyperproliferative disorders and has been observed in
a variety of cancers including gastrointestinal, prostate, ovarian, NSCLC, and breast
cancers causes these molecules to be natural targets for cancer therapeutics (12, 26). More
specifically, the epidermal growth factor receptor is overexpressed in a substantial
percentage of colorectal, pancreatic, lung, and NSCLC and had been found to be mutated
in NSCLC as well as in glioblastomas (37) One class of drugs used against the ErbB
receptors are tyrosine kinase inhibitors (TKI’s), which can counteract the cascade of events
triggered by RTK signaling. One TKI, gefitinib (ZD1839), was approved by the FDA in
2003 for the treatment of NSCLC based on results obtained from phase II trials (26, 88).
Although phase I and II trials had indicated that treatment with gefitinib reduced EGFR
phosphorylation and exhibited some antitumor activity, later phase II trials failed to
achieve statistically significant differences between groups receiving gefitinib and groups
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receiving a placebo (88). Therefore, in 2005, the FDA limited use of gefitinib to patients
currently receiving the drug or patients enrolling in clinical trials for gefitinib at the time
(88). Gefitinib is a quinazoline, a class of inhibitors which works by competing with ATP
for its binding site on the EGFR (89). Abolishing the ATP binding site consensus
sequence on the EGFR was shown in 1987 to be critical for the kinase function of EGFR
as well as leading to be eventual down-regulation of this receptor from the cell surface
(90). Another quinazoline, erlotinib, was approved by the FDA in 2004 for the treatment of
NSCLC and pancreatic cancer, based on increased survival times shown in phase III
clinical trials (37). This drug has also shown responses in phase I/II trials for the treatment
of metastatic squamous-cell carcinoma of the head and neck and hepatocellular carcinoma
when combined with the anti-VEGF antibody, bevacizumab (91, 92), but failed to exhibit
advantageous effects as a single agent administered against recurrent glioblastoma, or in
combination with bevacizumab against ovarian, peritoneal, or fallopian tube cancers (93,
94). Given the incomplete effectiveness of TKI’s targeting EGFR, TKI’s reactive against
several RTK’s are now in clinical trials. One of these, Lapatinib, is a quinazoline with dual
specificity for EGFR and HER2 and has reached phase III clinical trials for the treatment
of breast cancer, renal cell carcinoma, and head and neck cancer (37). Phase II trials have
previously shown lapatinib to be effective in reducing HER2+ metastatic lesions in the
brain and have shown clinical benefit against advanced metastatic breast cancers
previously treated with Trastuzumab (95, 96). Interestingly, recent in vitro studies have
indicated a possible synergy between lapatinib and Trastuzumab, with lapatinib treatment
of HER2-overexpressing cells causing an accumulation of inactive HER2 molecules,
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thereby rendering these cells more susceptible to the effects of Trastuzumab (97). A major
drawback to TKI’s targeted to one or several RTK’s is the development of resistance,
which has been observed in the vast majority of patients treated with these drugs (98-100).
The development of cells that are resistant to TKI’s could result from any of several factors
including the induction of other growth factors such as hepatocyte growth factor (99),
through the activation of other RTK’s such as the insulin like growth factor-1 receptor
(101) or the fibroblast growth factor receptor (102), through mutations in the RTK that
may alter the binding site of the drug (98), or through increased activation and
heterodimerization of alternate ErbB molecules, mediated by increased release of ligands
such as heregulin and betacellulin which cause heterodimerization of alternate ErbB
receptors (103). Of further concern are the in vitro findings that indicate that TKI resistant
head and neck squamous cell carcinoma cells displayed a dramatically more aggressive
phenotype characterized by increased levels of phosphorylated EGFR, increased
proliferation, reduced apoptosis, enhanced angiogenic capacity, and acquired resistance to
ionizing radiation (104). Thus, while promising at the onset, the use of TKI’s currently has
limited effectiveness combined with a high probability of generating a drug resistant, and
possibly more aggressive, phenotype.
D. Vaccines: The prospect of creating vaccines for tumors by immunizing patients
with either whole tumor cells, peptides from specific tumor-associated antigens, DNA, or
dendritic cells loaded with antigen, has been a promising concept, however in most cases
has failed to produce substantial clinical results. The exploitation of the immune system to
treat cancer has several advantages over the administration of chemotherapies and other
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anti-cancer therapeutics, including increased specificity, an accompanying decrease in
toxicity, and the possible development of long term immunological memory to prevent
recurrence. The idea of using the immune system against cancer stemmed from the finding
that human T cells could be reactive to specific antigens expressed or overexpressed on
tumor cells that are not widely expressed otherwise; these are referred to as tumorassociated antigens (TAA) (105-107). Many TAA’s have been tested experimentally as
vaccines, including the immunodominant HLA-A2-binding epitope of HER2 designated as
E75, which is comprised of amino acids 369-377 (107). Vaccination for the prevention of
breast cancer in the FVBN202 mouse model has been done using heat shock protein 110 as
an immunoadjuvant coupled to the intracellular domain (ICD) of neu. This study showed
the induction of both an IFN-γ response and the secretion of IL-4, indicative of a Th2
response, as well as a strong antibody response, specifically against ICD in immunized
animals. Importantly, vaccination of tumor free FVBN202 animals in the initial phases of
mammary hyperplasia resulted in a significant delay of the onset of spontaneous mammary
tumors (108). In humans, vaccination in an early stage setting has been done is patients
with HER2/neu overexpressing ductal carcinoma in situ (DCIS), a preinvasive form of
malignancy (109). This study used dendritic cells activated with IFN-γ and bacterial
lipopolysaccharide in order to create cells that not only secrete high levels of IL-12, but
may also facilitate the breaking of self-tolerance. Although this study design was
successful in generating HER2/neu reactive, IFN-γ-secreting CD4+ and CD8+ T cells that
were shown to infiltrate breast and caused a reduction in residual DCIS, HER2/neu
expression was also decreased in a majority of patients after vaccination. This indicates
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that IFN-γ-mediated immune pressure can lead to the selection of HER2/neu negative
variants, which have a less aggressive phenotype than their HER2/neu positive
counterparts, but may also cause a relapsed phenotype resistant to HER2/neu targeted
therapies (109). Another vaccination strategy in humans which uses the E75 peptide in
conjunction with GM-CSF has also shown promise in lowering recurrences rates. Breast
cancer recurrence rates were significantly reduced in disease-free patients receiving
vaccination as compared to disease-free individuals who were not vaccinated, a difference
that was lost after 20 months (110). Mittendorf et al have also used the E75 peptide along
with GM-CSF to vaccinate disease-free women with node-positive breast cancer
previously treated by standard surgical and chemotherapeutic techniques at high risk of
recurrence. Induction of immune responses was confirmed in treated patients and after 22
months, 85.7% of patients receiving vaccination were disease free, as compared to 59.8%
disease free patients in the control group, a substantial, albeit not significant, difference
(107). Extrapolating this data to include vaccination of disease-free node-negative breast
cancer patients yielded an overall 26 month recurrence rate of 8.3% in the vaccinated
group versus 14.8% in the control group with mortality rates in the relapsed patients being
significantly lower in the vaccinated group as compared to the control group (107). Despite
promising results for breast cancer relapse prevention, vaccination of tumor bearing
individuals with E75 along with Freund’s Incomplete Adjuvant or with GM-CSF
succeeded in inducing CTL responses, but provided no clinical benefit (111, 112). It is
thought that the main reason for the failure of vaccination against established tumors is the
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low frequency of tumor specific T cells in vivo (113), although it seems that vaccination
may hold some promise in the area of preventative treatment.
As an alternative to peptide vaccination, the use of matured dendritic cells in
vaccines may have substantial clinical benefit given that DC’s in cancer patients are often
immature and tolerogenic (114, 115). Dendritic cell based vaccines have therefore been
investigated in several ways. Dendritic cells can be pulsed with one or several peptides or
with whole cell lysate prior to injection for efficient antigen presentation, they can be
transduced with full length cDNA clones or mRNA from known immunogenic peptides,
thus resulting in presentation of multiple epitopes of that peptide, or they can be used to
generate fusion cells (116). Vaccination with E75 has been evaluated by loading the
peptide onto dendritic cells prior to vaccination. While results from these trials showed
induction of immune responses and infiltration of CD4+ and CD8+ T cells, there has been
an extremely limited or complete absence of any clinical response (117, 118, 118, 119). On
the other hand, vaccination in mice using DC transduced with a truncated HER2 caused
significant tumor inhibition against challenge with HER2-expressing tumors and caused
the development of both cellular and humoral immune responses. Injection of HER2transduced DC also extended tumor-free periods and reduced the numbers of spontaneous
primary tumors and lung metastasis in FVBN202 animals, while DC pulsed with lysate
from highly HER2-positive tumor cells had no such effect (120). Various other dendritic
cell based vaccines have been developed using multiple antigens, for example, the human
telomerase reverse transcriptase, or hTERT, peptide, which is recognized by CTL and
expressed on over 85% of all human cancers, has also been used in conjunction with DC’s
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(121). A key study in 2000 demonstrated that transfecting DC’s with RNA encoding
telomerase and subsequent immunization with these DC’s was able to inhibit the growth of
several different tumors in mice. Tumor inhibition was most likely CTL-mediated as in
vitro assays showed that T cells from immunized mice lysed TERT+ targets as well as
TERT+ tumor cells. Importantly, these results were recapitulated with the use of human
cell in vitro (122). Several of these methods have produced promising early results. For
example, phase I and II trials loading DC’s with a novel fusion protein consisting of the
antigen prostatic acid phosphatase fused to GM-CSF resulted in measurable T cell
responses in vitro as well as a significant increase in the median time to disease
progression in patients exhibiting immune responses versus exhibiting no response (123).
A phase I trial investigating the use of autologous DC’s fused with autologous tumor cells
found that these cells were able to stimulate T cell proliferation in vitro and 8 out of 23
total patients vaccinated with fusion cells showed stabilization or regression of disease
(124). In addition to dendritic cell based vaccines, DNA vaccines may also have some
therapeutic potential. A recent study by Cho et al has shown that immunization of Balb/c
mice with a plasmid encoding for one of the dominant epitopes of the rat neu protein along
with the TLR 9 agonist CpG generated CD8+ T cell responses in vitro, and caused the
regression of established neu+ tumors in vivo. Additionally, vaccination of Balb-neuT
mice, which are transgenic for and tolerant to the activated rat neu oncogene, caused
substantial delay of onset of spontaneously arising neu+ tumors (125).
E. Adoptive Immunotherapy: Unlike vaccination techniques, the use of
adoptively transferred T cells to treat established disease has been an attractive method,
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mainly because it allows for very high numbers of effector T cells to be infused into the
patient. This method has exhibited some success, particularly in the case of melanoma and
in the treatment of patients with cancers expressing viral antigens, such as the Epstein-Barr
virus (126). In breast cancer, since one of the predominant sites of metastasis is the bone
marrow, it has been shown that the adoptive transfer of reactivated T cells isolated from
the bone marrow of patients with pre-existing immune responses resulted in 50% of
patients generating tumor-specific IFN-γ response. Patients that did not generate an antitumor response were those that were given lower numbers of transferred T cells and were
shown to have higher numbers of regulatory T cells in the bone marrow and higher levels
of IL-4 and IL-10 in response to tumor antigen (127). These drawbacks highlight the many
obstacles of adoptive immunotherapy (AIT) that must be addressed, including the fact that
transferred T cells may not properly expand once in vivo, T cells from tumor-bearing
individuals are usually of low avidity and occur at a low frequency, and
immunosuppressive environments in vivo may inhibit adoptively transferred T cells.
A lack of expansion by transferred T cells in vivo is caused by endogenous T cells
acting as “cytokine sinks” (128, 129). Consequently, it has been found that
lymphodepletion of the host immune cells results in greater efficacy of the adoptively
transferred cells because the newly transferred T cells have greater access to cytokines
such as IL-7 and IL-15 that are important for homeostatic proliferation (128, 130, 131).
Most AIT regimens therefore use a chemotherapeutic agent such as CYP, which has been
shown to create a lymphopenic environment in tumor bearing hosts, prior to transfer (132).
Dudley et al have shown that adoptive transfer of expanded autologous tumor infiltrating
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lymphocytes (TILs) from melanoma patients pre-treated with CYP and fludarabine for
lymphodepletion caused the regression of bulky metastasis at multiple sites in a majority of
patients when administered concurrently with the T cell growth factor IL-2 (133). Patients
with metastatic breast cancer that was refractory to other treatments received CYP and
fludarabine prior to allogeneic hematopoietic stem-cell transplants that had been T cell
depleted. Subsequent injections of the isolated T cells 42, 70, and 98 days after stem-cell
transplantation resulted in objective tumor regression in 6 out of 16 patients and was
associated with donor T cell engraftment (134). Additionally, a single dose of CYP prior to
AIT using TILs from ovarian tumors expanded in IL-2 resulted in 1 case of complete
regression and 4 cases of regression exceeding 50% of the tumor were reported out of a
total of only 7 patients (135). The fact that the latter 2 trials did not use IL-2 injections in
vivo indicates that the use of CYP for the creation of lymphopenia may be the most
important factor in achieving expansion of transferred T cells. However, homeostatic
proliferation within a lymphopenic host may still be ineffective if the expanded T cells are
specific for only one antigen. One mechanism of immune escape by tumor cells is antigen
loss. Therefore, it is important to adoptively transfer T cells that have specificities for
multiple tumor antigens and antigenic epitopes (136). T cells derived from parental FVB
mice are therefore ideal candidates for evaluating the efficacy of protocols for expanding
the neu-specific T cells in the absence of the nominal antigen, ex vivo since these mice are
exposed to whole tumor cells in vivo, generating an immune response effective enough to
completely reject MMC cells. Bryostatin-1, a protein kinase C activator, and ionomycin,
which increases intracellular calcium levels, are able to cause vast expansion of tumor23

specific T cells, while not expanding naïve, non-sensitized T cells, without the addition of
specific tumor antigen by mimicking the signals that result from TCR stimulation (137). T
cells expanded in this manner were able to cause regression of MCA-105 pulmonary
metastasis in vivo, as well as of established 4T07 and 4T1 mammary tumors (138, 139).
In addition to the activation of donor T cells by bryostatin-1 and ionomycin, the
means of T cell expansion by gamma chain cytokines may also have an important effect on
T cell generation. The growth factor interleukin-2 has been used to mediate high levels of
ex vivo expansion of tumor specific T cells. However, there is evidence that IL-2 expansion
may also lead to the induction and maintenance of regulatory T cells, and IL-2 is known to
cause activation-induced cell death and the upregulation of Fas/FasL molecules on the
surface of T cells (140-143). In particular, the expansion of TILs from breast cancer
patients in IL-2 has resulted in predominantly CD4+ cells and low levels of lysis in vitro
(113, 144) Alternatively, the cytokine IL-7 is needed for newly arising memory T cells
(145). IL-15 has also been known to be important in the generation and maintenance of
effector and memory CD8+ T cells. IL-15 can protect effector CD8+ T cells from
apoptosis, as well as augmenting the cytotoxic effects of effector CD8+ T cells through the
induction of molecules such as IFN-γ, perforin, and granzyme B (146-148). Therefore a
better understanding of how these cytokines may work in concert and an optimized
expansion protocol are needed to allow for the generation of the most effective pool of
anti-tumor T cells to be generated ex vivo.
A need for the generation of high avidity T cells for transfer into tumor-bearing
individuals has led to the development of T cells with genetically engineered T cell
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receptors (TCRs). The first successful demonstration of this was done by transfecting
Jurkat T cells with cDNA clones encoding the α and β chains of the TCR from a line of T
cells recognizing the MART-1 TAA of melanoma. The transfected Jurkat T cells were then
able to recognize MART-1 targets, demonstrating the feasibility of transferring the
specificity of a reactive T cell clone to other T cells (149). This transfer was subsequently
accomplished in primary human peripheral blood T lymphocytes, resulting in CD8+ T cell
clones that could recognize and lyse melanoma cells in vitro (150).The first clinical trial
using TCR gene therapy was completed in 2006. In this study, T cells from melanoma
patients that were unresponsive to standard therapies were retrovirally transduced with
MART-1 specific TCRs and were adoptively transferred back into patients following
lymphodepletion. Out of 17 total patients, 15 showed persistence of transferred T cells for
at least 90 days and 2 patients showed complete tumor regression (151). The potential
efficacy of this for breast cancer has recently been shown in a mouse model using T cells
with chimeric receptors specific for human HER2, which were capable of eliminating
pulmonary micrometastases of an aggressive breast cancer line expressing human HER2
(152) However, potential concerns include the mis-pairing of transduced and endogenous
TCR α/β chains, resulting in novel combinations that may be autoreactive, and aberrant
integration of retroviral vectors potentially leading to malignant transformation (153).
III. Suppressor Cells Abrogate Anti-Tumor Immune Responses
A. Regulatory T cells: In terms of inhibition of adoptively transferred T cells, the
potential role of regulatory T cells (Treg) has been investigated. In a murine model of
breast cancer, it has been shown that the adoptive transfer of Treg-depleted tumor
25

infiltrating lymphocytes was more advantageous against established tumors than transfer
of total T cell populations and resulted in an increased Th1 response and IFN-γ secretion
(154). Immunostimulatory treatments in mice bearing 4T1 mammary tumors were capable
of mediating tumor rejection and survival in 65% of treated mice when combined with the
attenuation of Treg, an effect mediated by tumor-specific T cell cytotoxicity and increased
IFN-γ (155). Furthermore, the removal of CD25+ T cells in vivo has resulted in the
rejection of B16 melanomas transduced with IL-12, and the transfer of CD25-depleted
cells has resulted in complete regression of leukemia in nude mice (156, 157). Clinically,
Treg infiltration has been observed in breast cancer patients where they have been linked to
more aggressive cancerous phenotypes, poor prognosis, higher histological grade, and the
presence of T cells expressing inhibitory molecule B7-H1 (158-160). Increased numbers of
CD4+CD25+ T cells were also observed in cases of early-stage NSCLC, late stage ovarian,
and metastatic melanomas. These cells have been found to secrete the immunosuppressive
molecule TGF-β and suppress the proliferation and cytokine production by tumor
infiltrating CD4+ and CD8+ T cells (161, 162). However, several studies contradict the
role of Treg in cancer therapeutics. It has been found that administration of IL-2 to
lymphopenic patients along with autologous T cell transfer increases the generation of
Treg as compared to patients that did not receive IL-2 (143). It was further shown that Treg
increase in response to IL-2 treatment in patients with renal cancer or melanoma who were
not lymphopenic (163). These findings do not correlate increased Treg levels with clinical
outcome and are in direct opposition to previous results showing regression of metastatic
melanoma after treatment with CYP followed by AIT and IL-2 (133, 164). Therefore,
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although mechanisms have been developed to deplete Treg from patient samples to be used
for AIT (165), the role of Treg in AIT currently remains highly ambiguous and this cell
type may not cause major inhibition in the case of adoptively transferred T cells. The role
of other cell types, such as myeloid-derived suppressor cells, which have been shown to be
highly suppressive in many models of mouse and human cancers, should therefore be
evaluated in the context of AIT (166-169).
B. Myeloid-Derived Suppressor Cells: Myeloid-derived suppressor cells (MDSC)
are a heterogeneous population of immature myeloid-derived cells, which may include
macrophages, dendritic cells, and granulocytes, at various stages of differentiation. These
cells have thus far been characterized by expression of the surface markers CD11b and
Gr1. The accumulation of these cells has been noted in many types of cancers, including
the murine colon carcinoma MCA-26, Lewis lung carcinoma, the highly metastatic breast
carcinoma 4T-1, the neu+ breast carcinoma MMC and melanoma (B16) (167, 170-173).
The critical role of MDSC in cancer patients is underscored by the observation that
patients with renal cell carcinoma, melanoma, head and neck cancer, and breast cancer had
increased MDSC (174-178). Importantly, increases in the circulating levels of MDSC
correlate with clinical cancer stage and metastatic burden of breast cancer (178) Increased
numbers of MDSC are associated with enhanced myelopoiesis resulting from factors
secreted by the tumor itself, predominantly GM-CSF, which stimulates myelopoiesis, and
VEGF, which has been shown to block the maturation of hematopoietic progenitor cells
(168). This is supported by the finding that resection of solid fibrosarcoma tumors has
resulted in a decrease in the number of CD11b+ Gr1+ cells and in increased number of
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CD4+ and CD8+ cells in the spleens of mice (179). In renal cell carcinoma patients,
removal of the primary tumor also resulted in the spontaneous regression of pulmonary
metastasis (180). In fact, recent data from patients with renal cell carcinoma have
demonstrated an increased quantity and intrinsic arginase activity of MDSC. In vitro
depletion of MDSC from the PBL of these patients restored the tumor-specific IFN-γ
production and T cell proliferation (174). In BALB-neuT female mice, which also develop
spontaneous mammary carcinomas, CD11b+Gr1+ cells were observed to increase, not
only with age, but also with tumor multiplicity. This increase was shown to be mediated by
increased hematopoiesis within the host, as transfer of wild-type bone marrow cells into
irradiated BALB-neuT hosts showed increasing numbers of transferred CD11b+Gr1+ cells
upon reconstitution as the tumor number of the host increased (181). T cell proliferation in
these mice also decreased with the increasing numbers of tumors and MDSC. Expanded
MDSC populations have also been shown to have suppressive effects both in vivo and in
vitro, however, the mechanism by which these cells exert their suppression is still
controversial.
i. Mechanisms of T Cell Suppression by MDSC: Several groups have
reported contact-dependent suppression by MDSC. In particular, Gabrilovich et al have
shown antigen specific contact-dependency, reporting that while Gr1+ cells do not affect T
cell proliferation induced by Concanavalin A, they do have an adverse effect on the
number of IFN-γ-producing CD8+ T cells in response to specific peptide in what they
determined to be an MHC class I dependent manner (166). It has also been reported that
MDSC may work through the down regulation of the TCR zeta chain, an affect that was
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only seen in the absence of transwell inserts (182). This affect was not shown to be antigen
specific, however, suppression by MDSC was dependent on their derivation from a
chronically inflamed environment. This is in agreement with current literature has found
that MDSC isolated from tumor bearing mice are suppressive, while MDSC from nontumor bearing mice have little to no suppressive effect, also supporting the notion that
MDSC must be activated, presumably by the IFN-γ secreted by effector T cells, in order to
function (167). Further defects in the T cell receptor have been found to be mediated
through direct contact between MDSC and T cells resulting in nitration of critical tyrosine
residues in the TCR-CD8 complex, causing T cells to be unable to recognize MHC-peptide
complexes, an effect caused by the production of reactive oxygen species and peroxynitrite
(183).
The function of activated MDSC has also been argued to be dependent on the
production of nitric oxide, as well as other soluble factors, by these cells (184). The
enzyme nitric oxide synthase (NOS) is responsible for the production of nitric oxide, and
there are three main types of this enzyme: inducible NOS, endothelial NOS, and neuronal
NOS. Although all three of these have shown some correlation with tumor progression and
can be produced by the tumor cells themselves, the inducible form of NOS is of primary
importance in MDSC. Nitric oxide can work in a variety of ways, including by the
inhibition of JAK1, JAK3, and STAT5 molecules that mediate signaling through the IL-2
receptor (184, 185). Interestingly, inhibition of T cell proliferation by NO has been shown
to be potent against T cells stimulated in both antigen-specific and non-specific fashions.
Significantly, inhibition of iNOS by L-NMMA has been shown to reverse MDSC mediated
29

inhibition of naïve T cell proliferation upon stimulation with anti-CD3 and anti-CD28, as
well as in T cells stimulated with specific peptide or Concanavalin A (170, 184). In all of
these cases, IFN-γ was required for the production of NO by MDSC.
In addition to nitric oxide, indoleamine 2,3-dioxygenase (IDO) has also been
implicated as one of the effector molecules of MDSC. IDO is an immunomodulatory
enzyme that can also be secreted by alternatively activated macrophages as well as
dendritic cells and by a variety of malignant human cancer cells. IDO is the rate limiting
enzyme of the kynurenine pathway of tryptophan catabolism, metabolites from which
cause T cell apoptosis. Thus, an excess of IDO facilitates the breakdown and subsequent
depletion of the essential amino acid tryptophan, resulting in inhibition of T cell activation
and proliferation. IDO is therefore important in maintaining peripheral tolerance and has
also been implicated to play a significant role in a mother’s tolerance to her fetus and in the
suppression of transplant rejection (186). Importantly, much like NO, IDO production in
APC’s is initiated by IFN-γ, and therefore would be a logical mediator of suppression by
IFN-γ activated MDSC. In a study using the neu transgenic mouse model, it was shown
that the IDO inhibitor 1-methyl–tryptophan (1-MT), when combined with a
chemotherapeutic agent such as cyclophosphamide, resulted in a reduced tumor volume, an
effect that was shown to be dependent on endogenous T and B cells. The lymphocytedependent effect of 1-MT was not, however, a result of direct effects on T and B cells, as
proliferation of these cells was unaffected in vitro; thus it was the inhibition of IDO+ DC
by 1-MT that resulted in the restoration of T cell proliferation (187).
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A third soluble mechanism of MDSC suppression is the expression of arginase I,
which depletes L-arginine from the environment and thus causes T cell dysfunction by
inhibiting expression of the CD3 zeta chain (188). This finding correlates with reports of
reduced TCR zeta chain expression in clinical studies done on patients with breast cancer,
melanoma, and gastric cancer (182, 189-191) and the fact that increased levels of arginase
activity have been found in CD11b+ cells in the peripheral blood of renal cell carcinoma
patients and was concurrent with a decrease in serum arginine and increased serum
ornithine, a metabolic breakdown product of arginine (174). It was later shown that the
production of arginase by MDSC was a result of tumor-derived soluble factors from the
injected Lewis Lung Carcinomas (3LL). In particular, prostaglandin E2, produced through
the action of COX-2, which is constitutively expressed along with COX-1 in 3LL tumors,
was found to induce arginase 1 expression in MDSC via the E-prostanoid 4 receptor.
Specific inhibition of COX-2, but not COX-1, completely ablated the induction of arginase
1 in MDSC in this model (173).
ii. MDSC and COX-2: COX-2 has proven to be a key molecule in
promoting inflammation and tumor induced angiogenesis, and is expressed by
inflammatory cells after exposure to proinflammatory cytokines. COX-2 overexpression
can also be found in many human cancers including breast carcinoma and is believed to be
upregulated in tissues in response to carcinogens such as ultraviolet light, nicotine, and
Helicobacter pylori. Expression of this enzyme leads to the production of prostaglandinE2 from arachidonic acid, which subsequently upregulates the Th2 response (resulting in
increased pro-angiogenic factors such as IL-6 and VEGF) while simultaneously
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downregulating the Th1 response, leading to decreased apoptosis in tumor cells through
the induction of bcl-2 (192). Indeed, COX-2 expression and activity has been correlated
with increased aggressiveness in breast cancer. It has been shown that COX-2 protein
expression and activity were greatly increased in a metastatic breast cancer cell line as
compared to a nonmetastatic cell line (193). This difference was shown to be mediated by
increased methylation of the COX-2 promoter region in DNA from the nonmetastatic
carcinoma. Conversely, the promoter region in metastatic breast carcinoma lines remained
unmethylated. Treatment of cells with the DNA demethylating agent 5-aza-2’deoxycytidine correlated with an increase in COX-2 expression and activity (193).
In accordance with the correlation between increased COX-2 expression and the
development of cancer, it has been observed that the use of nonsteroidal anti-inlfammatory
drugs (NSAIDs) is linked with a decreased mortality rate from human breast and colon
cancers (194, 195). Likewise, several studies have indicated that use of COX-2 inhibitors
slow the progression of tumors. Rozic et al showed that both the non-selective inhibitor
indomethacin and the selective inhibitor NS-398, resulted in an inhibition of the migration,
invasion and angiogenesis of a highly metastatic C3L5 mammary tumor, while the
selective COX-1 inhibitor valeryl salicylate did not have a significant effect (196). Kundu
and Fulton confirmed the effectiveness of indomehtacin, and another COX-2 inhibitor,
celecoxib, against tumor volume, incidence, and metastasis in the murine mammary tumor
cell line 410 but also found the COX-1 selective inhibitor, SC560, to be effective (197).
Here, the discrepancy of the effectiveness of COX-1 inhibition lies in the fact that the cell
line used in the first study expressed very low levels of COX-1 whereas the 410 mammary
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carcinoma of the latter study expressed higher levels of this enzyme and therefore would
be more susceptible to its inhibition.
Also of significance is the finding that administration of celecoxib greatly reduced
the number of 1,2-dimethylhydrazine induced intestinal tumors and that this decrease in
tumor burden was correlated with a substantially decreased number of CD11b+ Gr1+
splenocytes in the mice that were given celecoxib in addition to 1,2-dimethylhydrazine
versus mice that were given 1,2-dimethylhydrazine alone. Additionally, this study showed
greatly decreased mRNA levels of NOS-2, arginase, and COX-2 in the spleens of animals
given celecoxib treatment versus animals given 1,2-dimethyhydrazine alone (198). These
findings and others, which have indicated that COX-2 expression in tumors is also linked
to increased numbers of CD11b+ Gr1+ MDSC and these cells can work through a variety
of mechanisms, including through the production of arginase 1, which is a direct result of
prostaglandin E2 production via COX-2 expressing tumors, provides some interesting
insights into the crosstalk and feedback mechanisms that exist between tumor-derived
soluble factors and myeloid-derived suppressor cells (173). Interactions between known
tumor-derived soluble factors, as well as yet-unknown factors, should be thoroughly
investigated in order to determine the multi-factorial parameters of MDSC activation and
function within the tumor-bearing host.
iii. Mechanism of MDSC Induction: In addition to its role in tumorogenesis
through activation by ErbB1, STAT3 is also believed to downregulate the expression of
proinflammatory cytokines and can have a profound impact on the immune response to
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cancer (199). It has been found that blocking STAT3 causes an increase in several
proinflammatory cytokines in melanoma, colon carcinoma, and breast carcinoma cell lines
(199). These proinflammatory cytokines proved essential in causing the activation of
potent dendritic cells in the context of the innate immune response, and transduction of
tumor cells with a dominant negative form of STAT3, STAT3β, caused increased
infiltration of immune cells to the tumor site in addition to causing the apoptosis of B16
melanoma cells. Increased apoptosis induced by blockade of STAT3 is caused by STAT3
expression upregulating the anti-apoptotic proteins BCL-XL, MCL1 (myeloid cell
leukemia-1, a member of the Bcl-2 family that controls mitochondrial integrity), myc, and
survivin. Tumor expression of STAT3 was additionally found to inhibit the maturation of
dendritic cells, particularly because of the fact that STAT3 expression upregulates
immunosuppressive molecules such as IL-10 and TGF-β. Binding of IL-10 to its receptor
on dendritic cells can subsequently activate STAT3 within the dendritic cell, and cause the
downregulation of critical maturation factors such as MHC Class II molecules, and the costimulatory molecules CD80 and CD86 (199, 200). Thus, the activation of STAT3 in
tumor cells leads to and maintains the activation of STAT3 in MDSC. This was also shown
by Nefedova et al who demonstrated that it was Jak2 activation by tumor-derived soluble
factors, particularly M-CSF and to a lesser extent VEGF and IL-10 secreted by C3 and
CT26 cell lines, that lead to the hyperactivation of STAT3 in MDSC (201). IL-6, which
has anti-apoptotic and pro-angiogenic effects and can regulate the differentiation of
myeloid lineages and dendritic cells, has also been shown to activate STAT3 (202). In fact,
COX-2 overexpression in a human non-small cell lung carcinoma cell line caused
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increased STAT3 phosphorylation of both the tyrosine 705 and the serine 727 residues,
which was at least partly mediated by increased IL-6 expression, in these cells (203).
Phosphorylation of the tyrosine 705 residue of STAT3 results in its dimerization and
nuclear translocation, whereas phosphorylation of serine 727 is believed to cause the
subsequent activation of transcription (199). The effect of tumor-derived soluble factors on
STAT3 was confirmed in vivo by the fact that STAT3 DNA binding was significantly
increased in Gr1+ cells from CT-26 tumor bearing mice over that of control mice. One
mechanism by which STAT3 activation causes increased MDSC is by maintaining a high
rate of proliferation amongst these cells, however, further studies should be done to
investigate other potential surface molecules or soluble factors upregulated in these cells as
a result of STAT3 hyperactivation that may cause a positive feedback loop which initiates
the accumulation of more MDSC either by contact-dependent mechanisms or by actively
blocking the maturation of newly recruited hematopoietic cells, in addition to the increased
proliferation of existing MDSC (201).
MDSC can act in a variety of ways to cause suppression of anti-tumor immune
responses including, but not limited to, the secretion of soluble factors such as nitric oxide
and arginase I. There are also a variety of mechanisms by which the actions of MDSC may
be induced, regulated, or altered. Adding to the complexity are the means by which MDSC
may be induced and regulated. Several groups support the idea of activation of MDSC by
IFN-γ, which requires STAT1 to exert its effects. Meanwhile, recent data also supports an
important role for STAT3 in MDSC function. The data are therefore seemingly
contradictory given that the effects of STAT1 and STAT3 have been shown to contradict
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one another in terms of cellular proliferation as well as apoptosis (204-206). Suppressive
activity by these cells may therefore require a balancing act between opposing signals, or
alternatively, may require that one pathway be able to overcome another in order to
maintain a suppressive phenotype. The role that individual cytokines and chemokines play
in inducing and maintaining the suppressive phenotype of MDSC therefore is of critical
importance and warrants further investigation in varying tumor models, particularly as the
tumor microenvironment and subsequent cytokine profiles will vary in different tumor
models.
iv. MDSC and Soluble Factors: A correlation between tumor burden and increased
MDSC suggests that tumor-derived factors may cause accumulation of MDSC in cancer patients.
Pan et al found that abrogating the secretion of stem-cell factor, or blocking its receptor, ckit,
reduced MDSC expansion in mice bearing MCS26 colon carcinomas (207). In a transgenic model
of breast carcinoma which expresses the activated form of the neu oncogene, VEGF serum levels
were found to correlate with tumor multiplicity and progression, as well as accumulation of
MDSC (181). Continuous VEGF administration in mice has been shown to result in the inhibition
of dendritic cell development as well as an increase in Gr1+ cells and blocking VEGF in vitro
prevents the negative effects of tumor-derived soluble factors on dendritic cells (208). In humans,
high levels of VEGF in the plasma of patients with head and neck cancer, lung cancer, and breast
cancer were closely correlated with a decrease in functional dendritic cells in the peripheral blood
concurrent with an increase in circulating immature myeloid cells (209). GM-CSF has also been
linked to the accumulation of MDSC, both in murine models through GM-CSF transduced tumor
cells lines (167), and in humans, where a correlation was made between levels of circulating
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CD34+ myeloid cells in patients with head and neck carcinoma and the ability of the tumor cells
to secrete GM-CSF (210). Interestingly, a review compiling the results from multiple clinical trials
using GM-CSF has found that the dosage of GM-CSF was paramount, with lower doses (40-80µg)
eliciting an immune response, whereas higher doses showed no advantage (211). For example,
melanoma patients receiving peptide vaccination along with either 100 or 500µg doses of GMCSF for 6 days showed a decrease in the induction of specific T cell responses (212),which was
associated with increased levels of MDSC (213). In a mouse model of melanoma, increasing the
concentration of GM-CSF beyond the therapeutic dose of 300ng/106 cells/24 hours resulted in
decreased survival and increased CD11b+Gr1+ cells in multiple organs (214). However, there is
no direct evidence identifying the major tumor-derived soluble factors that could induce
generation of MDSC from bone marrow progenitor cells and/or support MDSC survival
v. Subsets of MDSC and the Ly6G Molecule: Given the broad range of
heterogeneous cells commonly defined as CD11b+Gr1+ MDSC, recent studies have
explored more specific and extensive phenotyping for these cells. These studies identify
different epitopes of the Gr1 molecule, namely Ly6G and Ly6C in distinguishing subsets
of MDSC that may be more prone to expansion and/or suppression in various tumor
models (171, 215, 216) . The Ly6 family members are cysteine-rich molecules that are
usually glycosyl phosphatidylinositol (GPI)-anchored to the cell surface and it has recently
been reported that expression of Ly6G correlates with a granulocytic phenotype, while
expression of Ly6C correlates with a monocytic phenotype (171, 215). It is important to
note, however that the subsets have not been identified in FVBN202 mice bearing neu+
(MMC) tumors. Given the discrepancies between subset phenotypes, expansion, and
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suppressive capabilities in various models, we believe it is important to investigate the
specific subsets of MDSC present in FVBN202 MMC tumor bearing animals.
Furthermore, given differences in the profiles of soluble factors secreted by various
tumors, we thought it imperative to identify the specific soluble factor(s) involved in the
generation and accumulation of MDSC, MDSC subsets, and the function of these subsets
in mice with neu+ tumors.
Although MDSC in mice are becoming fairly well-defined, MDSC phenotypes in
humans are still a topic of debate. MDSC were first broadly defined as being negative for
lineage markers indicative of mature lymphocytes or myeloid cells including CD3, CD19,
CD57 and CD14 (178, 209). These cells also consistently express the myeloid marker
CD33, and in tumor-bearing individuals this is often the predominant marker used for
MDSC isolation (178, 217, 218). These cells are also frequently identified as being HLADR negative or low (178, 218, 219). However, the presence of other markers has varied
significantly between different cancers, with MDSC in renal cell carcinoma patients being
described as CD15+ CD14- while identification of MDSC in patients with hepatocellular
carcinoma did not use CD15 as a marker, but found MDSC to be CD14+ and HLA-DR
negative or low(218, 219). MDSC in patients with breast cancer have been defined as
being lineage negative or low, HLA-DR- CD33+ and CD11b+ (178) The phenotypic
markers used to identify MDSC not only vary between different types of cancer, but also
between groups, as Rodriguez have recently identified a subtype of arginase I producing
MDSC in patients with renal cell carcinoma as expressing high levels of CD66b, CD11b,
and VEGFR1 while expressing low levels of CD62L and CD16 while Ko et al have
38

recently identified MDSC in renal cell carcinoma patients with the more conventional
CD33+ HLA-DR- CD15+ CD14- designation (218, 220). Since MDSC can use a variety of
mechanisms of suppress T cell activation and proliferation, and since MDSC, being
derived from multi-potent bone marrow cells and existing at various stages of
differentiation, are inherently heterogeneous, the identification of specific markers of
MDSC that correlate with specific function would offer the most advantageous means of
developing treatments to counteract the detrimental effects of these cells.
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Materials and Methods
Mouse Model:
Parental FVB (Jackson Laboratories) and FVBN202-transgenic female mice (Charles
Riveer Laboratories) were used between 6-10 weeks of age throughout these studies.
FVBN202 mice overexpress an unactivated rat neu transgene under the regulation of the
MMTV promoter (25). These mice develop pre-malignant mammary hyperplasia similar to
ductal carcinoma in situ (DCIS) prior to the development of spontaneous carcinoma (221).
These studies have been reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC) at Virginia Commonwealth University.
Tumor cell lines
The MMC cell line was established from a spontaneous tumor harvested from an
FVBN202 transgenic mouse as previously described (136). The antigen negative variant
(ANV) cell line was derived from a relapsed MMC tumor in the FVB strain as previously
described and is characterized by a loss of neu expression (136). Both cell lines were
maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). Mice were
challenged with 3-5X106 MMC cells intradermally (i.d.) where indicated.
Flow cytometry
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Flow cytometry analysis was performed as previously described by our group (136).
Briefly, splenocytes or bone marrow cells were homogenized into a single cell suspension
and red blood cells were lysed using 1X ACK Lysis buffer for 5 minutes. Cells were
washed and resuspended in 1XPBS with 2% FBS and 0.0065% sodium azide. Cells were
counted and 106 cells were aliquoted into each sample tube. Non-specific binding to Fc
receptors was blocked with anti-CD16/CD32 antibody (Biolegend) for 20 minutes on ice.
The following primary antibodies were purchased from Biolegend and used to stain the
surface antigen CD11b (FITC or PE, clone M1/70), Gr1 (PE or PE/Cy5, clone RB6-8C5),
CD4 (PE or PE/Cy5, clone GK1.5), CD8 (PE or PE/Cy5, clone 53-6.7), CD44 (PE, clone
IM7), CD62L (FITC, clone MEL-4), CD69 (FITC, clone H1.2F3), CD25 (FITC, clone
PC61), LFA-1 (FITC, clone 2D7), CD127 (FITC, clone SB/199),CD86 (PE, clone
YTS156.7.7), PD-L1 (PE, clone 105.9G2), I-Aq (Biotinylated, clone KH116), and CCR7
(PE/Cy5 clone 4B12). Primary antibodies purchased from BD Pharmingen were against
the surface antigens CD8a (FITC, clone 53-6.7), PD1 (PE, clone J43), H-2Dq/H-2Lq
(Biotinylated, clone KH117), and Ly6G (FITC, clone IA8). A purified mouse monoclonal
antibody against rat neu was purchased from Calbiochem (anti-c-ErbB2/c-Neu). All
primary antibodies were added at the manufacturer’s recommended concentration and
incubated on ice in the dark for 20 minutes. Cells were washed twice and secondary
antibody added where applicable (FITC anti-mouse IgG and PE/Cy5 Streptavidin, both
from e-bioscience) and incubated and washed as before. Cells were fixed with 1%
paraformaldehyde or were washed again in 1X Annexin V buffer (BD Pharmingen) and
the Annexin V staining protocol was followed for the addition of Annexin (FITC or PE)
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and/or propidium iodide (BD Pharmingen). Whole blood was obtained by retro-orbital
bleed. 50X106 whole blood cells were used per sample and were blocked and stained as
described above, and subsequent red blood cell lysis with 1X ACK. Samples were run on a
Beckman Coulter FC 500 and analyzed using Expo 32 or Summit version 4.3 software.
Cytotoxicity assay
Neu-specific effector lymphocytes were cultured with MMC at 10:1 and 20:1 E:T ratios in
complete medium (RPMI 1640 supplemented with 100 U/mL penicillin, 100 µg/mL
streptomycin, and 10% FBS) and 20 U/mL recombinant IL-2 (Preprotech) in 6 well culture
dishes. After 24 hours, 3 mL fresh media was added to the existing 3 mL of media. After
48 hours, cells were harvested and stained for neu (anti-c-ErbB2/c-Neu, Calbiochem),
Annexin V and PI according to the manufacturer’s protocol (BD Pharmingen). Flow
cytometry was used to analyze the viability of neu positive cells
IFN-γ ELISA
Effector lymphocytes were cultured in complete medium at a 10:1 ratio with irradiated
MMC cells or ANV cells (15,000 rad) or in medium alone for 24 hours. Supernatants were
collected and stored at -800C until used. IFN-γ was detected using a Mouse IFN-γ ELISA
Set (BD Pharmingen) according to the manufacturer’s protocol.
Expansion of effector T cells from FVB mice
FVB parental mice were inoculated with 5X106 MMC cells and splenocytes harvested
after 20-30 days. Splenocytes (106 cells/mL) were stimulated in complete medium
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containing 15% FBS with bryostatin-1 (5 nM) and ionomycin (1 µM) along with 80 U/mL
of IL-2 for 16 hours. Cells were washed 3 times and cultured at 106 cells/mL in complete
medium, Cells expanded in IL-2 alone received 40 U/mL of IL-2, while cells expanded in
IL-7 and IL-15 received 10ng/mL of each cytokine. Media was changed and fresh
cytokines added every other day for a total of 7 days. Cells expanded with alternating
gamma chain cytokines were cultured on day 1 with 10 ng/mL IL-7 and 10 ng/mL IL-15.
On day 2, 40 U/mL of IL-2 was added. Medium was changed on days 3 and 5, each time
culturing with 10 ng/mL each of IL-7 and IL-15 and cells were harvested for infusion on
day 7. All cytokines were from Peprotech. Aliquots of cells were taken at indicated time
points and samples were stained with combinations of the following antibodies and
assessed by flow cytometry: FITC-CD25, FITC-CD62L, FITC-CD8, PE-CD44, PE-CD69,
PE-CD8, PE/Cy5-CD4, PE/Cy5-CD8, PE/Cy5-CD69 from Biolegend and PE-CD25, PECD4 from BD Pharmingen. All antibodies were used at the manufacturer’s recommended
concentration.
Adoptive immunotherapy
For MDSC depletion and CD62L+/- AIT studies: twenty-four hours prior to AIT,
FVBN202 mice were treated with Cyclophosphamide (CYP, 100 mg/kg) by intraperitoneal
(i.p.) injection in order to induce lymphopenia. Mice were challenged i.d. with 3-5X106
MMC cells and then received 70X106 T cells by tail vein injection later the same day. For
AIT with Gemcitabine studies: CYP (100 mg/kg given i.p.) was given 48 hours prior to
adoptive transfer and 3X106 MMC cells were administered i.d. 24 hours prior to adoptive
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transfer. AIT was then administered on Day 0 as before. In all cases, tumor growth was
monitored by digital caliper and tumor volumes were calculated by: V(volume)=
[L(length) X W(width)2]/2. Blood was collected from the orbital sinus periodically to
determine antibody responses and levels of CD11b+Gr1+ cells by flow cytometry. At the
termination of the experiment, splenocytes were harvested and stained for activated T cells
or used in IFN-γ release assays, as indicated.
Depletion of MDSC in vivo
For AIT using IL-2 expanded T cells, LEAF purified monoclonal antibody against the
surface antigen Gr1 (clone RB6-8C5) was ordered from Biolegend and 300µg was
administered i.p. starting on day 6 after tumor challenge and continuing every 3 days for
the indicated time period. For AIT using alternating gamma chain cytokine expanded T
cells, anti-Gr1 antibody was purified from the RB6-8C5 hybridoma by collecting
supernatant from the CELLine CL 1000 flask (IBS Integra Biosciences) according to the
user manual. Supernatant was stored at -80οC until IgG purification using a MEPHypercell column. Where indicated, mice were injected i.p. with 250µg of purified antiGr1 antibody for a total of 6 times at 3-day intervals, followed by a final injection of
200µg on day 25. In all cases, depletion was verified by flow cytometry of the peripheral
blood for the CD11b and Gr1 surface markers. The dose of anti-Gr1 antibody was proven
completely effective in mice bearing MMC tumors that were 25mm3 or smaller.
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Gemcitabine Treatment
Mice receiving CYP and MMC challenge were given 75mg/kg of Gemcitabine i.p. on days
6, 11, and 16 after MMC challenge. Gemcitabine injections after re-challenge with MMC
were also 75mg/kg each and administered on the days indicated. Flow cytometry of
peripheral blood showed complete inhibition of MDSC after 2 injections.
Recombinant neu protein
The cDNAs coding for sub-domain II and sub-domain IV of the extracellular domain of rat
neu (ECDII:187-332 aa and ECDIV: 503-642 aa) were amplified by PCR using the
following primers: ECDII: 5’- GTGGAATTCACCAATCGTTCCCGGGCC-3’(sense) and
5’-CTCCTCGAGACAACGCTGTGTTCCGTC-3’(antisense); ECDIV: 5’ACGAAGCTTGAGGACTTGTGCGTCTCG-3’ (sense) and 5’AGTGGATCCTCGTTCATCCAGATCCAC-3’ (antisense). Restriction sites are
underlined. The resulting ECDII fragments were cleaved with EcoRI and XhoI restriction
enzymes and ligated into the EcoRI-XhoI fragment of pRSET B, while fragments from
ECDIV were cleaved with HindIII and BamHI restriction enzymes and ligated into the
HindIII-BamHI fragments of pRSET B to generate the constructs. The cDNA for full
length ECD (23-654 aa) was amplified using the primers 5’ATTGGTACCACCCAAGTGTGTACCGGCACA-3’ (sense) and 5’TGCAGAATTCGTCACCGGGCTGGCTCT-3’ (antisense) with underlined restriction
sited cleaved with KpnI and EcoRI. Resulting fragments were ligated into the KpnI-EcoRI
fragment of pRSET B. The recombinant proteins were expressed in E.coli using IPTG as
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an inductor of expression. Purification of His-tagged protein was performed under
denaturing conditions using the Guanidinium Lysis Buffer. After elution, proteins were
dialyzed in 20 mM Tris, pH 9.0 overnight (4°C). Dialyzed proteins were concentrated
using 10,000 MW cut-off columns (Viva Spin), filter-sterilized and protein concentration
was determined using Bradford assay.
ELISA
Blood was collected from mice via the retro-orbital sinus, allowed to sit at room
temperature for 10 minutes, and then spun for 10 minutes at 10,000 rpm. Serum was
harvested and stored at -80οC until used. For measuring the antibody response against neu,
96 well plates were coated with 10 µg/mL of full length ECD or 4 µg/mL of subdomain II
(ECDII) or subdomian IV (ECDIV) of ECD and incubated overnight at 4οC. Plates were
washed with PBS+0.05% Tween-20 and blocked with 2% skim milk for one hour. After
washing, 5-fold serial dilutions of the sera were added (100 µl/well) and incubated for 2
hours at room temperature. Horse-radish-peroxidase (HRP)-conjugated anti-mouse IgG1
from Caltag was added at a 1:2000 dilution for 1hour. Plates were washed and reactions
developed by adding 100 µl/well of the TMB Microwell peroxidase substrate (Kierkegaard
& Perry). The reaction was stopped with 2 M H2SO4, and the O.D. read at 450 nm. Mean
antibody titers were then calculated where indicated.
Isolation of MDSC in vitro
Gr1+ cells were isolated using an EasySep PE Selection kit from StemCell Technologies.
The protocol from the manufacturer was followed using splenocytes homogenized from
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MMC tumor-bearing FVBN202 mice labeled with 2 µg/mL of PE-Gr1 or PE-CD11b
antibody from Biolegend. Purity of Gr1+ cells was confirmed by flow cytometry and was
>90%.
In vitro proliferation assays and BrdU labeling
Splenocytes or sorted CD11b+Gr1+ cells were cultured in 96 well plates. For T cell
stimulation assays using splenocytes, plates were coated with 10 µg/mL of anti-CD3 (BD
Pharmingen) and were washed 3 times with PBS after 24 hours to remove any unbound
antibody. Cells were brought to a concentration of 1X106 cells/mL in complete media and
2X105 cells were added to each well. Cells were labeled by adding 10 µM BrdU (5-bromo2-deoxyuridine, BD Pharmingen) directly to the culture medium. Soluble anti-CD28
antibody (BD Pharmingen) was also added to wells for T cell stimulations at 1µg/mL. For
sorted CD11b+Gr1+ proliferation assays, 100ng/mL of GM-CSF (Peprotech) was added.
Cells were allowed to proliferate for 72 hours at 37οC, 5%CO2. Staining for BrdU was
done following the protocol from the manufacturer (BD Pharmingen) using the FITCconjugated anti-BrdU flow kit. Where indicated, MDSC were depleted from the splenocyte
populations using the PE Selection protocol above with either PE-Gr1 or PE-CD11b
antibodies (Biolegend). Isolated MDSC were added to wells where indicated at a 1:2
MDSC to splenocyte ratio either in the absence of a transwell insert, or in the top chamber
of a transwell insert with 8.0um pore (Corning Life Sciences). MDSC sorted on the basis
of Ly6G and Ly6C expression were added to splenocytes at a 1:2 MDSC to splenocytes
ratio where indicated and labeled with BrdU and stained as above.
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MMC-derived supernatants
MMC-derived conditioned medium was generated by culturing 10X106 MMC cells in
10mL of media for 24 hours in RPMI1640 supplemented with 10% FBS. Supernatant was
then removed and concentrated to a volume of 600µL using 10,000kDa molecular weight
cut-off columns (Viva Spin). Concentrated supernatant or control medium was then
injected i.d. into FVB mice (n=3, 200µL per mouse). Injections were repeated once per
day on 3 consecutive days; mice were then sacrificed on day 4 and spleens, blood, and
bone marrow were subjected to flow cytometry analysis of CD11b and Gr1 levels, as
described above.
Multiplex cytokine array of MMC supernatants
MMC cells were cultured at a concentration of 106 cells/mL for 24 hours. Supernatants
were harvested and sent to Allied Biotech, Inc. for Multiplex array analysis in a blinded
fashion.
Cell sorting
Bone marrow cells were harvested from naïve FVBN202 mice and stained for surface
expression of CD11b and Gr1 as described. Cells were kept in sterile RPMI1640 with 10%
FBS throughout. Cells were sorted on a Cytomation MoFlo by gating on the granulocyte
region and then sorting CD11b+Gr1+ and CD11b-Gr1- cells. MDSC subsets were triple
sorted from the spleens of tumor-bearing mice by first staining with anti-Ly6G, followed
by anti-CD11b and anti-Gr1. Cells were gated on CD11b+ cells from within the gated
granulocyte region, and subsequently sorting this population based on expression of Ly6G
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and Ly6C. After sorting, an aliquot of each population was restained for the CD11b and
Gr1 surface markers as well as either Annexin V or Ly6G (as previously) and run on the
Beckman Coulter FC 500. Purity of sorted cells was consistently greater than 96%.
Culture of sorted or whole bone marrow cells
Total bone marrow cells from one FVBN202 mouse were cultured in 10mL dishes with
100ng/mL GM-CSF (Peprotech). Cells were split on day 3 and fresh cytokine added. On
day 6 all floating and adherent cells were harvested and used for analysis by flow
cytometry. Sorted bone marrow populations (CD11b+Gr1+ and CD11b-Gr1-) were
cultured in 6 well plates (1-2X105 cells/well) for a total of 6 days. GM-CSF (100ng/mL),
VEGF (50ng/mL), or MCP-1 (50ng/mL) were added directly to the culture medium on day
0 (all cytokines/chemokines from Peprotech) or sorted cells were cultured in the bottom of
a 6 well dish with a 24mm Transwell insert with a 0.4µm pore on top (Corning Life
Sciences). To the Transwell insert, 0.1X105 MMC cells were added on day 0. On day 3,
cells were split and fresh cytokine was added. Transwell inserts were discarded on day 3
and a fresh insert with 0.1X105 MMC cells was added. On day 6, all cells were harvested
and aliquoted into tubes for analysis by flow cytometry.
Isolation of RNA and RT-PCR
RNA was isolated from magnetically selected or sorted cells via TRIzol reagent and was
treated with DNase. Total RNA (5µg) was used as a template for reverse transcription
(20µL total volume). cDNA was used in a PCR master mix containing 1X PCR buffer,,
1.5mM MgCl2, 2.5U Taq polymerase, and 1µM gene-specific primers: β-actin [5’49

GTGGGCCGCTCTAGGCACCAA-3’ (sense) and 5’CTCTTTGATGTCACGCACGATTTC-3’ (anti-sense)]; GAPDH [5’ACCACAGTCCATGCCATCAC-3’ (sense) and 5’-TCCACCACCCTGTTGCTGTA-3’
(anti-sense)]; TGF-β [5’-AAGACCATCGACATGGAGC-3’ (sense) and 5’TGTCACAAGAGCAGTGAGCG-3’ (anti-sense)]; IL-10 [5'ATGCAGGACTTTAAGGGTTACTTGGGTT-3' (sense) and 5'ATTTCGGAGAGAGGTACAAACGAGGTTT-3' (anti-sense)]; and IDO [5’GTACATCACCATGGCGTATG-3’ (sense) and 5’-GCTTTCGTCAAGTCTTCATTG-3’
(anti-sense)]. PCR conditions were as follows: TGF-β: 94ºC 5 min, 94ºC 1 min, 58ºC 1
min, 72ºC 2 min (42 cycles) followed by a 7 min extension at 72ºC; IL-10: 94ºC 5 min,
94ºC 30 s, 60ºC 30 s, 72ºC 1 min (35 cycles) followed by a 7 min extension at 72ºC; IDO:
94ºC 3 min, 94ºC 30 s, 60ºC 1 min, 72ºC 2 min (40 cycles) followed by a 5 min extension
at 72ºC. Amplified fragments were visualized by ethidium bromide staining of the agarose
gel and photography under UV light in Gel Doc 2000TM (BioRad). β-actin or GAPDH
were used as internal controls.
In vivo treatments with GM-CSF, IL-6, VEGF and MCP-1
Recombinant GM-CSF (500ng), GM-CSF+IL-6 (500ng and 120 units, respectively),
VEGF (1.5µg), or MCP-1 (2.5µg) or PBS was injected i.d. into FVB mice once per day for
3 consecutive days. Mice were sacrificed on day 4 and spleens, bone marrow, and blood
analyzed by flow cytometry for the expression of CD11b and Gr1. GM-CSF (2.5µg) was
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administered i.d. for 2 consecutive days and mice were sacrificed on day 3 for analysis of
the spleen, bone marrow, and blood, as above.
Tumor re-challenge studies:
FVBN202 mice that rejected initial MMC challenge were challenged again with 3-5X106
MMC cells (as indicated) i.d. on the contralateral side. Subsequent challenges were done
i.d. on the side contralateral to the first re-challenge.
Statistical Analyses:
Analyses were done using the students, one-tailed, unpaired T-Test. Significant values are
less than or equal to 0.05.
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Chapter 1
I. Study Rationale
Our lab has had a long standing interest in developing an effective means of
treating neu positive mammary tumors with adoptively transferred T cells. The FVBN202
mouse model is a clinically relevant means by which to investigate adoptive
immunotherapy (AIT) because of their immunological tolerance to the neu oncoprotein.
Despite this tolerance, it has previously been shown that FVBN202 mice develop atypical
hyperplasia of the mammary glands preceding spontaneous tumor development (25) and
that this increase in mammary epithelium provides a “danger signal” that results in
antibody responses against the neu ECD as well as IFN-γ secretion in response to the neu
protein in FVBN202 mice (221). This break in self tolerance, however, was not successful
in inhibiting subsequent tumor challenges with neu+ MMC cells, since we have shown that
both a non-self entity and a danger signal are needed to mount effective anti-tumor
immune responses in these mice (221). Additionally, atypical hyperplasia generated an
immunosuppressive microenvironment characterized by the increased expression of IL-10
and the IL-10 receptor, as well as suppressor of cytokine signaling (SOCS)-1 and SOCS-3
(222), which may lead to increased MDSC. We have observed elevated levels of MDSC in
FVBN202 mice during the premalignant stage and have correlated this with mammary
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hyperplasia and the failure of the pre-existing immune response to prevent spontaneous
tumor development (172, 221).
Previous attempts in our lab to use adoptively transferred T cells to cure neu+
tumors in FVBN202 mice have proven unsuccessful, despite the fact that T cells were
activated and expanded from FVB mice that had successfully rejected a neu+ tumor
challenge. Efforts to identify reasons why expanded T cells from FVB mice fail to reject
tumors in FVBN202 mice lead us to the observation that tumor-bearing FVBN202 mice
exhibited large increases in their granulocytes. Previous finding in a transgenic mouse
model similar to ours that expresses the activated rat neu oncogene have revealed that
increases in spontaneous mammary tumor development coincided with increases in
CD11b+Gr1+ MDSC (181), which lead us to determine the prevalence of these cells in our
model and in response to MMC tumor challenge. The increase in granulocytes previously
observed was, in fact, because of large increases in CD11b+Gr1+ cells. A subsequent
finding showed that the transfer of T cells into chronically inflamed environments
characterized by MDSC resulted in the suppression of those T cells via TCR
downregulation (182). The increase in MDSC in tumor-bearing FVBN202 mice, combined
with the fact that these mice also exhibit atypical hyperplasia of the mammary glands and
elevated MDSC prior to spontaneous mammary development led us to hypothesize that the
failure of adoptively transferred T cells in FVBN202 mice is a result of the presence of
elevated levels of MDSC. We further hypothesized that the attenuation of these cells or the
ability to overcome/circumvent these cells in vivo would allow adoptively transferred T
cells to mediate tumor regression.
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II. Results
FVBN202 Mice Bearing Neu Positive MMC Tumors Accumulate Large
Numbers of CD11b+Gr1+ Cells in their Spleens, Bone Marrow, and Blood
In the FVBN202 mouse model of spontaneously arising mammary carcinomas, we
have observed a large increase in cells of the granulocyte region in mice bearing neuexpressing MMC tumors. This increase in the overall percentage of granulocytes has been
observed in the spleen, bone marrow, and blood of these mice (Fig. 2). Representative dot
plots show that the granulocyte region in the spleens of tumor-bearing mice increases fourfold from 6% to 24%, while also increasing 2.7-fold from 22% to 59% in the bone marrow
and 4.3-fold from 7% to 30% in the blood (Fig. 2). Analysis of the absolute numbers of
granulocytes present in the spleen and the bone marrow of the tibias and femurs shows a
statistically significant increase in granulocytes in MMC tumor-bearing FVBN202 mice
over tumor-free FVBN202 mice (Fig. 3). In the spleen, tumor-bearing mice showed an
average of 6.56X107 granulocytes, whereas tumor-free mice had an average of 1.11X107
granulocytes (P=0.004, Fig. 3A). Similarly, the number of granulocytes present in the
bone marrow recovered from the tibias and femurs of tumor-bearing animals averaged
1.95X107 whereas the average number of granulocytes in the bone marrow recovered from
the tibias and femurs of tumor-free mice was 7.2X106 (P=0.003, Fig. 3B). There is no
such influx in cells of the lymphocyte region, as shown in Figure 4, the increased
granulocytes cause a significant decrease in the overall percentage of cells in the
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lymphocyte region of the spleen (39.2% in tumor-bearing vs. 59.3% in tumor free,
P=0.0377), although this is not accompanied by a significant decrease in the absolute
number of these cells (11.3X107 in tumor-bearing vs. 8.99X107 in tumor-free), indicating
that the presence of the granulocytes does not inhibit the persistence of cells in the
lymphocyte region in the periphery, but rather causes a shift in the lymphocyte to
granulocyte ratio (Fig. 4A,C). In the bone marrow, however, both the percentage and the
absolute number of cells in the lymphocyte region recovered from the tibias and femurs are
significantly decreased, with tumor-bearing mice having only 2.4X106 cells in the
lymphocyte region whereas tumor free-mice averaged 9.4X106 cells in the lymphocyte
region (Fig. 4D, P=0.001). Furthermore, the percentage of cells in the lymphocyte region
decreased by 4.9-fold, from 43.7% in tumor-free bone marrow, to 9% in tumor-bearing
bone marrow (Fig. 4B,D P=0.001). This indicates that the increased number of
granulocytes may out-compete cells in the lymphocyte region for available cytokines.
Further investigation of the granulocyte region in these mice reveals the presence of cells
staining double positive for the integrin CD11b and the glycosylphosphatidylinositollinked myeloid differentiation protein Gr1. We have found in every compartment in vivo,
that the presence of CD11b+Gr1+ cells increases in MMC tumor-bearing FVBN202 mice
as compared to naïve FVBN202 mice. We have found these cells to increase both as a
percentage from within the granulocyte region, as well as a percentage of the overall
spleen (Fig. 5). In the spleen, the total percentage of CD11b+Gr1+ cells increases from 3%
to 34% in naïve versus tumor-bearing animals and from 8% to 92% in comparing naïve
versus tumor-bearing granulocytes, respectively. A similar observation was made in the
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bone marrow, where the total percentage of CD11b+Gr1+ cells increased from 28% in
naïve mice to 76% in tumor-bearing mice and from 77% of the granulocytes in naïve mice
to 91% of the granulocytes in tumor-bearing mice (Fig. 5). Likewise, large increases in
double positive cells are observed in the blood (4% of the total peripheral blood
leukocytes, or PBL, in tumor-free versus 34% of the total PBL in tumor-bearing). The
percentage of double positive cells comprising the granulocyte region of the blood
increases to 84% in tumor-bearing mice from 54% found in tumor-free mice. A somewhat
smaller population of double positive cells (9%) was also observed at the tumor site itself
when MMC tumors were excised and subjected to flow cytometry (Fig. 5).
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Bryostatin-1/Ionomycin (B/I) stimulation followed by IL-2 expansion generates
highly activated neu-specific effector T cells
Since parental FVB mice recognize the rat neu protein as a foreign antigen and are
subsequently able to reject MMC, whereas FVBN202 mice often tolerate neu protein and
are unable to reject MMC, FVB mice were used as donors for AIT transfers into FVBN202
recipients in these studies. Since B/I selectively activates effector T cells regardless of their
antigen specificity (139), we sensitized FVB mice with MMC cells in order to increase the
pool of neu-specific effector T cells. We first compared the populations of CD4+ and
CD8+ T cells from these donors immediately after harvest, after activation with B/I, and
after a 7-day expansion with IL-2. Representative data from duplicate experiments are
presented in Figure 6. FVB donor splenocytes contained 35% and 9% CD4+ and CD8+ T
cells, respectively. These populations were similar immediately after B/I activation (27%
and 12% CD4+ and CD8+, respectively) but were greatly increased after 7 days of culture
with IL-2 (Fig. 6A, 55% and 32% CD4+ and CD8+, respectively). Furthermore, IL-2
treatment increased the absolute number of viable T cells by 9.5-fold over the cell number
that was cultured after B/I expansion (Fig. 6B). The Annexin V+ CD4+ population
remained nearly constant during ex vivo expansion, starting at 20% on day 0 compared
with 24% after B/I activation and cytokine treatment (Fig. 6C). The CD8+ T cells,
however, showed a marked increase in Annexin V+ staining from day 0 to day 7, with the
fresh splenocytes being only 13% Annexin V+, while the post-B/I and post-cytokine
values were 23% and 54%, respectively (Fig. 6C).
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In order to determine T cell phenotypes, flow cytometry was performed for
memory T cells (CD44+CD62L+) and effector T cells (CD44+CD62L-), as well as for the
activation marker CD25, and the very early activation marker CD69, in both the CD4+ and
CD8+ populations. As expected, B/I activation greatly increased the effector phenotype in
the CD4+ population from 16% to 79% and in the CD8+ population from 5% to 66%
while naïve (CD44-CD62L+) and memory (CD44+CD62L+) CD4+ and CD8+ T cells
were greatly decreased (Fig. 6D). After IL-2-induced expansion, both CD4+ and CD8+ T
cells showed a marked increase in CD44+CD62L+ memory T cells (74% and 58% in the
CD4+ and CD8+ compartments, respectively), while maintaining increased levels of
CD44+CD62L- effector T cells compared to pre-B/I treatment (16% vs. 22% and 5% vs.
38%, respectively). Additionally, the expression of CD25 on CD4+ and CD8+ T cells was
markedly increased to over 80% in both cases after B/I activation, and increased to over
90% in both populations after IL-2 expansion (Fig. 6E). The very early activation marker,
CD69, was greatly increased from about 0.1-0.2% in fresh splenocytes to 87% in CD4+ T
cells and 93% in CD8+ T cells after B/I activation. This value, however, dropped again
after a 7-day culture with IL-2, with 0.8% CD69 expression in CD4+ T cells, and, notably,
3% remaining in the CD8+ T cells. However, most cells retained a late effector phenotype
(CD44+CD69-) on day 7 (Fig. 6F).
To confirm anti-tumor efficacy in vitro, T cells derived from MMC sensitized FVB
mice prior to (Pre-B/I) or after a 7-day ex vivo expansion (Post-Cytokine) were co-cultured
with MMC target cells (E:T ratio of 10:1) for 48 hours followed by staining with
antibodies directed towards neu, Annexin V, and PI. Control wells were seeded with MMC
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in the absence of T cells (No Treatment) (Fig. 7). Gating on neu positive cells and
analyzing the percentages of Annexin V and PI positive cells allowed for the determination
of specific killing of neu positive MMC cells by T cells. The viability of MMC in the
absence of T cells was 86% (Annexin V and PI negative) while it dropped to 44% in the
presence of the freshly isolated T cells (Pre-B/I). Viability of MMC was further decreased
to 27% when cultured with B/I-activated, IL-2-expanded T cells (Post-Cytokine) (Fig. 7A)
Absolute numbers of viable MMC also reflect the increased anti-tumor efficacy of B/Iactivated, IL-2-expanded T cells compared to freshly isolated T cells (P=0.026) (Fig. 7B).
No killing was detected against the neu negative tumor variant, as determined by trypan
blue exclusion (data not shown).
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In vivo Depletion of MDSC is Required for the Efficacy of IL-2 Expanded Adoptively
Transferred T cells
We next wanted to determine if transfer of these IL-2 expanded, highly cytotoxic T
cells could result in tumor inhibition in FVBN202 mice. To test this, FVB mice were
inoculated i.d. with 5X106 MMC cells. Spleens were harvested after the mice had fully
rejected the tumors and cells were activated with B/I and subsequently expanded in the
presence of IL-2 as before. Twenty-four hours prior to the transfer of expanded T cells,
FVBN202 mice were treated with 100 mg/kg of cyclophosphamide (CYP) in order to
create a lymphopenic environment, which has been shown to be beneficial for the
expansion of transferred T cells (128, 129). After 24 hours, mice were challenged i.d. with
5X106 MMC cells and 70X106 expanded T cells were transferred into each FVBN202
mouse that was to receive adoptive transfer via tail vein injection. Since FVBN202 mice
bearing MMC tumors exhibit a pronounced accumulation of MDSC in vivo, (Fig. 5), we
hypothesized that adoptively transferred T cells may be prevented from working in such an
immunosuppressive environment. Therefore, one group of mice that received MMC
challenge and adoptive transfer of T cells also received i.p. injections of an anti-Gr1
antibody (300µg per injection starting on day 6 and every three days thereafter for a total
of 4 injections). Tumor growth measurements in Figure 8 show that the tumor volumes did
not differ significantly between the control group (CYP +MMC) and the group that also
received adoptively transferred T cells. Strikingly, there was significant tumor inhibition in
the group treated with anti-Gr1 antibody compared to the control group at weeks 6
(P=0.018) and 7 (P=0.032), with the mice receiving Gr1 depletions having an average
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tumor volume of only 26.9mm3 on week 6 as compared to 588.9 mm3 in the control group,
and 32.7 mm3 on week 7 as compared to 1121.4 mm3 in the control group. Therefore,
adoptive transfer of anti-neu T cells expanded with IL-2 and highly effective in vitro is not
effective unless combine with the depletion of endogenous MDSC. To eliminate the
possibility that the depletion of endogenous MDSC may, on its own, result in tumor
rejection by these mice by allowing them to break tolerance to MMC tumors, FVBN202
mice were inoculated with 5X106 MMC cells intradermally (i.d.) and were treated with
anti-Gr1 antibody starting 6 days after tumor inoculation and continuing every three days
for a total of 3 injections. As shown in Figure 9, all mice in this group had large tumors by
week 3, therefore confirming that MDSC depletion alone cannot cause the rejection of
tumors to which an individual is tolerant.
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The Efficacy of in vivo MDSC depletions can be directly correlated with the
effectiveness of the anti-tumor response
In order to make sure that the anti-Gr1 antibody injections were effectively
removing MDSC from MMC-challenged FVBN202 mice in vivo, flow cytometry of the
peripheral blood was done regularly. High levels of CD11b+Gr1+ cells were observed in
control mice and mice receiving adoptive transfer without MDSC depletion. As expected,
these levels were consistent with those seen previously in tumor bearing mice
(representative plots from tumor bearing mice shown in Fig. 5). However, flow cytometry
of the peripheral blood from mice receiving anti-Gr1 antibody on day 21 showed that this
depletion was almost completely effective in 2 out of three mice (Fig. 10A), with the
granulocyte regions almost completely ablated in both cases (1% remaining in mouse 1
and 2% remaining in mouse 2). In contrast, mouse 3 was less responsive to treatment with
anti-Gr1 antibody and maintained 14% granulocytes on day 21 (Fig. 10A). The level of
surface expression of the Gr1 molecule is depicted in Fig. 10B. The mean fluorescent
intensity (MFI) of the Gr1 molecule in mouse 3 is 102.6, whereas the MFI of the Gr1
molecule in mouse 1 and mouse 2 are 1.4 and 1.5, respectively. Interestingly, the efficacy
of Gr1 depletions seems to correlate positively with tumor rejection, with the tumor
volumes of mouse 1 and mouse 2 on day 21 being 8.9mm3 and 0 mm3, respectively,
whereas the tumor volume of mouse 3 on day 21 was 283.19mm3 (Fig. 10B). This trend is
seen in Figure 11, where mouse 1 and mouse both eventually rejected tumors, while mouse
3 had a tumor measuring 545.5mm3 by the end of week 4. Not only did the depletion of
MDSC in vivo significantly aid in tumor rejection, but it also resulted in an antibody
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response against the extracellular domain (ECD) of neu. Figure 12 shows that only mice
receiving adoptive transfer along with MDSC depletion displayed an antibody response,
whereas control mice and mice receiving adoptive transfer alone showed no antibody
response, as is typical in this tolerant model. Interestingly, the strength of anti-neu
antibody responses seems to also correlate with the efficacy of MDSC depletion. As shown
in Figure 13, mouse 1 and mouse 2, which showed the highest degree of depletion, had
noticeably stronger antibody responses than mouse 3, which was not efficiently depleted of
MDSC in vivo.
In order to determine if the reason for tumor regression in mice receiving adoptive
transfer of neu specific T cells with along with MDSC depletion was a greater persistence
of activated T cells, mice were sacrificed 47-51 days after tumor inoculation and their
spleens were analyzed by flow cytometry for the presence of activated T cells. Staining for
CD25 expression on CD4+ and CD8+ T cells showed that in both cases (CD4 and CD8),
mice receiving adoptive transfer alone had the highest percentage of activated T cells
(9.2% CD25+CD4+ T cells and 4.1% CD25+CD8+ T cells). In contrast, control mice and
mice receiving adoptive transfer along with MDSC depletion had similarly low levels of
CD25+ T cells (4.6% CD25+CD4+ in control mice and 5.3% CD25+CD4+ in mice
receiving MDSC depletion; 1.8% CD25+CD8+ in control mice and 1.7% CD25+CD8+ in
mice receiving MDSC depletion, Fig. 14). Therefore, the presence of activated T cells
alone is not sufficient for the rejection of MMC tumors, and in the absence of suppressive
MDSC, mice can remain tumor free even in the absence of high levels of activated T cells.
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T Cell Expansion Using Alternating Gamma Chain Cytokines Generates More Potent
Anti-Tumor T cells with Greater Levels of Expansion.
In an effort to generate T cells that may be more potent in the face of high levels of
MDSC, we sought to devise a superior method of T cell expansion. We had previously
attempted T cell expansion in the presence of IL-7 and IL-15, and noticed that although
viability was improved over that seen in expansion with IL-2 alone (10% Annexin V+
CD4+ T cells after IL-7/15 as compared to 24% Annexin V+ CD4+ T cells after IL-2
expansion and 13% Annexin V+ CD8+ T cells after IL-7/15 expansion as compared to
54% Annexin V+ CD8+ T cells after IL-2 expansion), expansion levels were not great
enough to generate enough T cells for injection on Day 7 (Figs. 6C,15B, 16). Also
noteworthy is a severe reduction in the levels of activated T cells on day 7 after expansion
with IL-7/15 (45% CD25+CD4+ and 9% CD25+CD8+, Fig. 15D) as compared to
expansion with IL-2 (99% CD25+CD4+ and 92% CD25+CD8+, Fig. 6E). In order to
optimize the benefits of both types of expansion, we decided to use treatment with IL-7/15
(10ng/ml) on days 1, 3, and 5, with a one time “pulse” of IL-2 (40 U/ml) on day 2. We
refer to this as “alternating gamma chain cytokine” treatment. This type of expansion
increased the percentage of CD8+ T cells (47% in Fig. 15A vs. 32% in Fig. 6A) and
showed an 11-fold expansion in overall viable T cell number as compared to a 9.5-fold
expansion with IL-2 treatment (Fig. 16). Alternating gamma chain cytokines also greatly
enhanced the viability of T cells on day 7 of culture when compared to expansion with IL2 alone (Fig. 15B shows 13% Annexin V+ CD4+ T cells and 11% Annexin V+ CD8+ T
cells compared with 24% Annexin V+ CD4+ T cells and 54% Annexin V+ CD8+ T cells
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in Fig. 6C). Of note, there were more CD44+CD62L- effector T cells in both the CD4+
and CD8+ compartments after expansion using alternating gamma chain cytokines as
compared to expansion with IL-2 alone (33% vs. 22% CD4+ T cells and 48% vs. 38%
CD8+ T cells, Figs. 15C and 6D). Like expansion in IL-2 alone, expansion with alternating
gamma chain cytokines generated only CD62Llow effector memory T cells whereas
expansion with IL-7 and IL-15, generated a population of CD62Lhigh central memory T
cells. It has previously been shown that the adoptive transfer of B/I activated CD62Llow
cells was able to mediate complete regression of the 4T07 murine mammary tumor while
adoptive transfer of the CD62Lhigh fraction resulted in only a 17% regression of tumors
(137). While the percentage of CD4+CD25+ T cells and CD4+CD69+ T cells remained
unchanged, CD8+CD25+ T cells decreased from 92% to 69% and CD8+CD69+ T cells
decreased from 3% to 0.3% in comparing the IL-2-expanded T cells with alternating
cytokine-expanded T cells, respectively (Figs. 6 E,F and 15 D,E). Although levels of
CD25+ CD8+ T cells dropped in cells expanded with alternating cytokines as compared to
cells expanded in IL-2 alone, levels of activated T cells were greatly increased in
alternating cytokine-expanded cells as compared to IL-7/15 expanded cells (Fig. 15 D).
Expression of the IL-7Rα (CD127), necessary for IL-7 to exert its effects in maintaining
pools of memory T cells (223, 224), was measured after each type of cytokine expansion,
and also on day 3 of alternating gamma chain cytokine expansion. CD127 is expressed on
only 9% of CD4+ cells and 15% of CD8+ cells after expansion in IL-2 (Fig 17). However,
after expansion in IL-7/15, expression of CD127 is negligible (0.08% on CD4+ cells and
0.03% on CD8+ cells) indicating the inability of these cells to expand is because of the
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downregulation of at least one of the necessary cytokine receptors. Interestingly, on day 3
of the alternating gamma chain cytokine expansion regimen, expression of CD127 is
present on only 2% of CD4+ cells and 3% of CD8+ cells. However, these levels rise and
are greatly elevated by day 7, with 21% of CD4+ cells and 18% of CD8+ cells expressing
CD127 (Fig. 17). This is interesting since IL-2 has been shown to promote expression of
CD127; however IL-2 expanded cells, and alternating cytokine expanded cells after IL-2
pulse, show low levels of CD127, which increase without additional exogenous IL-2 (223).
However, it has been shown in humans that CD8+ T cells with low IL-7Rα expression
have increased levels of the IL-2/IL-15Rβ chain and respond to IL-15 with increased
proliferation (225). Therefore the low expression of CD127 in Figure 17 could be
indicative of cells with increased responsiveness to IL-15, which has been shown to be
important for the maintenance and function of memory CD8+ T cells (148). Since the
CD127 receptor is necessary for the homeostatic expansion of cells in vivo and for
maintenance, particularly of CD8+ memory T cells, it is imperative to expand the cells in
such a way that facilitates the continued expression of this receptor, as opposed to
expansion methods that may cause receptor downregulation by negative feedback
mechanisms (226). Another concern in the generation of T cells in vitro has been the
induction of regulatory T cells, particularly in response to IL-2 expansion. Figure 18 shows
flow cytometry staining for regulatory T cells both before and after B/I stimulation and
after each type of cytokine expansion. Plots are gated on CD4+CD25+ cells so as to
discern the percentage of FoxP3+ cells amongst activated CD4+ cells. Very low expression
of FoxP3 before stimulation with B/I indicates that 5.1% of CD4+CD25+ T cells also
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express FoxP3. This number drops to 1.54% after activation (1.54%), but increases
substantially after IL-2 expansion to 10.03%. Conversely, Tregs constituted only 4.08% of
activated T cells after expansion in IL-7/15, whereas expansion in alternating gamma chain
cytokines resulted in 12.0% of CD4+CD25+ cells containing FoxP3. Given the fact that
Figure 16 shows that T cell expansion in vitro was the greatest using alternating gamma
chain cytokines (which had the highest percentage of Foxp3+ cells), and that expansion
using IL-7/15 produced the smallest number of cells despite having the lowest percentage
of Foxp3+ cells, we have determined that CD4+CD25+FoxP3+ cells do not necessarily
constitute a regulatory phenotype in our model and are not capable of inhibiting cytokinedriven expansion of activated T cells. Additionally, transferred CD4+CD25+FoxP3+ T
cells did not inhibit effective anti-tumor responses in the absence of MDSC (Fig. 8). The
cytotoxic effect of T cells against MMC, in vitro, was also greater using alternating gamma
chain cytokines compared to that using IL-2 (14% viable MMC in Fig. 19A vs. 27% viable
MMC in Fig. 7A). Absolute numbers of viable MMC also reflects a slight increase in antitumor efficacy of B/I-activated, alternating cytokine-expanded T cells compared to IL-2expanded T cells (0.4x106 in Fig. 19B vs. 0.5x106 in Fig. 7B). Cells expanded in
alternating cytokines also exhibited a strong IFN-γ response when stimulated with
irradiated neu positive MMC (15000 rad), but not with neu-negative ANV cells (P=0.006),
thus confirming the neu specificity of these cells (Fig. 19C).

99

100

101

102

103

Adoptive Transfer of T Cell Subsets Expanded with Alternating Gamma Chain
Cytokines Inhibits Tumor Growth when Combined with In Vivo MDSC Depletion
We hypothesized that a more robust and highly viable population of anti-tumor T
cells expanded in vitro may be able to overcome inhibition by MDSC in tumor-bearing
FVBN202 mice. To test this hypothesis, FVB mice were inoculated with MMC (5x106
cells/mouse) and donor splenocytes were prepared 21 days after tumor challenge, when
animals had rejected MMC. T cells were activated with B/I and were then expanded in the
presence of alternating gamma chain cytokines as described above (Fig. 15). All FVBN202
mice were treated with i.p. injection of CYP (100 mg/kg) in order to create lymphopenia.
Flow cytometry of the peripheral blood before, and 24 hours after, CYP injection, showed
no effect of this drug on the CD11b+Gr1+ population. FVBN202 mice were challenged
with MMC (3X106) 24 hours after CYP treatment. MMC-challenged mice then received
no treatment, the alternating gamma chain cytokine-expanded T cells alone (i.v. injection
of 70x106 lymphocytes/mouse), or AIT combined with the depletion of MDSC by i.p.
injection of 250µg of anti-Gr1 antibody starting 6 days after tumor inoculation and
continuing every 3 days for a total of 6 injections, followed by a final injection of 200µg
on day 25. Figure 20 shows that AIT alone offered no protection against MMC tumors.
However, the in vivo depletion of MDSC improved the efficacy of AIT and caused
significant tumor inhibition (P=0.001 for week 4 and P= 0.0003 for week 5). The efficacy
of MDSC depletion was above 98% nine days after tumor challenge (data not shown).
Flow cytometry analysis of blood collected on day 9 from mice receiving MDSC depletion
showed a complete lack of granulocytes, as compared to blood from the same mice taken
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on day 35, 10 days after the last injection of anti-Gr1 antibody (Fig. 21A). Quantitative
analysis of CD11bGr1 levels from each group 24 days after the tumor challenge showed
that the group receiving Gr1 depletions had a significantly reduced percentage of MDSC
(P=0.044 as compared to mice receiving no treatment and P=0.023 as compared to mice
receiving AIT alone, Fig. 21B). However, it is noteworthy that 38% of the granulocytes
were still CD11b+Gr1+ at this time, a problem that we believe to be caused by slightly
increased tumor burden in these mice leading to increased recruitment of MDSC (Fig. 20).
Despite the residual MDSC in these mice, we were not able to increase the frequency of
antibody injections because of toxicity of the antibody (data not shown).
Since the ECD-specific antibody response is also involved in the protection against
neu positive mammary tumors (87, 227-229), we sought to determine whether FVBN202
mice mounted an antibody responses against ECD following AIT. Serum taken from mice
receiving adoptive transfer of T cells expanded with alternating gamma chain cytokines
with and without the in vivo depletion of MDSC, along with control mice, indicated that
only mice that were depleted of Gr1+ cells were able to mount an antibody response
against the neu ECD (P=0.006) (Fig. 22).
In order to determine if the depletion of MDSC resulted in an increased frequency of
activated or effector T cells, mice were sacrificed 28 days after tumor inoculation and
splenocytes were analyzed for the expression of CD44, CD62L, CD25, and CD69 on both
CD4+ and CD8+ T cells. As shown in Figure 23A, the percentage of activated,
CD4+CD25+ T cells was approximately equal in mice receiving AIT alone versus mice
receiving AIT with MDSC depletion (10.9% vs 10.0%). Likewise, the percentage of naïve
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(CD62L+CD44-), effector memory (CD62LlowCD44+), and effector (CD62L-CD44+)
CD4+ T cells were similar between the two groups (Fig. 23B). However, in the CD8+
population, it is noteworthy that the levels of naïve T cells were actually higher in the
group receiving MDSC depletion (35.5% in AIT alone mice vs. 42.6% in MDSC depleted
mice), while levels of effector memory CD8+ T cells were reduced (49.4% central memory
in the AIT alone group vs. 35.5% in the MDSC depleted group). Levels of CD8+CD44+ T
cells were similar between the 2 groups (12.1% in the AIT alone group vs. 10.4% in the
MDSC depleted group, Fig. 23B). We also wanted to look for expression of the early
activation marker, CD69. As shown in Figure 23C, CD69 expression on CD4+ and on
CD8+ cells from both groups is similar. To determine if the overall proportion of
lymphocytes in animals receiving MDSC depletion may be increased, therefore aiding the
tumor rejection, we analyzed the percentages of CD4+ and CD8+ cells from the total
spleens of mice from each group, and the percentages of these cells specifically from the
lymphocyte region. No significant differences were found in the total percentages of CD4+
(black bars) or CD8+ (gray bars) cells between the three groups (Fig 24A). Likewise,
gating on the lymphocyte region and analyzing the percentages of CD4+ and CD8+ T cells
also provided no significant differences between the groups (Fig. 24B).
In an effort to devise an AIT treatment that could avoid the use of MDSC-depleting
antibody in vivo, we next wanted to determine of the migration patterns of adoptively
transferred T cells would have an impact on their effectiveness. Since we have previously
observed very high numbers of MDSC in the spleens of tumor bearing mice, while
observing very few at the tumor site (Fig. 5), we hypothesized that transferring CD62L114
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effector cells would allow them to go directly to the tumor site without first homing to the
immunosuppressive environment of the secondary lymphoid organs. In order to test this,
FVB mice were inoculated with MMC cells as before and were sacrificed 22 days later.
Spleens were removed and cells were stimulated with B/I and expanded in alternating
gamma chain cytokines as previously. FVBN202 mice were pre-treated 24 hours in
advance with CYP as before. On day 7 of the donor cell expansion, FVBN202 recipient
mice were divided into 3 groups, those receiving no treatment, those receiving the adoptive
transfer of CD62L+ cells, and those receiving the adoptive transfer of CD62L- cells. All
recipient mice were challenged with 3X106 MMC. Donor T cells were then stained with a
PE labeled anti-mouse CD62L antibody and were subjected to positive magnetic bead
selection of PE-labeled cells. Both the positively selected PE-labeled cells (CD62L+
fraction) and the non-PE labeled cells (CD62L- fraction) were collected; 70X106 CD62L+
or CD62L- cells were injected i.v. into mice receiving treatment. Figure 25A shows that
the three groups of mice, those receiving no treatment (squares), those receiving CD62L+
T cells (triangles), and those receiving CD62L- T cells (diamonds) exhibited extremely
similar rates of tumor growth. Serum was collected from mice on day 21 and tested for
antibody responses against neu ECD. Figure 25B shows that, in the absence of any MDSC
depletion, none of the groups showed an antibody response against neu, regardless of the
type of T cell transfer.
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Gemcitabine is an Effective Inhibitor of MDSC in Tumor Bearing FVBN202 and
Allows for the Complete Rejection of Neu Positive Mammary Tumors.
Since Gemcitabine has been reported to decrease MDSC in vivo without affecting
lymphocyte populations (70), we hypothesized that combining Gemcitabine treatment with
AIT may result in a more clinically relevant means of inhibiting this population in vivo,
and would therefore result in the success of AIT treatments. T cells were therefore
harvested from FVB donors and were stimulated and expanded in alternating gamma chain
cytokines as previously. All FVBN202 recipient mice were treated 48 hour prior to AIT
transfer with CYP (100mg/kg). Twenty-four hours prior to transfer, recipient FVBN202
mice were challenged with 3X106 MMC cells. On the day of adoptive transfer, FVBN202
mice were divided into four groups: mice receiving no treatment (CYP), mice receiving
AIT only (AIT), mice receiving Gemcitabine only (Gem), and mice receiving AIT transfer
along with Gemcitabine treatment (Gem+AIT). 70X106 expanded donor T cells were
transferred i.v. into recipient mice receiving AIT. Gemcitabine treatment was administered
i.p. at a dose of 75mg/kg per mouse on days 6, 11, and 16. To test the efficacy of
Gemcitabine in diminishing MDSC in vivo in tumor bearing mice, blood was drawn at
several time points and analyzed by flow cytometry for the presence of CD11b+Gr1+ cells.
By day 8 after tumor inoculation, mice not receiving Gemcitabine had increased MDSC
levels from 0.885% of the total blood on day 0 to 2.55% of the total blood on day 8 (Fig
26A). In contrast, mice receiving Gemcitabine, either alone or with AIT, showed more
modest increases of MDSC on day 8. The Gemcitabine alone group increased total levels
of MDSC from 0.39% on day 0 to 0.87% on day 8 and the Gemcitabine with AIT group
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increased levels of MDSC from 0.62% on day 0 to 1.23% on day 8, thus showing a stunted
accumulation on day 8 in mice that had received one injection of Gemcitabine at that time
(Fig 26A). By day 14, after 2 Gemcitabine injections, there was a significant decrease in
MDSC in both groups of mice receiving Gemcitabine treatment (Fig 26B). Untreated mice
had an average of 15.5% MDSC out of their total peripheral blood leukocytes, whereas
mice treated with Gemcitabine alone had only 2.61% MDSC (P=0.026 compared to
untreated) and mice given Gemcitabine with AIT had 0.33% MDSC (P=0.017 compared to
untreated). Mice receiving both Gemcitabine and AIT also showed significantly reduced
levels of MDSC when compared to mice receiving Gemcitabine alone (P=0.0004, Fig.
25B), presumably because of the decreased tumor burden that was becoming apparent by
day 14 in mice treated with Gemcitabine and AIT (Fig 27A). Figure 27A shows that by
day 18, mice receiving Gemcitabine injections and AIT exhibited significantly reduced
tumor volumes (P=0.004 when compared to CYP control mice, P=0.009 when compared to
AIT mice, and P=0.024 when compared to Gem mice). The differences in tumor volumes
were also significantly different between the Gem+AIT group and all other groups on days
21 and 24. Additionally, by day 24, mice receiving Gemcitabine alone also exhibited a
significant reduction in tumor volume as compared to mice receiving AIT alone (P=0.037).
By day 28, all five mice treated with Gem+AIT were completely tumor free. In addition to
tumor volumes, we thought it important to monitor weights, to evaluate if the treatment
was well tolerated. Figure 27B shows that, by week 4, the weights of mice in the
Gemcitabine alone group had dropped significantly compared to those in the Gem+AIT
group (P=0.015). It is also noteworthy that during the fourth week, mice treated with
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Gemcitabine alone had significantly reduced weights as compared to mice receiving AIT
as well (P=0.012). Weeks 5 and 6 showed a continued significant reduction in the weights
of mice treated with Gemcitabine alone as compared to mice receiving Gem+AIT
(P=0.022 in week 5 and 0.005 in week 6). The survival of all four groups of mice is shown
is Figure 27C, with the CYP alone control group reaching 0% survival by the end of week
5, and the Gemcitabine alone and AIT alone groups reaching 0% survival by the end of
week 6. It is noteworthy that although the use of Gemcitabine alone offered some
reduction in tumor volume, the significant reductions in weight coupled with a lack of
increased survival indicates that despite the role of Gemcitabine as an anti-tumor drug, this
drug alone is not sufficient. However, the combination of Gemcitabine with AIT results in
potent anti-tumor activity.
Since the depletion of MDSC causes a restoration of antibody responses against the
ECD of neu in tolerant mice, we wanted to determine if MDSC inhibition by Gemcitabine
had the same effect. Serum was taken from FVBN202 mice that received either no
treatment (CYP), AIT alone (AIT), Gemcitabine alone (Gem), or Gemcitabine and AIT
(Gem+AIT). Serum was tested for antibody responses against ECDII and ECDIV of the
extracellular domain of neu. Optical density readings showed that only the group that
received both Gemcitabine and AIT generated an antibody response against ECDII (Fig.
28A). Analysis of antibody responses from individual mice within the Gem+AIT group
showed a large variation that correlated with the amount of time it took individual mice to
fully reject MMC tumors. The mouse with the highest antibody response, mouse 1, (O.D.
of 3.32 at a 1:20 dilution) took 27 days to fully reject the tumor, and therefore still had an
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active immune response at the time serum was taken. Mouse 3, which had an O.D. of 1.5
at a 1:20 dilution took 23 days to reject the tumor, whereas mouse 4, with an O.D. of 0.82,
took 17 days to reject the tumor, and the 2 mice with the lowest antibody responses (mouse
2 and mouse 5) both took only 8 days to fully reject their MMC tumors. Therefore, the
immune responses of some of these mice had fully contracted by the time that serum was
taken, thus accounting for the large amount of variation in antibody responses (Fig. 28
A,B). Conversely, no substantial antibody response was seen towards ECDIV of the neu
ECD (Fig 28 C). This correlates with a previous finding in the lab that after challenge with
MMC tumors, FVB mice mount an antibody response consisting almost entirely of
antibody against ECDII (Fig. 29). These mice successfully reject MMC tumors without
responses against ECDIV. Therefore antibody responses against ECDII are protective
against MMC tumors, while antibody responses against ECDIV are not needed.
Since 100% of the mice that were treated with both Gemcitabine and AIT fully
rejected their MMC tumors, we wanted to determine if these mice could rejected a second
challenge with MMC without adoptively transferred T cells. Mice were therefore
challenged on the contralateral side with 3X106 MMC cells 74 days after the initial MMC
challenge. Mice were treated on days 6 and 11 with 75mg/kg of Gemcitabine. As indicated
in Figure 30, MMC tumors never reached palpable status and were not able to be
measured. By day 16 all mice were completely tumor free. Serum was taken from all 5
mice 12 days after the re-challenge and tested for antibody responses against ECDII of
neu. As shown in Figure 31A, mouse 1 and mouse 3 exhibited strong antibody responses
against ECDII, whereas mouse 2 and mouse 4 had weak antibody responses and mouse 5
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had a negligible antibody response. Based on these data, the 2 mice with the lowest
antibody responses (mouse 4 and mouse 5) were sacrificed 18 days after the MMC rechallenge. Splenocytes from these mice were cultured for 24 hours either alone (-) or in the
presence of irradiated MMC cells (+) at an E:T ration of 10:1. Supernatants were collected
and assayed for IFN-γ by ELISA. Figure 31B shows very low or undetectable levels of
IFN-γ in wells containing media alone, MMC alone, or splenocytes alone that were taken
from a naïve FVBN202 mouse or from either of the mice that had rejected MMC challenge
(Re-challenged AIT). While the addition of MMC did not cause a significant increase in
IFN-γ secretion by naïve splenocytes, a large increase in IFN-γ by splenocytes taken from
mice that had rejected 2 MMC challenges was observed. The baseline level of IFN-γ
secretion from the splenocytes of each mouse was subtracted from the level of IFN-γ
secretion in the presence of MMC. After this normalization, it was determined that IFN-γ
secretion by splenocytes from both re-challenged AIT mice in the presence of MMC was
significantly higher (P<0.001) than that seen by splenocytes from the naïve control in the
presence of MMC (Fig. 31B). To determine if the 3 remaining mice could reject an MMC
challenge without Gemcitabine, these mice were challenged for a third time with 3X106
MMC cells 18 days after the second challenge (challenges are indicated by the black
arrows in Fig. 30). This was now day 0 of the third challenge. On day 7 of the third
challenge, 2 mice (mouse 1 and mouse 3) were tumor free and one mouse (mouse 2) had a
tumor size of 21.1mm3. By 14 days after the third challenge, this tumor had shrunk to
10.4mm3 and by day 21 was no longer visible (Fig. 30). To determine if these mice could
mount an antibody response without the aid of Gemcitabine, serum was taken sixteen days
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after the third MMC challenge. An ELISA against ECDII of neu showed that all three mice
indeed had an antibody response (Fig. 32). It is interesting to note, however, that the mouse
with the lowest antibody response (mouse 2 indicated by squares) is the same mouse that
grew a small tumor after the third challenge (mouse 2 indicated by squares in Fig. 30).
Therefore, AIT with Gemcitabine treatment not only causes full rejection of initial tumors,
but also causes the rejection of subsequent MMC challenges, and creates long-lasting
immunological memory capable of rejecting neu+ tumors even in the absence of
Gemcitabine.
Long term follow-up of the 3 remaining mice treated with Gemcitabine and AIT
revealed that by day 148 one mouse (mouse 3) had a tumor of 1076mm3. Isolation of the
tumor and staining for neu expression showed this tumor to be of the ANV relapsed
phenotype (Fig. 33, left panel vs. right panel) with a small amount of residual neu
expression but dramatic downregulation from the highly neu+ MMC cells (Fig. 33 left vs.
center).
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III. Conclusions and Significance
These studies have found that the adoptive transfer of B/I activated and IL-2
expanded T cells results in statistically significant tumor inhibition and increase in
antibody response in FVBN202 mice only when their Gr1+ cells are depleted in vivo.
Importantly, the depletion of MDSC was not effective in the absence of transferred T cells
showed no benefit, showing that tumor rejection requires both the presence of highly
effective anti-tumor T cells and the absence of MDSC. Furthermore, a correlation exists
between the efficacy of the Gr1+ depletions and the observed anti-tumor response. Efforts
to generate T cells with greater cytotoxicity towards MMC were successful through the use
of the gamma chain cytokines IL-7 and IL-15 with a one time pulse of IL-2. We conclude
that this is a superior method of T cell expansion based on increased viability, cytotoxicity,
and expansion levels as compared to expansion in IL-2 alone. The pivotal role of MDSC in
inhibiting the function of adoptively transferred T cells was confirmed after transfer of T
cells expanded in alternating gamma chain cytokines resulted in tumor inhibition and antineu antibody responses only when these cells were depleted, as previously. Efforts to
evade the large population of MDSC in the spleen through the transfer of CD62L- T cells
were unsuccessful and leads us to conclude that adoptively transferred T cells, regardless
of their expansion method, in vitro cytotoxicity, or migratory patterns, cannot mediate
effective tumor regression in vivo in the presence of MDSC and that the elimination of
these cells in vivo results in effective tumor rejection or inhibition in an otherwise tolerant
mouse model.
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The use of Gemcitabine as a clinically relevant means of inhibiting MDSC in vivo
in conjunction with AIT was found to be superior to treatment with either AIT or
Gemcitabine alone and was far superior to AIT in conjunction with depleting antibodies.
100% of mice receiving AIT with Gemcitabine exhibited complete rejection of the primary
tumor challenge. Of great significance is the fact that two subsequent tumor challenges
were also rejected by these mice, showing long-lasting immunological memory, which was
confirmed by the presence of high antibody titers against neu and strong IFN-γ responses
against MMC.
These studies have therefore identified MDSC as the major mediator of suppression
against adoptively transferred T cells and have developed a clinically achievable means of
achieving tumor rejection through the use of Gemcitabine as an MDSC inhibitor. These
findings are of great significance given the fact that adoptive immunotherapy has exhibited
extremely limited results for primary breast cancers (113), with some difficulty
encountered in expanding populations of cells with high percentages of CD8+ T cells and
cytotoxic activity (144). While there has been some success in the treatment of metastatic
lesions of breast cancer using AIT (230), overall clinical response rates and long-term
survival rates have been extremely low (231). We therefore propose that AIT in human
breast cancer patients, who have been observed to have increased levels of circulating
MDSC, be combined with the use of Gemcitabine for increased tumor rejection and longlasting immunity.
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Chapter 2
I. Study Rationale
MDSC have been reported to suppress T cell responses by a wide variety of
mechanisms, which include soluble factors such as nitric oxide or IDO (187, 232), but
some have reported contact-dependency between T cells and MDSC (184, 233). Given the
important role that MDSC play in suppressing AIT, we sought to determine the mechanism
of suppression by MDSC in our model and to characterize the existence of possible
effector molecules expressed either on the surface of, or within these cells. Suppression by
specific subsets of MDSC was also investigated to further pinpoint the cells responsible for
immune suppression so they may more precisely targeted in a therapeutic setting. Given
the equal tumor growth seen in mice treated with AIT consisting of CD62L+ and CD62Lcells, we hypothesized that MDSC may be exhibiting wide-spread suppression through
secreted soluble factors instead of relying on contact-dependent mechanisms, since
CD62L- T cells would not have come into direct contact with as many MDSC as CD62L+
T cells. Therefore MDSC were isolated from tumor-bearing animals, RNA extracted and
reverse transcribed, and tested for the expression of various suppressive soluble molecules.
These data indicated that the tested soluble factors are most likely not involved in
suppression my MDSC in our model, which lead us to investigate possible roles of several
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inhibitory molecules in mediating what we found to be contact-dependent suppression by
MDSC.
II. Results
MDSC in Tumor-Bearing FVBN202 Mice Suppress anti-CD3/CD28 Mediated
Proliferation of both CD4+ and CD8+ T cells
To determine the mechanisms by which MDSC suppress anti-tumor immune
responses, splenocytes were isolated from MMC tumor-bearing and tumor-free FVBN202
mice. Tumor-bearing mice had a large influx of MDSC in their spleens as compared to
tumor-free mice (Fig. 5). Splenocytes were labeled with the thymidine analog BrdU and
stimulated with antibodies against CD3 (10µg/mL, plate-bound) and CD28 (1µg/mL,
soluble), or were left unstimulated to serve as a control. After 3 days, cells were stained
using anti-CD4 and anti-CD8 antibodies and analyzed for BrdU uptake by flow cytometry.
We found significantly higher proliferation of CD4+ T cells from tumor-free mice
compared to those from tumor-bearing animals (Fig. 34A left panel, 91% vs. 59%,
P=0.002). The same trend was seen for CD8+ T cells (Fig. 34A right panel, 93% vs. 70%,
P=0.001). Similar trends were detected when analyzing absolute numbers of CD4+ and
CD8+ T cells (Fig. 34B left panel). Figure 34B shows that the average number of
BrdU+CD4+ and BrdU+CD8+ T cells from tumor-free mice is 3.3-fold higher than that of
BrdU+CD4+ and BrdU+CD8+ T cells from tumor-bearing mice (P=0.003 for CD4+ and
P=0.0004 for CD8+ T cells). To confirm that the suppression of T cell proliferation in
FVBN202 splenocytes was caused by the presence of elevated MDSC, we depleted MDSC
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in vitro from the splenocytes of tumor-bearing animals. As seen in Figure 34A, the
depletion of MDSC (Tumor Bearing-MDSC) significantly restored the proliferative
responses of both CD4+ (87% BrdU+) and CD8+ (92% BrdU+) T cells over those seen in
total splenocytes from tumor-bearing mice (P=0.028 for CD4+ and P=0.009 for CD8+ T
cells). Similar trends were found while comparing the absolute numbers of CD4+ and
CD8+ T cells, showing a 3.1-fold increase in proliferation in the CD4+ population
(P=0.027) and 2.5-fold increase in the CD8+ population (P=0.012) over total splenocytes
from tumor-bearing mice (Fig. 34B).
CD11b+Ly6G-Ly6C+ MDSC are Suppressive, while CD11b+Ly6G+Ly6C+ Cells are
not
It has recently been reported that various subsets of MDSC exist and can be distinguished
based on their differential expression of two epitopes of the Gr1 molecule; Ly6G,
corresponding to a granulocytic/ neutrophil phenotype, and Ly6C, corresponding to a
monocytic phenotype (171, 215, 216). We indeed found two different subsets of MDSC in
MMC tumor-bearing FVBN202 mice. In order to determine if these subsets have different
functions in our model, splenocytes were isolated from FVBN202 mice bearing neu+
MMC tumors and were stained for CD11b, Ly6G, and Ly6C. CD11b+ cells were sorted
into Ly6G+Ly6C+ and Ly6G-Ly6C+ populations. Sorted MDSC were then added at a 1:2
ratio to FVB naïve splenocytes with anti-CD3/CD28 stimulation for 3 days. As shown in
Figure 35A-B Ly6G-Ly6C+ subsets inhibited T cell proliferation whereas Ly6G+Ly6C+
subsets did not display any suppressive activity. Representative flow cytometry staining
for BrdU incorporation into CD4+ T cells showed 57.5% BrdU+ cells in culture with
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medium alone, 55.4% when in the presence of sorted CD11b+ Ly6G+Ly6C+ cells, and
only 13.0% proliferation when cultured with CD11b+Ly6G-Ly6C+ cells (Fig. 35A).
Repeated experiments confirmed these results, with the Ly6G-Ly6C+ fraction causing a
70% inhibition of CD4+ T cell proliferation when compared to the medium alone control,
in which proliferation was normalized to 100% (100% BrdU+ in media alone vs. 30.1%
BrdU+ in cultures containing Ly6G-Ly6C+ cells, P=0.008). In contrast, there was no
significant inhibition in cultures containing Ly6G+Ly6C+ cells (96.9% Brdu+, Fig. 35A).
Similar results were found in CD8+ T cells, with representative BrdU staining showing
38.1% and 51.6% proliferation in splenocytes cultured with medium alone or with
Ly6G+Ly6C+ cells, respectively (Fig. 35B). Strikingly, splenocytes cultured with sorted
Ly6G-Ly6C+ cells showed only 12.2% BrdU+ CD8+ T cells. Normalizing the
proliferation in control splenocytes alone to 100% shows a 62% inhibition of proliferation
in CD8+ T cells cultured with Ly6G-Ly6C+ cells from splenocytes alone (P=0.008),
whereas no significant inhibition of proliferation was seen in CD8+ T cells cultured with
Ly6G+Ly6C+ cells (Fig. 35B).
Suppressive MDSC Require Direct Cell-to-Cell Contact that is Independent of LFA1/ICAM and PD-1/PD-L1 interactions to Inhibit the Proliferation of CD4+ and CD8+
T cells
To further characterize the suppressive function of MDSC, we sought to determine if the
anti-proliferative effects of MDSC on T cells may be mediated by the release of
immunosuppressive soluble factors or by contact-dependent mechanisms. MDSC were
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isolated from tumor-bearing mice by using a magnetic bead selection kit to positively
select for PE-labeled Gr1+ cells. RNA was extracted and reverse transcribed. Resultant
cDNA was analyzed via PCR for the expression of the immunomodulating cytokine IL-10
(234, 235). Expression of mRNA for IL-10 was visible in both samples, but was relatively
faint (Fig 36). We also wanted to determine if there may be differential expression of
immunosuppressive molecules between the two subsets of MDSC. RNA was therefore
extracted from sorted populations of CD11b+Ly6G+Ly6C+ and CD11b+Ly6G-Ly6C+
cells from the spleens of tumor-bearing mice and reverse transcribed. The expression of
indoleamine 2,3-dioxygenase (IDO), an immunosuppressive enzyme that can inhibit T cell
responses and promote immune tolerance through the breakdown of tryptophan was
assessed by PCR (186, 187). After normalizing the data to the actin control, we found that
both the Ly6G+Ly6C+ fraction and the Ly6G-Ly6C+ fraction displayed extremely low
levels of IDO (Fig 37). In contrast, both fractions expressed TGF-β to a similar level after
normalization, which may be secreted or surface-bound and is an important modulator of T
cell tolerance, with mice lacking TGF-β exhibiting T cell hyper activation, even in the
absence of foreign antigen (236-239) (Fig 37). Since expression of IDO was almost
negligible and since TGF-β expression was observed to be similar in both populations, it is
unlikely that either of these molecules is the primary means of T cell suppression by
MDSC. We therefore wondered if suppression by MDSC may be achieved through direct
cell-to-cell contact. Therefore, CD11b+ cells were depleted from the splenocytes of
tumor-bearing and tumor free mice and equal numbers of lymphocytes (5X105) were
stimulated in the lower chamber of a plate containing a Transwell insert. CD11b+ cells
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enriched from tumor-bearing mice were then added to the lower chamber of the plate, or
were added to the top chamber of the Transwell insert, where they were separated from the
lymphocytes by 8.0µm pores. Staining for BrdU incorporation on day 3 showed potent
inhibition of both CD4+ and CD8+ T cells when CD11b+ cells were added back to the
cultures, but only in the absence of a Transwell insert (Fig. 38A). Gray bars indicate wells
to which CD11b+ cells from tumor-bearing mice were added, whereas black bars are
indicative of the proliferation seen in cultures of CD11b-depleted splenocytes alone. When
CD11b+ cells were added directly to the splenocytes (no Transwell), the proliferation of
CD4+ cells decreased from 80.5% to 50% (Fig 38A, P=0.001). On the other hand, the
addition of CD11b+ cells to the top of a Transwell insert had no effect on proliferation of
CD4+ cells (90.5% BrdU+ in splenocytes alone vs. 90% BrdU+ with CD11b+ cells). A
similar trend was seen in CD8+ cells, with the addition of CD11b+ cells directly to the
culture causing a reduction in BrdU+ staining from 88% to 53% (P=0.01, Fig. 38A). In
contrast, the addition of CD11b+ cells to the top of a Transwell insert resulted in no
reduction of proliferation, with CD8+ splenocytes alone staining 94.5% BrdU+ and CD8+
splenocytes staining 89% BrdU+ (Fig 38A). Analysis of the absolute cell numbers
recapitulated the above results; with the proliferation of CD4+ cells reduced significantly
only when CD11b+ cells were added directly to the culture (Fig 38B).
Since it has been reported that MDSC from tumor free animals are not suppressive
(167), we decided characterized MDSC in tumor free and tumor bearing animals to
determine if there were important differences that may account for the suppressive
capability in tumor-bearing mice. We looked at the expression of Annexin V, H-2q, Qa1,
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CD11c, CD86 and CCR7 on MDSC from tumor bearing and tumor free mice. We found
no significant differences in the expression of any of these molecules with the exception of
CD86, which was found to be significantly decreased on MDSC from tumor-bearing mice
(Fig 39).
We then hypothesized that, since T cells highly express the integrin LFA-1 (Fig
40A), and since the LFA-1/ICAM interaction between T cells and DC’s is necessary for T
cell priming (240) expression of LFA-1 on MDSC could allow MDSC to interact with
DC’s via ICAM-1 and cause DC’s to suppress T cells as well. Using flow cytometry, we
found that 100% of CD11b+Gr1+ MDSC express LFA-1 (Fig. 40B). However, we also
found LFA-1 to be highly expressed on CD11b-Gr1- cells of the granulocyte region as
well (Fig. 40B). Therefore, interaction through the LFA-1/ICAM-1 axis is unlikely given
the widespread expression of LFA-1 on non-MDSC as well as MDSC.
Programmed cell death 1 (PD-1), a member of the extended CD28/CTLA4 family,
is an immunoinhibitory receptor expressed on activated T cells (241). PD-1 had two
potential binding partners, PD-1 ligand 1 and PD-1 ligand 2 (PD-L1 and PD-L2,
respectively). Both ligands can be expressed on activated dendritic cells and macrophages,
and ligation of PD-1 by PD-L’s has been shown to inhibit TCR-induced proliferation,
induce T cell anergy, or cause apoptosis (241-243). Flow cytometry of splenocytes from
FVB mice that had rejected MMC cells showed low levels of PD-1 on the surface of CD8+
T cells (Fig 41). However, when these splenocytes were restimulated with MMC cells in
vitro, PD-1 expression increased to 3.94% on CD8+ T cells, a 4.4-fold increase (Fig 41).
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We therefore hypothesized that MDSC may express PD-L1 and that the PD-1/PD-L1
interaction may be the contact-dependent mechanism of MDSC suppression. MDSC were
then tested for the expression of PD-L1. As shown in Fig. 42, neither CD11b+Gr1+ nor
CD11b-Gr1- cells from the blood of FVBN202 mice showed any expression of PD-L1 or
PD-1 (Fig 42), suggesting that PD-1/PD-L1 interaction is not the mechanism by which
MDSC suppress activated T cells.
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III. Conclusions and Significance
From these studies we can conclude that MDSC require contact with T cells in
order to suppress CD3/CD28-induced proliferation. Furthermore, we have identified a
specific subset of CD11b+Ly6G-Ly6C+ cells that are responsible for mediating all
observed suppression. This finding is of significance given the fact that it will enable the
more direct targeting of MDSC in a therapeutic setting, while leaving the population of
non-suppressive CD11b+Ly6G+Ly6C+ cells intact, therefore limiting toxic side effects.
Indeed, we have seen some toxicity associated with the depletion of Gr1+ cells using
monoclonal antibodies in vivo, probably because most immature progenitor cells in the
bone marrow express the Gr1 molecule and complete depletion therefore reduces the
potential production of mature neutrophils and myeloid-dendritic cells. The identification
of a more specific subset of suppressive MDSC is therefore immensely important
Although Gemcitabine does not selectively inhibit certain subpopulations of MDSC and
shows little toxicity, resistance to chemotherapies is a widespread problem. Alternative
methods of inhibiting specific subpopulations of MDSC should therefore be investigated
for administration to Gemcitabine-resistant individuals. More extensive phenotyping of the
CD11b+Ly6G-Ly6C+ population should be done to identify potential surface markers that
may be unique to this population and therefore targeted with a humanized antibody.. We
further conclude that suppression of T cell proliferation by these MDSC in independent of
IL-10, IDO, and TGF-β. Contact between MDSC and T cells is also independent of LFA1/ICAM-1 interactions and PD-1/PD-L1 interactions. Other potential sites of contact
between MDSC and T cells should be investigated.
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Chapter 3
I. Study Rationale
We have observed large increases in MDSC in tumor-bearing mice, and therefore
hypothesized that MMC-derived soluble factors were responsible for the increase in
MDSC seen in vivo. We aimed to identify the particular cytokines or chemokines secreted
by MMC that may contribute to this increase. To more specifically elucidate how MMCderived cytokines or chemokines mediate the observed increase in MDSC, bone marrow
cells were sorted into two pure populations: existing CD11b+Gr1+ MDSC and progenitor
CD11b-Gr1- cells. Culture of these sorted populations as opposed to culture of total bone
marrow cells would allow us to determine the effects of MMC-derived cytokines or
chemokines both on the maintenance and proliferation of existing MDSC and on the
generation of new MDSC from progenitor cells to determine if the observed increase in
MDSC was a result of prolonged survival and/or proliferation of MDSC or to increased
generation of MDSC de novo. Considering our previous finding that only one MDSC
subset showed suppressive activity, we sought to establish the influence of various MMCderived soluble factors on determining the proportions of these subsets. We hypothesized
that the presence of MMC-derived soluble factors may specifically increase the proportion
of suppressive MDSC. Lastly, we hypothesized that exposure to MMC-derived soluble
factors may result in an inhibition of MHC class I and MHC class II molecules, as well as
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various maturation markers, thus contributing to the inability of these granulocytes to fully
mature and function properly as antigen presenting cells.
II. Results
MMC-Derived Soluble Factors Cause the generation of MDSC
To determine if soluble factors released by MMC cells are responsible for the
increase in MDSC, MMC cells (10X106cells/10mL) were cultured for 24 hours in
RPMI1640 supplemented with 10% FBS. Supernatant was then removed and concentrated
to a volume of 600µL. FVB mice (n=3) were then injected i.d. with 200µL of the
concentrated supernatant. FVB control mice (n=3) were injected i.d. with 200µL of control
medium alone. Mice were injected on three consecutive days, sacrificed on day 4 and their
blood, spleens, and bone marrow were subjected to flow cytometry analysis. Figure 43A
shows representative flow cytometry plots illustrating an increase in the overall
granulocyte region of the spleen from 7% in RPMI-treated animals to 13% in conditioned
medium (CM)-treated animals. Representative fluorescent staining for CD11b and Gr1 is
depict ed in Fig. 43B, with control animals having 17% CD11b+Gr1+ MDSC, while CMtreated animals had 55% MDSC in the granulocyte regions of their spleens. The difference
in MDSC in the granulocyte region of the spleens is statistically significant (P=0.003), as
seen in Fig. 43C, with RPMI-treated mice averaging 21% MDSC and CM-treated mice
averaging 54.7% MDSC. Differences in the percentage of MDSC in the total splenocytes
were also significant, with MDSC comprising only 1.5% of the total spleens of RPMItreated mice, while these cells comprised 7.33% of the total spleens of CM-treated mice

172

173

174

(P=0.002, Fig. 43D). Likewise, calculation of the absolute number of MDSC in the spleen
of each animal confirmed a significant increase in MDSC in CM-treated mice, with RPMItreated mice having 1.8X106 total MDSC, while CM-treated mice had 8.6X106 total
MDSC (P=0.006, Fig. 43E). We also wanted to determine if MDSC were increased in
other compartments of the body in CM-treated mice. Therefore, blood was also taken and
stained for CD11b and Gr1. Figure 44A shows an increase in the overall granulocyte
region from 10% in RPMI-treated mice to 15% in CM-treated mice. Furthermore,
representative data from within this granulocyte region shows an increase from 24%
MDSC in RPMI-treated mice to 93% MDSC in CM-treated mice (Fig. 44B).
Quantification of the above data shows a statistically significant difference between the
average percentage of MDSC in the granulocyte region of the blood of RPMI-treated mice
(21.5%) and CM-treated mice (78%, Fig 44C, P=0.00025). The percentage of the overall
blood comprised of MDSC also showed a significant difference between RPMI-treated
mice (1.4%) and CM-treated mice (10.1%, Fig. 44C, P=0.0033). Lastly, there was a
substantial increase in the overall percentage of granulocytes in the bone marrow as well,
with the bone marrow of RPMI-treated mice having 39% granulocytes and the bone
marrow of CM-treated mice having 54% granulocytes (Fig. 45A). The composition of the
granulocyte region was also significantly affected by treatment with CM, as control mice
had 35% MDSC while CM-treated mice had 48% MDSC (P=0.028, Fig 45B,D). These
results were also reflected in the overall percentage of MDSC in the bone marrow (29.3%
in RPMI-treated mice vs. 38.7% in CM-treated mice, P=0.0186, Fig. 45C), as well as the
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absolute number of MDSC recovered from the tibias and femurs (7X106 MDSC in RPMItreated mice vs. 13X106 MDSC in CM-treated mice, P=0.0156, Fig. 45E).
To determine if injection with MMC-conditioned medium influenced MDSC in any
other way, flow cytometry staining was done for the expression of the MHC class II
molecule I-Aq and the MHC class I molecule H-2q. We found that mice that were treated
with CM had significantly lower surface expression of I-Aq than mice treated with RPMI
(P=0.026, Fig. 46). We therefore wondered if MMC-derived soluble factors may be
affecting antigen presentation on mature antigen presenting cells as well. Figure 47 shows
the expression of I-Aq on CD11b+Gr1- cells, revealing that MMC-conditioned media does,
in fact, significantly reduce the expression of I-Aq on the surface of APC in mice treated
with CM (76.6%) as compared to mice treated with RPMI (93.9%, P=0.0054).
To determine the most prevalent soluble factors secreted by MMC that may be
contributing to the observed effects in vivo, a multiplex array detecting IL-1β, IL-2, IL-4,
IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-13, IFN-γ, TNF-α, GM-CSF, MCP-1, and
VEGF was performed on MMC-conditioned media after a 24 hour culture. We found that
high levels of GM-CSF, VEGF, IL-6 and MCP-1 were secreted by MMC (Fig. 48). Other
cytokines were below detectable levels.
Since GM-CSF, VEGF, IL-6 and MCP-1 were identified to be secreted by MMC
cells, we wanted to determine if administration any of the above cytokines could cause an
increase in MDSC in naïve FVB mice. We therefore injected varying mice once daily with
a dose of either 500ng of GM-CSF, 2500ng of GM-CSF, or 500ng of GM-CSF with 120U
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of IL-6. Injections were done i.d. and were administered once per day for 3 consecutive
days, with the exception of high dose GM-CSF (2500ng), which was administered i.d. for
2 consecutive days. Twenty-four hours after the last injection, mice were sacrificed and
their spleens, bone marrow, and blood subjected to flow cytometry analysis for
CD11b+Gr1+ cells. Figure 49 shows representative data from the spleens of FVB mice
receiving various treatments. Representative forward scatter vs, side scatter plots show that
there is no difference in the overall proportion of the spleen that is made up of granulocytes
when comparing mice treated with PBS, mice treated with 500ng of GM-CSF, 2500ng of
GM-CSF, or 500ng GM-CSF with 120U IL-6 (Fig. 49A). Although the percentage of
MDSC in the granulocyte region varies moderately between mice, with the 500ng dose of
GM-CSF causing a 4% increase over the control and the GM-CSF with IL-6 treatment
causing a 9% increase over the control, this difference did not constitute a substantial
fraction of the whole spleen (Fig. 49B,C), nor was it recapitulated in calculating the
absolute number of MDSC in the spleen (Fig. 49D). Flow cytometry analysis of the bone
marrow showed that levels of MDSC in the four treatments groups were indeed very
similar. Figure 50A shows that the granulocyte region of the bone marrow in PBS-treated
mice comprised 39% of the total bone marrow, whereas the granulocyte regions of mice
receiving 500ng GM-CSF, 2500ng GM-CSF, or 500ng GM-CSF with 120U IL-6
comprised 39%, 41%, and 41% of the whole bone marrow, respectively. Furthermore, the
percentage of MDSC making up the granulocyte region was similar in all cases, with PBStreated mice having the highest percentage of MDSC (88.3%) as compared to 84% in the
500ng GM-CSF mouse, 79.6% in the 2500ng GM-CSF mouse, and 83.4% in the GM-CSF
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with IL-6 mouse (Fig 50B). These observations were similar when observing the
percentage of MDSC that made up the whole bone marrow (Fig 50C) and was confirmed
by similar absolute numbers of MDSC recovered from bone marrow in the tibias and
femurs (Fig 50D). Flow cytometry of the peripheral blood also showed no discernable
increase in MDSC in the granulocyte regions of mice treated with 500ngof GM-CSF
(3.1%), 2500ng of GM-CSF (2.9%), or GM-CSF with IL-6 (4.8%) as compared to the
PBS-treated controls (4.1%, Fig 51A). The same is true for MDSC levels in the
granulocyte regions of these mice, as well the overall level of MDSC in the total peripheral
blood (Fig 51B,C). Therefore neither GM-CSF nor GM-CSF in conjunction with IL-6 was
able to increase MDSC in FVB mice after i.d. injection.
We next sought to determine of VEGF could be the MMC-derived soluble factor
responsible for the increase in MDSC seen after injection of MMC-derived supernatant.
We therefore treated naïve FVB mice with once-daily i.d. injections of 1.5µg of VEGF, or
with PBS for 3 consecutive days. Mice were sacrificed on the fourth day and their spleens,
bone marrow, and blood subjected to flow cytometry analysis. Representative data in
Figure 52A shows that there was not a substantial increase in the granulocyte region of the
spleen of VEGF-treated animals (4.9%) as compared to PBS-treated animals (4.2%).
Likewise, there was no appreciable difference in the levels of MDSC within those
granulocyte regions, with PBS-treated mice having 24.7% MDSC, while VEGF-treated
mice had 26.4% MDSC (Fig. 52B). The percentage of MDSC in the whole spleen was also
similar, with PBS-treated animals having 2.1% MDSC in their spleens, while VEGFtreated animals had 2.3% MDSC in their spleens (Fig. 52C).
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Calculation of the absolute number of MDSC in the spleens of each animal confirmed that
there was no significant difference between the number of MDSC in the spleens of PBStreated mice and VEGF-treated mice (Fig. 52D). The bone marrow of VEGF-treated mice
also did not show any increase in MDSC as compared to PBS-treated controls.
Representative flow cytometry data in Figure 53A shows that the percentages of
granulocytes in the two groups are nearly equal (35.4% in PBS-treated mice vs. 36.8% in
VEGF-treated mice). Levels of MDSC within the granulocyte region were also similar,
with MDSC making up 82.4% of the granulocytes in PBS-treated mice and 77.0% in
VEGF-treated mice (Fig. 53B). These data were confirmed by the percentage of MDSC
comprising the whole bone marrow (36.7%% in PBS-treated mice and 33.4% in VEGFtreated mice, Fig. 53C) and the absolute number of MDSC in the bone marrow recovered
from the tibias and femurs (7.5X106 MDSC in PBS-treated mice and 4.8X106 MDSC in
VEGF-treated mice, Fig. 53D). Figure 54 shows representative data from the blood of
PBS-treated and VEGF-treated mice. There was no difference in the percentage of
granulocytes in the blood, with the blood of PBS-treated mice composed of 3%
granulocytes while the blood of VEGF-treated mice was composed of 2% granulocytes
(Fig. 54A). Although there seemed to be a large increase in the composition of the
granulocyte region, with the control mice having 44% MDSC while VEGF mice had 66%
MDSC, this difference was not statistically significant (Fig. 54B and data not shown). The
percentage of MDSC in the entire population of peripheral blood leukocytes was similarly
low in both groups (Fig. 54C).
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Since injections of GM-CSF and VEGF failed to produce significant increases in
MDSC in vivo, we hypothesized that MCP-1 may play a role in the increase in MDSC
caused by MMC-derived soluble factors. We therefore injected FVB mice i.d. with 2.5µg
of MCP-1 or with PBS once per day for 3 consecutive days. Mice were sacrificed on the
fourth day and their spleens, bone marrow, and blood were subjected to analysis by flow
cytometry. Representative flow cytometry data in Figure 55A shows that the percentages
of granulocytes in the spleen are similar between the two groups (5% in PBS-treated mice
and 7% in MCP-1-reated mice). The percentage of MDSC in the granulocyte regions was
also similar, with PBS-treated mice having 4% MDSC and MCP-1-treated mice having 7%
MDSC (Fig 55B). Similar levels of total MDSC were also found in the spleen, with PBStreated mice having 0.19% MDSC and MCP-1-treated mice having 0.40% MDSC (Fig.
55C). Calculation of the absolute numbers of MDSC in the spleens confirmed that there
was no significant difference in MDSC in the spleens when comparing PBS-treated mice
and MCP-1-treatd mice (Fig 55D). The bone marrow of FVB mice treated with either PBS
or MCP-1 also had very similar levels of granulocytes (29% in both groups), and MDSC
within those granulocytes (78% in control mice and 80% in MCP-1-treated mice, Fig.
56A,B). The percentage of MDSC in the whole bone marrow was also similar between the
two groups (22.9% in control mice and 23% in MCP-1-treated mice, Fig. 56C). The
absolute number of MDSC in the bone marrow recovered from the tibias and femurs
reflects the above data, with control mice having 7.51X106 MDSC and MCP-1 treated
mice having 8.151X106 MDSC, a difference that was not statistically significant (Fig.56D).
Flow cytometry of the blood of PBS-treated and MCP-1- treated mice showed that there
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was not increase in the granulocyte regions of MCP-1-treated mice (2%) over PBS-treated
mice (3%, Fig. 57A). There was an increase in MDSC within the granulocyte region,
however this difference was not found to be statistically significant (Fig 57B and data not
shown). The percentage of the total peripheral blood leukocytes made up of MDSC was
again very similar between the groups with no increase seen in mice treated with MCP-1
(0.75%) as compared to mice treated with PBS (0.9%, Fig. 57C).
GM-CSF is Responsible for the Generation and Maintenance of MDSC
Considering the lack of responses to cytokines/chemokines that were found to be
secreted by MMC and were injected in vivo, we decided to look at responses to these
cytokines in vitro. Since GM-CSF is a well-established adjuvant therapy for the
differentiation of dendritic cells in vivo, (244, 245) we wanted to determine if GM-CSF
had any effect specifically on MDSC. Bone marrow was therefore isolated from naïve
FVBN202 mice and was cultured for 6 days in the presence of 100ng/mL of GM-CSF.
Flow cytometry staining was done for CD11b and Gr1 on day 6. As shown in Figure 58A,
77% of the bone marrow of FVBN202 mice is comprised of CD11b+Gr1+ cells on day 0,
while 5% of the cells are CD11b-Gr1+, 4% of the cells are CD11b+Gr1-, and 14% of the
cells are CD11b-Gr1- undifferentiated progenitor cells. In contrast, on day 6, only 25.1%
of the bone marrow cells remained as CD11b+Gr1+, while the CD11b-Gr1+ population
had decreased to 0.6% and the population of progenitor cells had decreased to 1.8%
However, 72.6% of the cells on day 6 were CD11b+Gr1- cells, a phenotype that is
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indicative of mature dendritic cells and macrophages. GM-CSF may therefore cause the
differentiation of CD11b+Gr1+ cells into CD11b+Gr1- cells, the expansion of
CD11b+Gr1- cells, or the differentitation of CD11b-Gr1- progenitor cells. Because the
absolute number of CD11b+Gr1+ cells actually increased on day 6 as compared to day 0
(6.0X106 MDSC on day 0 as compared t0 10.9X106 MDSC on day 6, Fig. 58B), we
hypothesized that instead of maturing these cells, that GM-CSF was actually maintaining a
population of these cells, and even causing the generation of more MDSC. We also wanted
to determine if a 6 day culture with GM-CSF affected the differentiation/ migration status
of MDSC. Flow cytometry was therefore done on day 6 for CD11b, Gr1, and CD86 as well
as CD11b, Gr1, and CCR7. Figure 59A shows that the maturation marker CD86 was
greatly increased from being expressed on 22.7% of MDSC on day 0 to being expressed on
58.3% of MDSC on day 6 (p=0.008). Furthermore, CCR7, a chemokine receptor that has
been demonstrated to be essential for lymphocyte homing to peripheral lymphoid organs
(246, 247) and expression of which has been correlated with dendritic cell maturation
(248) was observed to be down-regulated after 6 days of culture with GM-CSF (58.4% of
MDSC expressed CCR7 on day 0 and 35.9% of MDSC expressed CCR7 on day 6,
P=0.00078, Fig. 59B). This suggests that GM-CSF, which is secreted by MMC cells, may
have a direct effect on MDSC and affect their generation and/or maintenance in the
periphery.
In order to further test the effect that GM-CSF may be having specifically on
MDSC or MDSC progenitors and to determine which MMC-derived cytokine was
necessary for the increased production of MDSC, bone marrow cells from naïve FVBN202
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mice were harvested, stained with antibodies against CD11b and Gr1, and were sorted into
2 populations: CD11b+Gr1+ cells and CD11b-Gr1- cells. The purity of the sorted cells was
>96% (Fig. 60A). Sorted cells were cultured separately in the presence of GM-CSF
(100ng/mL), VEGF (50ng/mL), MCP-1 (50ng/mL), M-CSF (50ng/mL), G-CSF (50ng/mL)
or MMC cells on top of a Transwell insert. Control wells contained medium only. Media
was changed on day 3 and fresh cytokine or tumor cells added where applicable. On day 6,
cells were subjected to flow cytometry analysis to determine generation of MDSC from
CD11b-Gr1- progenitor cells or maintenance of existing CD11b+Gr1+ MDSC in vitro.
Figure 60B shows that MMC-derived soluble factors or GM-CSF caused the generation of
MDSC from hematopoietic CD11b-Gr1- cells while the presence of media resulted in a
negligible effect. At the end of a 6-day culture 46.9% and 56.8% of cells were MDSC in
the presence of MMC (P=0.007 as compared to media alone) and GM-CSF (P=0.001 as
compared to media alone), respectively. A Similar observation was made when GM-CSF
was used at a lower concentration of 10ng/mL (data not shown). VEGF or MCP-1, MCSF, and G-CSF did not induce generation of MDSC from CD11b-Gr1- cells (data not
shown). Figure 60C shows that sorted CD11b+Gr1+ MDSC exhibited a significant drop in
CD11b+Gr1+ levels from day 0 in all culture conditions. However, both GM-CSF (61.0%)
and MMC (42.5%), supported the maintenance of CD11b+Gr1+ cells when compared with
media alone (10.5%) (P=0.013 and P=0.006, respectively). Each cytokine/chemokine was
also tested for the induction of proliferation in sorted CD11b+Gr1+ cells, and it was
determined that none could induce proliferation of MDSC exceeding the baseline level
(data not shown). Therefore, GM-CSF was found to be the major cytokine involved in the
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conversion of CD11b-Gr1- cells to MDSC as well as maintenance, but not proliferation of
existing MDSC.
Since one of the characteristics of MDSC is their short half-life and high turnover
rates, (216) we sought to determine if any of the MMC-derived soluble factors could
inhibit apoptosis of newly arising MDSC or existing MDSC. Bone marrow cells were
harvested as before and were sorted into CD11b+Gr1+ and CD11b-Gr1- populations. Cells
were stained with Annexin V after sorting to determine the viability of each population just
before culture. The double negative and double positive sorted populations contained
63.0% and 36.8% Annexin V positive apoptotic cells, respectively (representative data of
duplicate experiments are shown in Fig. 61A). Cells were then cultured in conditions as
described for Figure 60 and were stained on day 6 with antibodies against CD11b and Gr1,
and with Annexin V. Figure 61B shows levels of apoptosis in the newly converted MDSC.
GM-CSF significantly reduced the percentage of apoptotic MDSC as compared to the
proportion of apoptotic cells in the presence of media alone (18.7% vs. 92.3%,
P=0.00005). Annexin V levels were also reduced in MDSC cultured with MMC in
Transwell as compared to those cultured in media alone (58.3% vs. 92.3%, P=0.024).
Interestingly, apoptosis was significantly reduced in MDSC when progenitor CD11b-Gr1cells were cultured with GM-CSF as compared to those cells cultured with MMC in
transwell (18.7% vs 58.3%, P=0.003). Figure 61C shows levels of apoptosis in previously
generated MDSC after a 6-day culture in vitro. The CD11b+Gr1+ sorted cells exhibited
significantly reduced apoptosis when cultured with GM-CSF as compared to media alone
(38.8% vs. 91.1%, P=0.0001). Annexin V positive MDSC were significantly reduced in
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the presence of MMC in Transwell as compared to media alone (65.0% vs. 91.1%,
P=0.001). Apoptosis was also significantly reduced when comparing Annexin V positive
MDSC in the presence of GM-CSF compared to those cultured with MMC in Transwell
(38.8% vs 65.0%, P=0.003). Levels of apoptosis in CD11b+Gr1+ cells on day 0 (Fig. 61A)
were similar to those seen on day 6 after culture with GM-CSF (Fig. 61C) (36.8% on day 0
vs. 38.8% on day 6), whereas CD11b-Gr1- cells cultured with GM-CSF showed decreased
Annexin V levels on day 6 (Fig. 61B) compared to day 0 (Fig. 61A) (63.0% on day 0 vs
18.7% on day 6, P=0.017). Therefore, GM-CSF seems to augment the survival of early
stage MDSC as compared to late stage MDSC. Annexin V staining on CD11b+Gr1+ cells,
both newly converted and existing, cultured with VEGF, MCP-1, or G-CSF were similar to
Annexin V levels on MDSC cultured in media alone (data not shown).
FVBN202 Mice Display Unique Subsets of MDSC with GM-CSF Selectively Driving
the Generation of the Suppressive Ly6G-Ly6C+ Subset
It has recently been reported that various subsets of MDSC exist and can be distinguished
based on their differential expression of two epitopes of the Gr1 molecule; Ly6G,
corresponding to a granulocytic/ neutrophil phenotype, and Ly6C, corresponding to a
monocytic phenotype (171, 215, 216). We report here that our model of neu+ tumorbearing FVBN202 mice, which has yet to be investigated, displays novel phenotypes and
characteristics of MDSC. Two main subsets exist in FVBN202 mice, Ly6G-Ly6Clow/int,
and Ly6G+Ly6Chigh, with the former displaying suppressive capabilities while the latter
showed no suppression against CD3/CD28 stimulated T cells (Fig. 35). Previously
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reported subsets include Ly6G-Ly6Chigh, Ly6G+/hiLy6Clow/int, and Ly6Gint/dullLy6Chi (171,
215, 216). These phenotypes display an inverse correlation between Ly6G and Ly6C
expression, where high Ly6G expression is associated with intermediate or low Ly6C
expression and low or absent Ly6G expression is associated with high Ly6C expression,
which is in direct contrast to the phenotypes we present here. Furthermore, reports have
differed in regards to which subset exhibits greater expansion and/or suppressive function.
Figure 62A shows CD11b+ cells from the spleens of tumor-free and tumor-bearing
FVBN202 mice, both of which display a smaller proportion of Ly6G-Ly6Cint (17% in
tumor-free and 16% in tumor-bearing) and a much larger proportion of Ly6G+Ly6Chigh
cells (24% in tumor-free and 83% in tumor-bearing). Figure 62C shows a significant
expansion of both the Ly6G-Ly6Cint and Ly6G+Ly6Chigh fractions (P=0.008 and 0.003,
respectively) in the whole spleens of tumor bearing mice as compared to tumor free mice.
Similar phenotypes and proportions of cells are seen in the bone marrow. As shown in
Figure 62B, tumor-free mice contain a population of Ly6G-Ly6Clow cells, with a lower
MFI than that seen in the spleen or in the bone marrow of tumor-bearing animals. Like
Ly6G-Ly6Cint cells, Ly6G-Ly6Clow cells are found at a lower proportion (19%) than
Ly6G+Ly6Chigh cells (80%) in the bone marrow of tumor-free mice. Although these
proportions are similar in the bone marrow of tumor-bearing animals, the expression of
Ly6C per cell increases on the Ly6G- fraction, creating a population of Ly6G-Ly6Cint cells
as seen in the spleen (Fig 62B). Figure 62D shows significant expansion of both the Ly6GLy6Clow/int population (P=0.002) and the Ly6G+Ly6Chigh population (P=0.001) in the
whole bone marrow of tumor-bearing animals as compared to tumor-free animals. It is
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noteworthy that both fractions expand similarly in the bone marrow (3.2 fold expansion of
the Ly6G-Ly6Clow/int fraction and 3.1 fold expansion of the Ly6G+Ly6Chigh fraction),
while expansion in the spleens of tumor-bearing mice showed a 23.6-fold increase in
Ly6G-Ly6Clow/int MDSC as compared to splenocytes from tumor free mice (P=0.008),
whereas the Ly6G+Ly6Chigh fraction showed a drastic 64.2-fold increase in tumor bearing
spleens (P=0.003).
Given the presence of these unique subsets and the fact that GM-CSF and MMCderived soluble factors induced the generation of MDSC from CD11b-Gr1- cells (Fig. 60),
we next sought to determine the effects of GM-CSF and MMC on MDSC subsets. Bone
marrow cells were therefore sorted from tumor-free FVBN202 mice as before and cultured
in the presence of GM-CSF, MMC in Transwell, or media alone for 6 days. Flow
cytometry was performed on day 0 and day 6 to analyze the expression of Ly6G and Ly6C.
As shown in Figure 62B, MDSC in the bone marrow of tumor free mice on day 0 were
comprised of 19% Ly6G-Ly6C+, correlating with a suppressive phenotype and 80%
Ly6G+Ly6C+ correlating with non-suppressive phenotype. Interestingly, culture of the
progenitor cells in the presence of MMC or GM-CSF resulted in a significant increase in
the suppressive Ly6G-Ly6C+ subset as compared to day 0 (58% with MMC, P=0.018 and
72% with GM-CSF, P=0.015, Fig. 63A). Furthermore, the amount of suppressive cells
generated from culture with GM-CSF was significantly higher than that generated from
culture with MMC in Transwell (Fig. 63A: 72% with GM-CSF and 58% with MMC,
P=0.045). It is noteworthy here that the mean fluorescent intensity (MFI) of Ly6C was
increased substantially in the Ly6G- fraction after culture with GM-CSF, and even more so
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after culture with MMC, as compared to levels seen in tumor free bone marrow on day 0
(Fig. 62B). This is consistent with an increase in Ly6C MFI that we have observed in the
bone marrow of tumor-bearing mice when compared to tumor free mice (Fig. 62B).
Residual MDSC in the presence of medium alone showed a negligible percent of viable
cells of either population (data not shown). Figure 63B shows that culture of CD11b+Gr1+
cells with MMC maintained a proportion of Ly6G-Ly6Clow/int cells similar to that on day 0
(17% vs. 19%), while the percentage of Ly6G+Ly6Chigh non-suppressive cells decreased
significantly from day 0 (47% vs. 80%, P=0.001). Culture of sorted CD11b+Gr1+ cells
with GM-CSF, however, resulted in a significantly reduced percentage of Ly6G-Ly6Clow/int
cells (8% vs. 19%, P=0.011) as well as a significant reduction in Ly6G+Ly6Chigh cells
(41% vs. 80%, P=0.0004, Fig. 63B). Again, MDSC in the presence of medium alone
showed negligible percent of viable Ly6G-Ly6Clow/int or Ly6G+Ly6Chigh cells (data not
shown).
We next wanted to determine if culture of bone marrow progenitor cells with MMC
in Transwell or with GM-CSF could affect the status of MHC class I and MHC class II
molecules on MDSC, as we have observed previously (Figs. 46,47). Sorted CD11b-Gr1bone marrow cells from tumor free FVBN202 mice were therefore cultured for 6 days as
before. Flow cytometry analysis on day 6 shows that culture with MMC or GM-CSF
causes the downregulation of H-2q on the surface of MDSC. Representative data in Figure
64A shows that, of MDSC cultured in media alone, 72.3% expressed H-2q as compared to
18.6% and 26.5% of newly-derived MDSC expressing H-2q after culture with MMC and
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GM-CSF, respectively (Fig 64A). These data differed slightly after subtraction of
background levels of autofluorescence, with H-2q expression on MDSC after culture in
GM-CSF being lower than that seen on MDSC after culture with MMC, however this was
not a significant difference. On the other hand, both of these adjusted values are
significantly lower than those seen in media alone (P=0.003 and P=1.9X10-5 in comparing
media to MMC and GM-CSF cultures, respectively). Likewise, the expression of the
MHC class II molecule I-Aq was also reduced after culture with both MMC and GM-CSF.
Culture with media alone resulted in 54.9% of MDSC expressing I-Aq, while culture with
MMC reduced this number to 14.7% and culture with GM-CSF resulted in 24.2% of
MDSC expressing I-Aq (Fig. 64B top row). As previously, subtraction of background
autofluorescence yielded even more substantial differences between the cells cultured in
media and those cultured with MMC (P=0.005 as compared to media alone) or GM-CSF
(P=0.0098 as compared to media alone) (Fig. 64B bottom graph). We further wanted to
elucidate if existing MDSC are able to proliferate in response to GM-CSF or MMCderived soluble factors in vitro. To clarify this point, sorted CD11b+Gr1+ cells from the
bone marrow of tumor free mice were pulsed with BrdU on day 0 of the culture period and
then were cultured for 3 days with media alone, MMC on a Transwell insert, or 100ng/mL
of GM-CSF. On day 3, cells were harvested and strained for CD11b and Gr1 as well as for
the intracellular incorporation of BrdU. Figure 65A shows the change in the percentage of
BrdU+ CD11b+Gr1+ cells cultured with MMC or GM-CSF as compared to media alone.
The increase in BrdU incorporation over baseline was less than 10% in both cases and was
not statistically significant. This is recapitulated by the absolute cell numbers in Figure
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64B. As indicated by the diamonds, the starting cell number on day 0 was 1.5X105 cells.
The bars under the diamonds indicate the number of viable cells remaining on day 6. There
was no proliferation seen in any of the cultures as assessed by absolute cell numbers (Fig.
65B).
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III. Conclusions and Significance
These studies clearly demonstrate that MMC-derived soluble factors do, in fact,
cause the increase in MDSC in the spleen, blood, and bone marrow of FVBN202 mice.
Furthermore, MHC class II expression was decreased on both CD11b+ and Gr1+ cells and
CD11b+Gr1- cells. Cell sorting and subsequent culture with one of the predominant
cytokines or chemokines secreted by MMC showed that GM-CSF, but not VEGF, IL-6, or
MCP-1, specifically supported the maintenance of existing MDSC and the generation of
new MDSC. GM-CSF was also increased the viability in both cell populations, although
CD11b-Gr1- cells were more highly affected by GM-CSF than were CD11b+Gr1+ cells.
CD11b+Gr1+ cells were not observed to proliferate in responses to GM-CSF; we therefore
conclude that increases in MDSC can result from both the generation of new MDSC from
bone marrow progenitor cells and the maintenance and survival of existing MDSC, but not
from proliferation of MDSC, in response to GM-CSF. Strikingly, GM-CSF was found to
specifically increase the suppressive CD11b+Ly6G-Ly6C+ phenotype of MDSC while
decreasing the non-suppressive population arising from sorted CD11b-Gr1- progenitor
cells, a trend not recapitulated with culture of existing MDSC. Exposure to GM-CSF also
resulted in significant decreases of MHC class I and MHC class II on the surface of newly
converted MDSC, an effect not seen with culture of existing MDSC. Therefore, exposure
to GM-CSF at an early stage of differentiation can profoundly affect the resultant cellular
profile, with increases in CD11b+Ly6G-Ly6C+ MDSC as well as sustained decreases in
MHC class I and class II molecules, resulting in suppressive populations of granulocytes
that do not express molecules for antigen presentation.
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These results offer significant findings as to the mechanisms of MDSC
accumulation and identify GM-CSF as a major tumor-derived soluble factor responsible
for these effects which is of substantial clinical important given that many tumor vaccines
use GM-CSF as an adjuvant and most human tumors also secrete GM-CSF, which has
been correlated with increased levels of circulating myeloid cells (210, 244, 249). We
propose that the use of GM-CSF as an adjuvant, in combination with tumor-derived GMCSF, may elevate overall serum levels to a detrimental level and result in increases in
MDSC in vivo as suggested by the finding that peptide vaccination coupled with GM-CSF
in melanoma patients caused an increase in MDSC that was not observed in patients
receiving peptide vaccination alone (213). Furthermore, neutralization of GM-CSF in
patients with elevated serum levels may offer clinical benefit in conjunction with other
immunotherapies.
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Discussion
I. Chapter 1
Neu+ tumors in FVBN202 Mice Cause an Increase in MDSC that Prevents Successful
Adoptive Immunotherapy
We have observed significant increases in granulocytes in the spleens, bone
marrow, and blood of FVBN202 mice bearing MMC tumors, and found that the absolute
number of granulocytes in these mice was significantly increased as well. These
observations were concurrent with a significant decrease in the absolute number of cells in
the lymphocyte region from the bone marrow of the tibias and femurs of tumor-bearing
mice. This indicates that granulocytic precursors are able to overtake or out compete
lymphocytic precursors in the bone marrow, or that lymphocytic precursors in the bone
marrow may be more sensitive to inhibition by MDSC than mature lymphocytes in the
spleen, where no significant decrease in absolute number was observed.. This population
of granulocytes in tumor-bearing mice was found to be mainly comprised of CD11b+Gr1+
cells and we found a dramatic increase in these cells in both the total population and within
the granulocyte population in the spleen, bone marrow, and blood. The increase in MDSC
in the spleens of TB mice is also associated with a decrease in CD11b single positive cells,
although this phenomenon is not seen in the bone marrow. There is also a decrease in
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CD11b+ cells in the granulocyte region of the blood, showing that although similar
numbers of CD11b+ cells are present in the BM of tumor bearing and naïve mice, fewer of
these cells are making it to the periphery. This increase in CD11b+Gr1+ cells and decrease
in CD11b+ cells results in a decreased APC to T cell ratio, thus hindering antigen
presentation in vivo. Given the prevalence of these cells in tumor- bearing mice, we
hypothesized that these cells could be responsible for the failure of adoptively transferred
neu-specific T cells to reject neu-positive mammary carcinomas.
Although the adoptive transfer of tumor-specific T cells that have been activated
and expanded in vitro is a promising means of systemically treating residual cancers after
resection of the primary tumor, the presence of immune suppressor cells may be a
substantial obstacle to the success of these treatments. In particular, CD11b+Gr1+ MDSC
represent a potent population of suppressor cells that are elevated in many different types
of cancer and have been associated with suppression of T cell responses by multiple
mechanisms.
To test our hypothesis, T cells from donor FVB mice donor mice that had rejected a
challenge with neu+ MMC cells were activated with bryostatin and ionomycin and
expanded in IL-2 for subsequent adoptive transfer. Although activation and expansion of
these cells resulted in activated CD44+CD62L- and CD44+CD62L+ effector and memory
T cells that showed cytotoxic effects against MMC in vitro, the transfer of these T cells
offered no protection against MMC tumors in FVBN202 mice. In contrast, the profound
inhibition of MMC tumors that we observed in mice that were given AIT in conjunction
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with MDSC depletion confirmed the hypothesis that elevated MDSC can result in the
failure of AIT. Importantly, the level of MDSC remaining in tumor-bearing mice was
inversely correlated with the ability to reject tumors, showing the importance of effectively
depleting MDSC in vivo. Furthermore, AIT coupled with MDSC depletion resulted in a
robust antibody response generated against the extracellular domain of neu, which was not
seen in the control group or the group receiving AIT alone. The presence of higher
percentages of activated (CD25+) CD4+ and CD8+ T cells in the spleens of mice that
received AIT alone as compared to both control mice and mice that received MDSC
depletion is indicative of the a continued response by transferred T cells against MMC
tumors in these mice. Mice that received MDSC depletion and exhibited tumor regression
showed substantially lower levels of activated T cells most likely because these cells had
undergone the contraction phase of the immune response, making the percentage of
activated T cells similar to that seen in mice not receiving adoptive transfer. Therefore, the
depletion of MDSC in vivo results in an anti-neu immune response which is capable of
rejecting neu+ mammary tumors and tumor rejection requires both MDSC depletion and
the presence of anti-tumor effector T cells, given that depletion of MDSC alone offered no
protection against neu+ tumors.
T cell Expansion Using Alternating Gamma Chain Cytokines Results in Greater
Expansion, Cytotoxicity, and Viability
In an effort to generate highly aggressive T cells that may overcome the
suppressive effects of MDSC, we compared the phenotypes of T cells after expansion with
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either IL-2 alone, IL-7/IL-15 alone, or with all three cytokines, called “alternating”
cytokine expansion. We found expansion in alternating gamma chain cytokine conditions
to be more effective than IL-2 alone or IL-7/IL-15 alone for the generation of large
numbers of neu-specific anti-tumor effector T cells. Having compared IL-2 and IL-7/IL-15
with alternating gamma chain cytokines, we found that the alternating cytokine expansion
was superior to expansion in IL-2 and equal to expansion in IL-7/IL-15 in terms of
generating highly viable T cells. This is likely because IL-2 is known to up-regulate
Fas/FasL and cause activation induced cell death (141) as well as the fact that IL-7 and IL15 are important for the maintenance of memory T cells (130, 146, 223, 250, 251). Thus,
cultures containing exogenous IL-7/IL-15 had more viable cells than cultures with IL-2
alone. Along with increased viability, cultures with added IL-7/IL-15 had more CD8+ T
cells, with the proportions of CD4+ and CD8+ T cells being roughly equal, whereas
cultures expanded in IL-2 alone showed fewer CD8+ T cells and a higher proportion of
CD4+ T cells. IL-15 had been shown to be an important growth factor and activator of
CD8+ T cells, as well as being shown to enhance the anti-tumor effects of CD8+ T cells.
Furthermore, IL-7 and IL-15 in conjunction have been shown to be imperative for the
homeostatic proliferation of memory CD8+ T cells (131, 148, 252). In addition to
increased overall CD8+ T cells, the important role of IL-7/IL-15 in the generation and
maintenance of memory T cells is also apparent. Expansion with IL-7/15 alone elicited 2
distinct populations of memory cells: CD62LlowCD44high effector memory T cells and
CD62Lhigh CD44low central memory T cells, while expansion with IL-2 or with alternating
cytokines both resulted in only T cells of the effector memory phenotype. This implies that
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the addition of exogenous IL-2 for even s short period results in increased proportions of
cells with effector-like phenotypes. This is further confirmed by the fact that expansion in
IL-7/15 alone elicited substantially decreased levels of CD62L-CD44+ effector cells than
either IL-2 or alternating cytokine expanded cells. Concurrent with the fact that alternating
cytokine expansion resulted in the highest percentage of CD62L-CD44+ T cells, these cells
showed a higher anti-tumor efficacy than IL-2-expanded T cells in vitro, as evaluated by
cytotoxicity assays.
The markedly reduced expansion levels seen in cultures using IL-7/15 are a result
of a lack of expression of the IL-2Rα chain (CD25) and the IL-7Rα chain and on both
CD4+ and CD8+ T cells. IL-2 is a necessary T cell growth factor that is secreted by
activated T cells and can work in an autocrine or paracrine fashion; cells expanded in IL7/15 alone are not able to expand in response to IL-2 being made in the culture (253).
Furthermore, since CD25 expression is augmented by IL-2 itself, the low levels of CD25
expression attest to the fact that these cells are most likely making very low levels of IL-2
and are therefore not highly activated T cells. Importantly, IL-2 has also been shown to
promote the expression of the IL-7Rα chain, which is needed to maintain memory T cells
(223). Expression of this receptor was the highest on T cells expanded in alternating
gamma chain cytokines, indicating these cells may be able to respond better to homeostatic
cytokines once in vivo and that just a one-time pulse of IL-2 was in fact sufficient to
prevent receptor downregulation by IL-7. It is noteworthy that although IL-2 increases IL7Rα expression while IL-7 causes its downregulation (254), T cells expanded in alternating
cytokines had the highest expression of the IL-7Rα chain, exceeding levels seen in IL-2
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culture alone, despite the fact that staining was done 4 days after the removal of IL-2 from
culture. When combined with the fact that CD25 expression on CD8 T cells expanded in
alternating cytokines are at an intermediate level, thus reducing activation induced cell
death, we can conclude that T cell expansion in alternating gamma chain cytokines
provides a superior method by which to generate highly viable, cytotoxic T cells in vitro.
In addition to T cell phenotype, function, and viability, we wanted to minimize the
expansion of regulatory T cells during the in vitro expansion of neu specific activated T
cells. Staining for CD4+CD25+Foxp3+ cells was done after expansion in each of the three
cytokine regimens. Expansion with IL-7/15 generated the lowest percentage of
CD4+CD25+Foxp3+ cells and also resulted in the lowest absolute numbers of cells on day
7. Alternatively, while expansion with alternating cytokines generated the highest
percentage of CD4+CD25+Foxp3+ cells, this method also resulted in the greatest fold
expansion in vitro. In particular, the development of regulatory T cells has been of concern
when using IL-2 for T cell expansion, as IL-2 has been shown to be essential for regulatory
T cell development (142). However, although we saw that 10% of CD4+CD25+ cells were
also positive for Foxp3 expression after IL-2 expansion, these cells exhibited an almost 10fold expansion, whereas IL-7/15 expanded cells caused only 4% of CD4+CD25+ cells to
express Foxp3 and expanded only about 6-fold. Therefore, the generation of cells with a
regulatory T cell phenotype by IL-2 in in vitro expansions does not seem to suppress
cytokine-driven T cell proliferation.
AIT Using T cells Expanded in Alternating Gamma Chain Cytokines is only
Effective when Combined with MDSC Depletion
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Despite the advantages of T cell expansion in alternating gamma chain cytokines,
adoptive transfer of these T cells did not overcome the pre-existing immune suppressive
microenvironment in FVBN202 animals. We have previously shown that these mice have
increased levels of MDSC, even at the pre-malignant stage of mammary hyperplasia (172,
221). However, the combination of depleting MDSC in vivo with AIT expanded in
alternating cytokines resulted in a robust tumor regression as seen previously with IL-2
expanded T cells and MDSC depletion and the generation of an antibody response against
neu. Complete rejection of MMC tumors by the effector T cells, however, was hindered by
the fact that antibody-mediated MDSC depletion in FVBN202 mice was incomplete. This
resulted from increasing numbers of MDSC in tumor-bearing mice over time following the
cessation of injection of anti-Gr1 antibody, as preliminary depletions (9 days after tumor
challenge) were nearly 100% effective. However, by day 35 these levels had increased
dramatically and we were not able to inject the rat anti-mouse Gr1 antibody more than 6
times because of its toxicity.
It is important to note that when comparing the distributions of T cell phenotypes
and the absolute numbers of T cells from the spleens of mice that received either AIT alone
or AIT with MDSC depletion, there were no substantial differences. Mice receiving AIT
with MDSC depletion did not retain a greater number of either CD4 or CD8 T cells than
mice that received only AIT or MMC. Furthermore, MDSC depletion in mice receiving
AIT did not aid in maintaining higher proportions of activated, memory, or effector T cells
in comparison to mice that received AIT alone. Therefore, it can be concluded that tumor
rejection resulted from a lack of MDSC during the effector phase of the injected T cells
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prior to contraction and not from any subsequent alteration in T cell phenotype, number, or
distribution pattern. To confirm that the type of T cells (effector vs. central memory) and
migratory patterns were not the main determinant of the efficacy of AIT, we injected mice
with either CD62L+ cells (mostly effector memory and a small number of naïve) that
would home to the lymph nodes, or CD62L- cells (mostly effector cells) that could go
directly to the tumor site, after expansion in alternating cytokines. We found that AIT with
either population, in the absence of MDSC depletion, resulted in tumor growth rates
extremely similar to control mice receiving MMC alone. Furthermore, neither group
generated an antibody response, confirming that MDSC depletion alone, and not the state
of T cell differentiation or homing pattern, is responsible for the generation of antibodies
and tumor rejection.
The fact that these experiments use expanded T cells that recognize neu as foreign,
yet still fail to reject MMC tumors by themselves, attests to the strength of in vivo
suppression by MDSC, and upon proving that MDSC depletion does indeed facilitate an
otherwise ineffective AIT, we would next hope to use these procedures with the expansion
of splenocytes from tumor sensitized FVBN202 mice. In order to mimic the high affinity
response seen from FVB lymphocytes, FVBN202 lymphocytes can be expanded while
excluding those T cells having a lower affinity for the neu antigen. MHC-tetramer staining
complexes loaded with a cocktail of the most immunodominant epitopes of neu, and
fluorescently labeled, could be used to sort high affinity FVBN202 T cells at the start of
the procedure. The allogeneic model of rat neu expression in FVBN202 mice is a relevant
model in which to investigate breast cancer immunotherapy because, like human tumors,
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the oncogenic protein is largely tolerated. The presence of this rat protein could mimic the
fact that human tumors frequently have mutated oncogenes, which are no longer
completely tolerated as a normal syngeneic protein would be.
Although other groups have reported the role of MDSC in suppression of antitumor T cell responses (166, 167, 255), we have found that MDSC also suppress humoral
immune responses following AIT so that depletion of MDSC in vivo restored anti-neu
antibody responses in FVBN202 mice. This is very important because it has been reported
that collaboration of humoral and cellular immune responses is required for optimal
elimination of HER2/neu positive tumors (228). In addition, a novel HER2/neu specific
antibody, Pertuzumab, is currently in phase III trials and has been shown to have antitumor function through recognition and blockade of the dimerization domain of
HER2/neu, ECDII (256). Curiously, there was no antibody response in the groups that
received AIT alone, indicating that the presence of adoptively transferred CD4+ T cells
alone is not sufficient to facilitate IgG1 isotype switching by the recipients’ B cells
because of the presence of MDSC. It is unclear at this point whether the restoration of the
antibody response results from lifting MDSC suppression of B cells as well. The role of
MDSC in the suppression of the humoral response should be further investigated and could
have many applications beyond cancer immunotherapy, since increased MDSC have also
been seen in some parasitic infections such as Trypanosoma cruzi (257) and in cases of
polymicrobial sepsis (258).
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AIT in Conjunction with Gemcitabine Results in Complete Tumor Rejection and
Long-Lasting Immunological Memory
In light of these findings, we thought it extremely important to develop a regimen
of AIT with MDSC inhibition or depletion that could be more clinically relevant. Previous
studies have shown that the use of Gemcitabine can eliminate CD11b+Gr1+ cells in Balb/c
mice with neu-expressing tumors, and shows promise when used in conjunction with
vaccination strategies (259). We therefore decided to test Gemcitabine in conjunction with
AIT for the treatment of MMC tumors. Gemcitabine did in fact significantly reduce MDSC
in tumor-bearing FVBN202 mice, and by itself caused a significant inhibition of tumor
growth. However, the combination of Gemcitabine with AIT resulted in 100% complete
tumor rejection in FVBN202 mice. The effect of Gemcitabine in inhibiting MDSC has
recently been shown to be independent of its direct anti-tumor effects, as a single dose of
Gemcitabine to mice with established 4T1 mammary carcinomas was able to significantly
reduce the MDSC burden in as little as 24-48 hours, prior to any noticeable reduction in
tumor volume (260). It is also important to note that lymphocytes isolated 24-48 hours
after a single dose of Gemcitabine exhibited increased IFN-γ responses towards 4T1 cells
and increased expansion in vitro as compared to lymphocytes isolated from the spleens of
control mice (260), thus confirming the functional significance of specific MDSC
inhibition by Gemcitabine treatment. The modest tumor inhibition seen in mice receiving
Gemcitabine alone or AIT alone in these studies confirms the previous finding that both
effector T cells and MDSC inhibition are needed to facilitate tumor rejection. Importantly,
mice treated with Gemcitabine and AIT also maintained a healthy weight and appearance
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and exhibited strong antibody responses against ECDII of neu, which was not the case in
mice treated with Gemcitabine alone. The generation of an antibody response specifically
against ECDII of neu is significant in the fact that we have shown that in FVB mice,
responses against this domain are protective and sufficient for tumor rejection, while
responses against ECDIV are not protective. Antibody responses against ECDII of neu are
of great importance since this could inhibit the dimerization of neu with all other ErbB
molecules.
Since one important goal of AIT is to generate immunological memory, we decided
to re-challenge all 5 mice that had previously received AIT and Gemcitabine and rejected
MMC tumors. Re-challenge was done 74 days after the initial challenge to test for longlasting immunity. All mice received only 2 doses of Gemcitabine, as the recall response
was powerful enough to eliminate the need for the third dose of Gemcitabine. None of the
5 mice grew tumors large enough to be accurately measured by a digital caliper, and all 5
mice quickly became tumor free. Serum taken 12 days after this re-challenge showed very
high antibody titers in 2 mice, slightly elevated titers in 2 mice, and a low titer in one
mouse. It is important to note that several of the titers reached levels much higher than
those observed after the first challenge, consistent with the increased strength characteristic
of a recall response. IFN-γ responses to MMC from 2 of the mice confirmed the strong
recall response against MMC and indicated that tumor rejection was most likely immune
mediated and not mediated by Gemcitabine. Therefore, 18 days after the first re-challenge,
the 3 remaining mice were challenged again with MMC but were not treated with
Gemcitabine. Two of the mice never developed measurable tumors, while the third
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developed a small tumor that was subsequently rejected. Serum taken16 days after this
second re-challenge indicated that antibody titers were again elevated against sudomain II
of neu. The fact that no Gemcitabine was given after this re-challenge suggests that the
existing high antibody titers in these mice against ECDII was able to mediate tumor
rejection without allowing tumors to reach a size that would cause an increase in MDSC. It
is interesting to note that the mouse that developed a small tumor after the second rechallenge was the mouse with the lowest antibody titer out of the three on day 16.
Therefore, while we have shown that Gemcitabine does reduce MDSC, treatment with
Gemcitabine alone is not sufficient for the rejection of MMC tumors. However, the
combination of Gemcitabine with AIT results in complete tumor rejection, the generation
of antibody responses, and long-lasting humoral and cellular immunity capable of rejecting
further challenge without the anti-tumor effects of Gemcitabine.
Ongoing studies include long-term follow-up of mice treated with AIT and
Gemcitabine in order to determine if these mice develop relapsed tumors that may lack
expression of neu, as has been observed in one mouse thus far. We have previously shown
that IFN-γ can cause downregulation of neu expression on MMC cells in vitro and the
emergence of ANV cells in vivo after initial immune-mediated rejection of MMC cells in
FVB mice (136). Therefore, it is important to determine if the anti-tumor response that was
able to reject 3 MMC challenges in FVBN202 mice given AIT and Gemcitabine may lead
to tumor relapse through the process of tumor immunoediting (136). The ANV phenotype
of one relapsed tumor (Fig. 33) indicates, along with the in vitro IFN-γ responses observed
(Fig. 31) indicates, preliminarily, that strong IFN-γ reponses may lead to immune-mediated
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tumor escape variants with a more aggressive phenotype. Also of importance is to
determine if T cell-mediated rejection of MMC challenge can be achieved when T cells are
isolated from tolerant FVBN202 mice, expanded in alternating gamma chain cytokines,
and used in conjunction with Gemcitabine. The improved expansion method may be
capable of generating highly effective anti-tumor T cells even from FVBN202 mice and
the ability of Gemcitabine to directly inhibit MDSC could eliminate any tolerance that may
be exerted on these cells. In the clinical setting, where T cells would be taken from a
tumor-bearing individual, it may be important to pre-treat the individual with Gemcitabine,
as has been done by Le et al in the 4T1 mouse model of mammary carcinoma. Pretreatment of tumor-bearing mice with Gemcitabine resulted in significantly higher levels of
lymphocyte expansion and increased subsequent IFN-γ secretion after sacrifice (260).
However, these expanded cells were not able to mediate tumor regression when transferred
into mice with established 4T1 tumors (260). In this experiment, the recipient mice were
not treated with Gemcitabine, and, given their established tumors, likely had elevated
levels of MDSC which inhibited the transferred T cells. Future studies should therefore use
Gemcitabine to pre-treat the donor prior to the isolation of cells for expansion, and should
subsequently treat the recipient with Gemcitabine to allow the transferred T cells to be
effective.
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II. Chapter 2
Suppression by MDSC is Contact-Dependent
In order to further confirm that failure of AIT to induce regression of MMC in
FVBN202 mice was indeed a result of inhibition of T cell function by MDSC, we
performed in vitro assays to assess MDSC-mediated inhibition of T cell proliferation.
Consistent with the fact that tumor-bearing animals exhibit about a 4-fold increase of
MDSC in the granulocyte region of their splenocytes (172), total splenocytes from tumorbearing mice showed a marked reduction in the number and percentage of proliferating T
cells. Significantly, depleting the MDSC from the culture using either an anti-CD11b or an
anti-Gr1 antibody caused the restoration of TCR-mediated T cell proliferation. These
observations suggest that MDSC suppress TCR-induced proliferation of T cells. To further
determine exactly which MDSC were suppressive against CD3/CD28 stimulation,
CD11b+ cells were isolated from tumor bearing mice and sorted based on the differential
expression of the Gr1 epitopes, Ly6G and Ly6C. Sorting based on these parameters
resulted in 2 populations, one that was Ly6G+Ly6C+ and one that was Ly6G-Ly6C+.
Suppression assays using these cells instead of whole CD11b+Gr1+ MDSC showed a
significant reduction in CD3/CD28 mediated T cell proliferation only in the presence of
Ly6G-Ly6C+ cells. This is in contrast to recent reports that have shown different subsets
of MDSC to be equally suppressive. Specifically, reports by Movahedi et al using MDSC
from EG7 thymomas and BW-Sp3 lymphomas and Youn et al, using MDSC from EL-4
thymomas have shown that both subsets of MDSC are suppressive against OT-1
splenocytes stimulated with specific peptide; however, neither group reported suppression
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against splenocytes stimulated with anti-CD3/CD28(171, 215). Our subsets reported here,
therefore, may represent unique populations of MDSC found in MMC tumor-bearing
FVBN202 mice. Consequently, in this model, broadly defining MDSC as CD11b+Gr1+
cells is inaccurate as not all of these cells are suppressive. The term MDSC in regards to
the FVBN202 mouse model should therefore be defined specifically as CD11b+Ly6GLy6C+ cells.
The possible contact-dependent mechanism of T cell suppression by MDSC has
been an area of some debate. Using different tumor models, most groups have found
suppression of T cells by MDSC to be mediated by soluble factors such as arginase-1,
nitric oxide, reactive oxygen species and peroxynitrites (173, 261). In particular, arginase-1
has been implicated in downregulation of the TCR zeta chain and the induction of this
enzyme has been linked to tumor-derived soluble factors such as prostaglandin E2 as well
as IL-4 and IL-13 (173, 182, 188). Furthermore, arginine-depleted conditions can cause
TCR zeta downregulation in the absence of cell-to-cell contact (188). Indoleamine 2,3dioxygenase, has also been found to be expressed in macrophages and dendritic cells as
well as human tumors and contributes to T cell anergy CD8 T cell suppression through the
catabolism of tryptophan(186, 187, 262). Inconsistent expression of IL-10 and extremely
low expression of IDO lead us to conclude that these molecules were not paramount in
mediating suppression by MDSC. Furthermore, a role for TGF-β was excluded as higher
expression of this molecule was seen in the non-suppressive population of
CD11b+Ly6G+Ly6C+ cells than was observed in the CD11b+Ly6G-Ly6C+ suppressive
population. This led us to hypothesize that suppression by MDSC in our model may be
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contact-dependent. Indeed, Transwell assays confirmed that cell-to-cell contact was
required for the suppression of T cell proliferation. Although other mechanisms may be
involved in suppression of cytotoxic responses by T cells, we report here that no
suppression of T cell proliferation was seen when MDSC were added to the top chamber of
a transwell insert. Nagaraj et al have recently shown that direct cell-to-cell contact between
CD8+ T cells and MDSC causes nitration of tyrosines in the TCR-CD8 complex, therefore
disrupting binding of specific antigen-MHC class I complexes to the TCR’s of OT-1
transgenic T cells (183). It is unclear, however, if the effects of this nitration may be
exaggerated by transgenic expression of the TCR and what role this mechanism may play
in a TCR non-transgenic model. Furthermore, Gabrilovich et al have reported that blocking
the MHC class I molecules expressed on the surface of MDSC can reverse suppression of
CD8+ T cells, which involved MDSC production of nitric oxide, but reported that these
cells did not suppress CD4+ T cell responses towards MHC class II presented peptides
(166). In 2000, Kusmartsev et al. showed inhibition of CD3/CD28 T cell activation by
MDSC isolated from mice bearing MCA-26 colon carcinomas. However, this suppression
was reversed by the addition of a superoxide dismutase mimetic and a nitric oxide synthase
inhibitor and a possible role of contact was not investigated, and proliferation was not
determined in separate populations of CD4+ and CD8+ T cells (170). In contrast, we show
here that MDSC from mice bearing neu+ mammary carcinomas inhibit the proliferation of
both CD4+ and CD8+ T cells in contact-dependent manner. Therefore, although contact
between MDSC and CD8+ T cells has been speculated to be important in inhibiting the
IFN-γ response of CD8+ T cells towards specific peptide, we show here that contact is also
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necessary to inhibit CD3/CD28 T cell stimulation and can affect the proliferation of both
the CD4+ and CD8+ T cells populations.
Contact-Dependent Suppression is Independent of CD86, LFA-1, and PD-L1
The inhibitory receptor CTLA-4 (CD152) is rapidly upregulated upon T cell
activation and has a higher affinity for the co-stimulatory molecule CD86 (B7-2) than its
stimulatory counterpart, CD28 (263, 264). Furthermore, CD86, while expressed at low
levels on resting APC, is also rapidly upregulated following activation (265). We therefore
hypothesized that increased expression of CD86 on activated MDSC from tumor-bearing
mice may cause the inhibition of T cells through CTLA-4. While this mechanism is
normally in place as a regulator of the immune response, the increased frequency of
MDSC present in tumor-bearing individuals could potentially cause an overwhelming
amount of negative signaling through CTLA-4 and negate any and all positive signals
though CD28. However, we were surprised to see that the percentage of CD11b+Gr1+
cells from tumor-bearing mice expressing CD86 was actually significantly lower than
CD86 expression on CD11b+Gr1+ cells from tumor free mice. Although it is therefore
unlikely the CD86 is a mediator of active suppression by MDSC, considering that MDSC
make up over 90% of the granulocyte region in tumor-bearing mice (see Figure 5) and only
about 30% of these MDSC express CD86, it is likely that contact between TCR-MHC of T
cells and MDSC results in T cell anergy, which results from TCR activation in the absence
of co-stimulation (266).
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In addition to CD86, we were also able to rule out MDSC-mediated interactions
through LFA-1, which is also highly expressed by CD11b-Gr1- cells and therefore would
not limit suppression to the CD11b+Gr1+ population. Contact of the PD-1 molecule on T
cells by PD-L1 on MDSC’s seemed likely as PD-L1 is known to be expressed on dendritic
cells and macrophages and can inhibit TCR-induced proliferation, induce T cell anergy, or
cause apoptosis (241-243). However, we saw no expression of PD-L1 on CD11b+Gr1+
cells, and therefore are able to rule out contact through the PD-1/PD-L1 axis as a means of
contact-dependent suppression. We can therefore conclude that tumor-bearing FVBN202
mice have unique subsets of MDSC, only one of which is suppressive, and that this
suppression requires direct contact with T cells that is independent of interactions with
LFA-1, PD-L1, and CD86. Future studies aim to identify the exact point or points of
contact required between T cells and MDSC for MDSC to mediate T cell suppression.

III. Chapter 3
MMC-Derived Soluble Factors Drive the Accumulation of MDSC
The accumulation of MDSC in tumor-bearing hosts is a major obstacle to the
effective treatment of cancer (267) and many studies have shown a link between tumorderived soluble factors and increased MDSC. Identification of such soluble factors could
offer therapeutic intervention to avoid generation of MDSC. Injection of MMC
conditioned medium confirmed that MMC-derived soluble factors did indeed cause a
significant increase in the proportion of the granulocytes that were MDSC, as well as
causing a significant difference in the overall percentage and absolute numbers of MDSC
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in the spleen, blood, and bone marrow of the tibias and femurs. The fact that MMCderived soluble factors also caused a significant decrease in the percentage of MDSC
expressing the MHC class II molecule I-Aq lead us to hypothesize that in addition to
increasing MDSC, tumor-derived soluble factors may also play a role in dampening the
immune response by reducing antigen presentation. In support of this hypothesis, we did in
fact find expression of I-Aq to be significantly decreased in the CD11b+Gr1- DC
population in mice receiving injection of MMC conditioned medium as compared to mice
receiving control medium. Since mature APC’s are one of only a few cell types that
constitutively express MHC class II molecules, and since antigen stimulated helper CD4+
T cells are imperative for somatic hypermutation and isotype switching of B cells as well
as for the induction of cytotoxic CD8+ T cell responses, the decrease in APC’s expressing
MHC class II could negatively affect the ability of the host to respond to tumor antigens
and mount an effective anti-tumor response (268). Interestingly, there was not a
measurable difference in the expression of the MHC class I molecule, H-2q on
CD11b+Gr1- cells, indicating that inhibition of the anti-tumor response occurs mainly
through the inhibition of helper T cells. Our studies also found that MMC derived
supernatant did not influence the expression of AnnexinV, CD86, CD11c, H-2q, Qa1, or
CCR7 on CD11b+Gr1+ cells.
A multiplex cytokine array to determine the main soluble factors secreted by MMC
returned interesting results. We found that MMC cells secrete large amounts of VEGF and
MCP-1 and IL-6, as well as smaller amounts of GM-CSF. It is also important to note that
these cells do not produce substantial mIL-1β, which has been shown by Bunt et al to
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increase MDSC’s in a 4T1 model (269). Also they do not secrete measurable IL-4 or IL13; it has been published that MDSC’s can respond to IL-4 and IL-13 in a way that causes
them to take on an alternatively activated phenotype (167). The lack of secretion of IL-10,
which is important in inducing the suppressive phenotypes in Tregs, indicates that these
cells probably do not play a crucial role in this model (270).
Despite secretion of GM-CSF, VEGF, IL-6, and MCP-1 by MMC cells, injection
of these cytokines in vivo did not result in statistically significant increases in MDSC in the
spleen, bone marrow, and blood of FVBN202 mice, as was seen after injection of MMCconditioned media. We believe this is because of the short half –lives of these molecules,
as groups that have seen in vivo responses have used a means of continuous in vivo
administration such as the use of GM-CSF-transfected melanoma cells that secrete up to
6000ng per 1X106 cells per hour, or subcutaneously implanted osmotic pumps delivering
VEGF at a constant rate of 50 or 100ng per hour, which has been shown to have a half life
of only 25 minutes (208, 271, 272). We therefore decided to use in vitro studies to analyze
the effects of these cytokines/ chemokines on sorted populations of both CD11b-Gr1progenitor cells and CD11b+Gr1+ MDSC from the bone marrow of FVBN202 mice.
GM-CSF is the Main Determinant of MDSC Generation and Survival
GM-CSF has been used in dendritic cell vaccination strategies to induce tumorspecific immune responses. For example, Driessens et al have recently found that
administration of GM-CSF-transduced renal cell carcinoma cells along with dendritic cells
is able to mediate responses in 50% of mice and also resulted in immunological memory
(273). GM-CSF is a crucial factor in the generation of dendritic cells and plays an
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important role in regulating and activating these cells and has been shown to increase
numbers of circulating dendritic cells in patients receiving exogenous GM-CSF with along
with either G-CSF or Flt3 (274, 275). Patients who received GM-CSF with Flt3 generated
increased numbers of DC1 cells, which stimulate a Th1 response, while patients who
received GM-CSF in conjunction with G-CSF showed increased DC2 cells, which cause a
Th2 polarization (275). This is not surprising given fact that GM-CSF has a broad range of
biological activity and can exert different effects in varying cells types depending on
concentration, differentiation status, and surrounding environment and cytokine milieu
(276). Showing the diversity of responses elicited by GM-CSF, a recent study in patients
with stage IV melanoma has shown that administration of GM-CSF in combination with a
multi-epitope vaccine offered no improvement in anti-tumor immune responses as
compared to those seen in patients that received vaccination alone (277), while another has
shown that vaccination of patients with metastatic melanoma using irradiated autologous
melanoma cells engineered to express GM-CSF resulted in anti-tumor responses in 11 out of 16
patients (278).

Given that the role of GM-CSF on MDSC has only recently been investigated and
considering the heterogeneity of responses that can occur as a result of GM-CSF, we found
it imperative to investigate the role of this cytokine in MDSC generated in the FVBN202
mouse model. In agreement with literature that has implicated GM-CSF as an important
factor in the development and differentiation of a variety of hematopoietic cells (276), we
found that total bone marrow cells, most of which were CD11b+Gr1+, cultured with GMCSF resulted in the generation of a large population of CD11b+Gr1- dendritic cells
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(72.6%). Despite the fact that the CD11b+Gr1+ population dropped from 77% of the total
bone marrow on day 0 to 25% on day 6, quantification of the absolute number of these
cells showed that this population actually increased, albeit not significantly, during this
time period. This led us to conclude that GM-CSF is in fact maintaining the MDSC
population throughout the culture period. Furthermore, CD86 expression on MDSC was
significantly increased by day 6 of culture, which is of interest given the previous finding
that CD86 levels on MDSC were significantly reduced on MDSC from tumor-bearing
mice as compared to those from tumor-free mice (see Figure 39). Therefore while GMCSF alone may result in MDSC with a slightly more mature phenotype, the presence of
other tumor-derived soluble factors in conjunction with GM-CSF negates this effect.
Although we did not see a significant difference in CD86 expression on MDSC after
injection with MMC-derived supernatant, it is possible that a longer time period is required
for this effect, as only 3 injections of MMC supernatant over the course of 3 days were
given. Contrary to the increase in CD86, 6 days of culture with GM-CSF caused MDSC in
the bone marrow to drastically downregulate their expression of the chemokine receptor
CCR7. CCR7 has only 2 ligands, CCL19 and CCL21, which are important in guiding
CCR7-expressing cells through high endothelial venules and into the lymph nodes (279).
CCR7 is expressed only on semi-mature and mature DC’s, and like CD86, is greatly
upregulated upon DC maturation. Although DC’s in Ccr7-/- mice do not migrate to the
draining lymph nodes after activation, T cells lacking CCR7 are still found in the red pulp
of the spleen and B cells were found in both the red and white pulp of the spleen,
indicating that migration into the spleen is still possible in the absence of CCR7 (246).
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Furthermore, it has been found that the addition of CCL19 to DC cultures induced their
maturation and that CCR7 ligands can increase the ability of mature DC’s to take up
antigen (280, 281). In light of these findings, although the upregulation of CD86 on MDSC
may indicate a maturing effect of GM-CSF on these cells, the concurrent downregulation
of CCR7 may prevent complete maturation, antigen uptake, and migration to the lymph
nodes while explaining the preponderance MDSC present in the spleens and periphery of
tumor-bearing mice, while increases have not been observed in the lymph nodes
(unpublished observation). We next sought to determine the effects of GM-CSF
specifically on existing MDSC or on the generation of MDSC by using pure sorted cells
populations.
The important role of GM-CSF in the expansion of MDSC has been suggested
previously by other studies. For example, GM-CSF-secreting tumors and GM-CSF
administration in vivo (5µg twice daily for 3 days) have been implicated in increased
numbers of MDSC (282).It was determined that only high-dose GM-CSF had such
deleterious effects (271), though differential effects of GM-CSF on progenitor cells versus
existing MDSC were not determined. We have determined that GM-CSF is the major
tumor-derived soluble factor that causes both the generation of MDSC from sorted CD11bGr1- cells and maintains existing sorted CD11b+Gr1+ MDSC for the duration of a 6 day
culture. Interestingly, CD11b+Gr1- cells were not abundant after culture of either of the
sorted fractions with GM-CSF, indicating that these cells may have, in part, expanded from
the existing 4% present on day 0 (see Figure 58). However, there was a substantial
difference on day 6 between cells cultured in GM-CSF as compared to cells cultured with
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MMC in Transwell. While the presence of GM-CSF alone with sorted CD11b-Gr1- cells
drove the production of a majority of MDSC, the presence of MMC with CD11b-Gr1cells resulted in an almost equal distribution of CD11b+Gr1+ cells and CD11b+Gr1- cells
on day 6. This indicates that tumor-derived soluble factors other than GM-CSF are
responsible for the generation of CD11b+Gr1- cells and explains a previous observation
that the tumor site contains a higher proportion of CD11b+Gr1- cells than the spleen, bone
marrow, or blood of FVBN202 mice (see Figure 5). In contrast, the effect on sorted
CD11b+Gr1+ cells was reversed, with culture with GM-CSF alone resulting in a greater
percentage of CD11b+Gr1- cells (21.8%) than culture with MMC in Transwell (only
7.3%). This shows that CD11b+Gr1+ cells are in fact capable of converting into
CD11b+Gr1- cells, but that the presence of other tumor-derived soluble factors besides
GM-CSF largely prevents this from occurring. Secondly, this highlights the drastically
different effects that the same treatment (GM-CSF or MMC cells) can have on these two
different cell populations. In fact, our data indicated that sorted CD11b-Gr1- progenitor
cells were more susceptible to the effects of GM-CSF not only in the generation of MDSC,
but also for the survival of these MDSC as compared to CD11b+Gr1+ bone marrow cells.
Although GM-CSF, and to a lesser extent MMC-derived soluble factors, significantly
augmented the viability of both existing and newly generated MDSC, lower AnnexinV
staining in newly generated MDSC derived from CD11b-Gr1- cells may be a result of high
turnover rates in MDSC such that previously generated MDSC are more prone to apoptosis
than newly generated MDSC even in the presence of GM-CSF. Interestingly, in both cases,
the protective effects of GM-CSF on MDSC appeared to be dose-dependent, because
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culture with GM-CSF at 100ng/mL caused a significant reduction in apoptosis as
compared to MMC secreting ~350 pg/mL GM-CSF.
MMC-Derived Soluble Factors or GM-CSF Support the Generation of a Suppressive
Ly6G-Ly6C+ MDSC Subset.
Identifying MDSC subsets is an important factor that may lead to more efficient
therapeutic means of eliminating or inhibiting these specific cell populations, while
minimizing undesirable side effects. We therefore sought to further characterize MDSC
subsets in FVBN202 mice through differential expression of the Gr1 epitopes Ly6G and
Ly6C. It has recently been reported that expression of Ly6G correlates with a granulocytic
phenotype, while expression of Ly6C correlates with a monocytic phenotype (171, 215).
The tumor-bearing FVBN202 transgenic mouse model of neu positive mammary
carcinoma displays novel phenotypes and characteristics of MDSC. Although Youn et al
observed increases in MDSC subsets in FVBN202 mice with ANV tumors, FVBN202
bearing MMC tumors were not evaluated (171). Two distinct subsets exist in MMC tumorbearing FVBN202 mice, Ly6G-Ly6Clow/int, and Ly6G+Ly6Chigh. Previously reported
subsets include Ly6G-Ly6Chigh, Ly6G+/hiLy6Clow/int, and Ly6Gint/dullLy6Chi (171, 215, 216).
These phenotypes display an inverse correlation between Ly6G and Ly6C expression,
where high Ly6G expression is associated with intermediate or low Ly6C expression and
low or absent Ly6G expression is associated with high Ly6C expression, which is in direct
contrast to the phenotypes presented here.
In addition to previously reported differences in suppressive activity of these two
subsets (see Figure 35), the expansion of MDSC subpopulations has also differed among
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groups. Like Youn et al, we observed the greatest expansion in the Ly6G positive subset in
the spleens of tumor-bearing mice as compared to tumor-free mice (Figure 62), however
we observed similar expansion of the two subsets in the bone marrow (171). In contrast,
Movahedi et al have reported a roughly equal distribution of Ly6G+ and Ly6G- subsets in
tumor-bearing spleens, and have also found both populations to expand with similar
kinetics (171, 215).
We next sought to determine the effects that GM-CSF or MMC would have on the
distribution or expansion of these MDSC subsets. Strikingly, culture with 100ng/mL of
GM-CSF, and to a lesser extent MMC, also resulted in a significantly higher percentage of
Ly6G- cells, previously found to be suppressive, and a significantly lower percentage of
Ly6G+ cells, which have shown no suppressive activity in this model. Like the protective
effects of GM-CSF, the reversal of the distribution of these cell populations seems to be
concentration dependent, as the Ly6G- population was also significantly increased as
compared to that seen after culture with MMC. It is interesting to note that the MFI if
Ly6C was greatly increased after culture with GM-CSF or MMC as compared to that seen
in the bone marrow on day 0. Considering there is a slight increase in the MFI of Ly6C in
the bone marrow of tumor-bearing versus tumor free mice, high expression of Ly6C may
represent a marker of activated MDSC with increased suppressive activity. The
suppressive capacity of Ly6G-Ly6Chigh cells remains to be determined and shoule be
compared to the suppressive effect seen previously in the Ly6G-Ly6Clow/int population.
Additionally, variances in the amount of GM-CSF secreted by other tumor cell lines may
explain the different subsets that have been found in different models.
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Further characterization of the effects of GM-CSF and MMC-derived soluble
factors on sorted CD11b-Gr1- progenitor cells revealed that, consistent with previous
findings, both the MHC class I (H-2q) and the MHC class II (I-Aq) molecules were
significantly reduced on MDSC that had arisen from these cells after 6 days. This suggests
that any cells arising under conditions of elevated GM-CSF may have stunted antigen
presentation capabilities. We did not, however, observe significant differences in H-2q and
I-Aq levels after the culture of sorted CD11b+Gr1+ cells, again highlighting the increased
susceptibility of progenitor cells to the effects of GM-CSF. This also explains the more
pronounced difference seen in the expression of these molecules as compared to that seen
previously after injection of MMC-conditioned medium, since these populations would
include cells that were already CD11b+Gr1+ as well as cells that were CD11b-Gr1- at the
time of injection (see Figures 46 and 47). Therefore, it has been consistently found that the
presence of GM-CSF, either alone or as secreted by MMC, can reduce the antigen
presentation abilities of both CD11b+Gr1+ as well as CD11b+Gr1- cells and may play a
role in preventing the full maturation of these cells, which is characterized by increases in
MHC class II expression, upon antigen uptake (279). GM-CSF does not, however, cause
the proliferation of existing sorted MDSC which is consistent with the fact that we did not
see a statistically significant difference between the absolute number of MDSC recovered
from the bone marrow of the tibias and femurs on day 0 as compared to after 6 days of
culture with GM-CSF. This is likely a result of the rapid turnover rate of MDSC in which
existing MDSC are more prone to apoptosis and will be replaced by newly arising MDSC
from the bone marrow. It is likely, however, that the accumulation of increasing numbers
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of MDSC is a result of the generation of new MDSC outpacing the apoptosis of existing
MDSC, and this may also account for the non-significant increase in MDSC numbers seen
in Figure 58 as GM-CSF drove the production of CD11b+Gr1+ cells from CD11b-Gr1bone marrow progenitor cells.
Given the effects of GM-CSF on CD11b+Gr1+ and CD11b+Gr1- cells, it is
conceivable that, since GM-CSF has been found to be secreted in 31% of tested human
tumor cell lines (282), administering GM-CSF in the clinical setting may have an additive
effect with tumor-secreted GM-CSF and therefore support the generation of MDSC from
bone marrow progenitor cells, as well as maintaining existing populations of MDSC and
driving the production of highly suppressive subsets of MDSC. A recent review on the
opposing effects of GM-CSF as an adjuvant in cancer patients also suggested activation
and expansion of MDSC by endogenous tumor-derived or exogenous GM-CSF (211).
However, a study on patients with high-risk melanoma treated with adjuvant GM-CSF
showed that GM-CSF mainly expanded DCs rather than MDSC (283). The authors used
CD33+HLA-DR- as markers for MDSC whereas, using CD34+ as a marker for MDSC,
others found that patients with head and neck squamous cell carcinoma (HNSCC) had
profound immune deficiencies associated with an increased intra-tumoral presence of
immune-suppressive CD34+ progenitor cells (210). Therefore different observations may
be attributed to different markers used for identification of human MDSC. Although
markers of MDSC in humans are not as well characterized as in mouse, we made similar
observations in mice when using unfractionated bone marrow cells in culture with GMCSF. This suggests a dual role for GM-CSF in the generation of DCs and MDSC. The
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frequency of distinct progenitor cells for DCs or MDSC in the bone marrow of cancer
patients may determine which effect of GM-CSF may prevail. Given these findings,
existing serum levels of MDSC in patients should be considered before administering GMCSF as an adjuvant therapy and levels should be monitored closely during treatment in an
effort to minimize the deleterious effects of GM-CSF.
Interestingly, we observed a complete lack of response when using either VEGF or
MCP-1 in culture with sorted CD11b-Gr1- cells or CD11b+Gr1+ cells. This was somewhat
surprising given that MMC cells secrete over 4.5 times as much VEGF and over 3 times as
much MCP-1 as GM-CSF. In particular, recent evidence has pointed towards VEGF as an
important mediator of myeloid cell accumulation and differentiation through the activation
of STAT3 which has been shown to prevent the differentiation of myeloid cells (201).
Increased levels of VEGF have also been shown to result in the inhibition of DC
development and the accumulation of Gr1+ cells (208, 272). Likewise, the link between
the chemokine MCP-1 (CCL2) and elevated levels of detrimental tumor-associated
macrophages in breast cancer patients made it a likely candidate for causing the generation
of suppressive macrophage and/or MDSC populations (284, 285). We have indeed
observed a higher percentage of CD11b+Gr1- cells at the tumor site, an effect that is
recapitulated in Figure 60B with sorted CD11b-Gr1- progenitor cells cultured with MMC
in transwell converting to 43.8% CD11b+Gr1- cells by day 6. However, neither sorted
populations of progenitor cells nor MDSC responded to either VEGF or MCP-1 alone.
GM-CSF, secreted at an average of 336pg/mL by MMC cells, is therefore the main
determinant of MDSC generation and maintenance.
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We showed that MMC or GM-CSF specifically supported the generation of the
suppressive Ly6G-Ly6C+ subset in vitro. On the other hand, tumor-bearing mice showed a
higher percentage of Ly6G+Ly6C+ than Ly6G-Ly6C+. Such discrepancies between in
vitro and in vivo observations could be attributed to the higher dose of GM-CSF or MMC
in co-culture with the progenitor cells compared to that in vivo. Alternatively, immune
responses against the tumor may compromise the effects of tumor-derived soluble factors
in vivo and reduce the proportion of the suppressive subset. This possibility is supported by
recent reports showing that immunological tolerance was broken against the neu positive
tumors in FVBN202 transgenic mice (221, 286).
GM-CSF therefore is the main factor having the ability to drive the production of
new MDSC from bone marrow CD11b-Gr1- progenitor cells, and, more specifically
augments the generation of a novel Ly6G-Ly6C+ suppressive subset of MDSC. In contrast,
VEGF and MCP-1, both previously linked to MDSC accumulation, had no effect on the
generation or maintenance of MDSC. Future studies will determine the suppressive
activities of the Ly6G-Ly6C+ and Ly6G+Ly6C+ subsets generated after culture with either
GM-CSF or MMC to elucidate if the highly expanded Ly6G-Ly6C+ subset remains
suppressive. Furthermore, comparisons between the suppressive activities of
CD11b+Ly6G-Ly6Clow cells found in naïve FVBN202 mice, the CD11b+Ly6G-Ly6Cint
cells found in tumor-bearing mice, and the CD11b+Ly6G-Ly6Chigh cells generated after
culture with MMC or GM-CSF should be conducted to determine if expression of the
Ly6C molecule may be a prognostic marker for identifying suppressive populations of
MDSC.
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